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Abstract 
 
Background 
Huntington’s disease (HD) is a life-limiting neurodegenerative condition in which 
the onset of symptoms, generally in midlife, is characterised by cognitive decline, 
psychological problems and movement disorder.  HD is inherited as a dominant 
genetic trait. Co-morbities are prevalent and include psychiatric effects such as 
depression, anxiety and psychosis. Death from suicide among people with HD is 
reported to occur four to five times more frequently than among the general 
population. The only treatment for HD supported by well established evidence for 
effectiveness is tetrabenazine for reducing chorea and one of its side effects is 
depression.  
 
Aim 
To identify and prioritise “what helps people with Huntington’s disease live with 
their condition” from the perspectives of people with Huntington’s disease, their 
carers, and healthcare professionals who treat them 
 
Method 
People with HD, family caregivers and health professionals generated 94 statements 
in answer to the question: ‘what helps people with HD live with their condition?’ 
The participants were based in community and institutional contexts.  They 
prioritised the statements by organising them into five levels of importance, least to 
most important. Finally the participants arranged the statements into groups or 
‘clusters’ to indicate which statements seemed subjectively to each participant to 
‘belong’ together. Specialised ‘concept mapping’ software (Ariadne ®) was used to 
graphically depict the consensus among participants of how the statements were 
clustered and prioritised.  
 
Results 
Expert assessment and treatment for co-morbid mental health problems were the 
highest priority for all participants. Flexibility in the provision of care and timeliness 
of help provided through integrated interdisciplinary teamworking with specialist 
HD expertise were also high priorities. People with HD prioritised being trusted and 
supported to maintain independence. They placed greater value on medical 
treatments than caregivers or professionals, who were more concerned with care and 
planning for future needs in more advanced stages of the disease. Overall 
participants were more concerned with lessening the impact of symptoms on living 
with HD than with measurably reducing specific symptoms such as chorea. 
 
Conclusions 
Healthcare professionals can help people with HD live with their condition by being 
more proactive in identifying and treating mental health problems, which is at 
present an important unmet need. 
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Chapter One 
Introduction 
 
Due to the complexity of its effects on individuals and families the treatment, care 
and service provision for people affected by Huntington’s disease (HD) poses a 
difficult challenge to professionals (Aubeeluck and Wilson 2008). As the disease 
progresses often over many years, the symptoms negatively impact on every area of 
independent living (Lechich et al 2008). There is reportedly no cure for HD or 
indeed any effective treatment aimed at slowing the deterioration of the brain as a 
result of the condition (Ramaswamy et al 2007; Adam and Jankovic 2008; van der 
Burg 2009) and the absence of curative therapies adds to the importance of the 
question that this thesis seeks to answer: what helps people to live with HD?    
This study considers the viewpoints of people who have HD, their caregivers and 
healthcare professionals who treat them, about what helps people with HD to live 
with the condition.  Knowledge of these perspectives is needed to ensure that 
professionals who provide care and treatment and who decide on the focus areas for 
HD research are informed about what matters most to those affected by the disorder, 
and any differences between the perspectives that should be taken into account.  
1.1 What is Huntington’s Disease? 
Huntington’s disease (HD) is a neurodegenerative disorder that commonly manifests 
between the ages of 35-50 (Handley et al 2006). Symptoms can be divided into three 
groups- motor impairment, psychiatric problems and cognitive deterioration 
(Langbehn et al 2004) and the mean length of time between onset of symptoms and 
death is reported to be in the region of 15-20 years (Handley et al 2006). The 
condition is inherited as a dominant genetic trait (Bonelli and Hofmann 2007) 
meaning that offspring are at 50% risk of developing the condition at some time in 
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their life. The responsible mutation was identified on the short arm of chromosome 4 
in 1993 (Gusella et al 1993; Huntington’s Disease Collaborative Research Group 
1993) making genetic testing for HD possible.  
1.2 Pathophysiology  
The HD gene ‘IT15’ is necessary for life and is responsible for regulating the protein 
‘huntingtin’. This protein is important for brain function and less widely appreciated 
is its expression more generally in body tissues and organs (Li et al 1993). IT15 
consists of a repetition of three nucleotide bases- cytosine, adenine and guanine (or 
CAG). The normal range for the number of CAG repeats in the gene has been 
reported to be between 13 and 31 (Sanchez et al 1997) but in HD it could be between 
36 and 250 although many individuals with up to 40 repeats do not develop HD 
(Langbehn et al 2004). These authors demonstrated a negative correlation between 
CAG repeat length and age of onset meaning that higher repeat number is associated 
with manifestation of the disease in younger people. More rapid brain deterioration 
following diagnosis and greater severity of symptoms are also associated with a 
greater CAG repeat number (Ruocco et al 2008). 
This trinucleotide expansion disrupts control of ‘huntingtin’ (Caviston and Holzbar 
2009). Through a process that has yet to be established this causes degeneration of 
neurones within the brain- specifically the basal nuclei and cerebral cortex (van der 
Burg et al 2009)- accounting for the movement disorder and cognitive and 
neuropsychiatric problems discussed below. However, van der Burg et al (2009) 
state that HD is not only a brain disorder as it also has ‘peripheral features’ including 
weight loss, skeletal-muscle atrophy, cardiac failure, testicular atrophy and 
osteoporosis. Within the brain itself appreciation for wider deterioration than initially 
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envisaged has grown in the last two decades before which time HD was 
characterised by the loss of striatal neurons (Reiner et al 1988). More recently the 
likelihood that clinical deficits relate to deterioration of the cortico-basal nuclei 
network rather than to damage restricted to the striatum is appreciated (Delmaire et 
al 2010).  
1.3 Detection of disease onset and clinical diagnosis 
Modern imaging techniques can detect structural and functional changes in the brain 
prior to the observable onset of symptoms (Squitieri et al 2009, Klöppel et al 2009). 
Paulsen et al (2007) demonstrated that measurable disease development can occur 
ten to twenty years before diagnosis as physical, cognitive and psychological 
impairment is subtle initially and progresses gradually (Harper 2005). There is 
controversy concerning which of these areas is the site of the first changes and a lack 
of uniformity in presentation between individuals appears to explain the disparity 
within the literature (Snowdon et al 2002). According to the UK NHS (National 
Health Service (NHS) 2013) behavioural changes are frequently the first apparent 
signs in a person who is developing HD but many individuals refuse to accept there 
is any problem at this stage. Clinical diagnosis is made on the basis of observed 
motor signs occurring in an individual with a family history of HD and this diagnosis 
is regarded as confirmed by a positive test for the expanded HD gene (Witjes-Ané et 
al 2007). It follows that people newly-diagnosed with HD may have relatives, friends 
and colleagues who become aware of problems long before this confirmation.  
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1.4 Effects of Huntington’s disease 
Cognitive decline 
Neuronal degeneration in HD is selective (Li et al 2001) and initially the striatum 
(part of the basal nuclei including the putamen and caudate nucleus) are affected and 
eventually damage becomes more widespread, particularly involving the frontal and 
temporal cortex (Montoya et al 2006). Disruption to these areas is associated with 
impaired attention, working memory and executive functions. Executive functions 
are necessary for ability to divide or switch attention between competing tasks and 
are thought of as supervisory cognitive processes in managing the brain’s cognitive 
skills (Alvarez and Emory 2006).  
Psychomotor speed - the relationship between mental processes and movement or 
muscular activity - is impaired as are language functions (Podoll et al 1988; 
Teichmann et al 2008), problem-solving ability and visuo-perception (Salmon et al 
2001; Salmon and Heindel 1998). Planning and organising daily activities become 
problematic and thinking is increasingly rigid and inflexible so that the person is 
easily ‘stuck’ continuously rehearsing a thought or a task (Aubeeluck and Wilson 
2008) and it becomes difficult to accept changes to routine (Pollard 2008). Problems 
with speech and language result from motor disorder and also from difficulty in 
organising retrieval of information from semantic memory. People with HD tend not 
to initiate conversation and prefer to use short phrases or single words when spoken 
to and there may be long silences prior to a response to a question (Aubeeluck and 
Wilson 2008; Pollard 2008). 
Memory function is impaired but this occurs later in the course of the disease process 
and is different to memory loss in dementia such as in Alzheimer’s disease (Peavy et 
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al 2010). Loss of memory function in HD is likely to be secondary to other cognitive 
deficits whereas in Azleheimer’s type dementia, memory loss features more 
prominently as a primary disease effect (Peavy et al 2010). Apathy and impulsive 
behaviour (disinhibition) can be detected in people who are positive for the HD 
genetic mutation prior to diagnosis and these initially subtle effects increase in 
relation to progression of motor disorder (Duff et al 2010) .  
Motor impairment. 
Typically the first visually noticeable signs of HD are fidgeting, twitching fingers 
and general restlessness (McNeil 2009). Involuntary jerking ‘choreic’ limb 
movements develop over time and eventually the trunk may writhe and twist. 
Although chorea is widely known as a characteristic feature of HD (Ramaswamy et 
al 2007), Phillips et al (2008) suggest that many patients do not seem to find it 
unduly problematic. Other associated movement disorders, commonly rigidity, 
dystonia and bradykinesia tend to become more prominent symptoms as chorea 
diminishes over time and are usually more disabling (Nance et al 2003).  
Despite the reports that many do not find chorea in HD greatly inconvenient Nance 
et al (2003) suggest that although many patients with HD are unaware of it, it should 
be acknowledged that some find it not only physically but also socially disabling 
(Oates et al 2006). It generally persists through all waking hours only subsiding 
during sleep and is aggravated by stress and anxiety (Rosenblatt et al 1999a&b). 
Speech deteriorates with cognitive decline, aggravating the problems of dysarthria 
(Nance et al 2003). Breathing is increasingly problematic as impaired motor control 
affects intercostal muscles and the diaphragm. Swallowing also becomes problematic 
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and in later stages of HD the most common cause of death is dysphagia leading to 
choking, aspiration or malnutrition (Nance et al 2003). 
Psychiatric problems 
Psychiatric disturbance is reported to occur frequently prior to the manifestation of 
motor or cognitive disorder in HD (Julien et al 2007). These authors found that 
depression presenting at this stage cannot be accounted for only by the natural 
concerns associated with living at risk of developing HD. Depression, anxiety, 
apathy, compulsive behaviour and psychotic episodes are among the conditions 
associated with HD (van Duijin et al 2007).  
In the past apathy has often been referred to as a psychiatric symptom in HD 
(Folstein and Folstein 1983). Thompson et al (2012) refer to apathy, irritability and 
depression associated with HD as neuropsychiatric symptoms. While their recent 
study involving neuropsychiatric assessments of 111 people with HD found that 
irritability increased only in early stages of the condition and depression occurring 
with HD did not increase at any stage, they found that apathy increased with the 
progression of HD and appears ‘intrinsically linked’ to the disease trajectory. 
Thompson et al (2012) concluded that previous studies may have underestimated 
neuropsychiatric symptoms as a problem occurring with HD.  
The risk of suicide in HD is greater than that among the general population (Novak 
and Tabrizi 2010). Paulsen et al (2005a) found that suicidal ideation among the 
participants with the HD genetic mutation was experienced most frequently at the 
time when the person was near to the threshold of being clinically diagnosed with 
HD. Depression and impulsivity are reported as risk factors associated with suicide 
in HD (Craufurd and Snowden 2002). However, Paulsen et al (2005a) suggest that 
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suicidal thoughts in HD can occur without depression and can sometimes be 
considered a rational response to having the condition.  
Stigma 
Difficulty in determining the prevalence of HD is attributed by Rawlins (2010) to a 
tendency within many families to avoid acknowledging symptoms or the presence of 
HD due to the stigma associated with the disease, which led to significantly lower 
estimates of prevalence in the past than likely to be true. In support of this proposed 
explanation, Rawlins (2010) cited a graphic historical account by Wexler (2010) 
which reports a number of specific examples of social stigma experienced by 
families affected by HD.  
1.5 Epidemiology 
Prevalence 
Accurate and up-to-date figures of the prevalence of Huntington’s disease from 
reliable sources do not appear to be available. Harper (1992) calculated estimates 
using population surveys and analysis of death rates and concluded that the 
prevalence of HD in North and South European countries is somewhere between 
four and eight per 100,000 population.  Harper (1992) also noted differences 
internationally and suggested a similarly high occurrence in some Asian regions and 
in India but lower prevalence in Finland and Japan.   
Based on a UK population of over 63,000,000 (Office of National Statistics (ONS) 
2013) Harper’s (1992) European estimate would suggest that there are likely to be 
between 2,500 and 5000 people in the United Kingdom (UK) with a confirmed HD 
diagnosis. In 2002 Harper narrowed this estimate of prevalence in the UK to 6-7 per 
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100,000 population (Harper 2002) and this would equate to between 3600 and 4200 
in a 63,000,000 UK population. More recently Rawlins (2010) challenged this and 
basing his calculations on numbers registered with the Huntington’s Disease 
Association and claimed that the UK prevalence might well be in excess of 12.4 per 
100,000. Hoppitt et al (2010) accessed a primary care database holding data on seven 
million patients registered at 479 GP practices and calculated a prevalence of HD of 
between 5.96 and 6.54 per 100,000. They suggested that if patients with unspecified 
chorea and patients undiagnosed with a family history of HD were taken into 
account a prevalence of 10 per 100,000 population seemed a reasonable maximum 
estimate. Hoppitt et al (2010) stated that the higher figure proposed by Rawlins 
(2010) needed further support.  
Loy et al (2010) report that their experience in clinics in New South Wales fits with 
Rawlins’s suggestion of increasing HD prevalence in the UK and they offer 
additional reasons to that put forward by Rawlins. They state that ‘the baby boomers’ 
are now in their 50’s and 60’s; the age of peak HD prevalence. They also state that 
they continue to encounter new patients with no family history of HD and cite the 
claim by Ramos-Arroyo et al (2005) that 4% of HD cases are due to new mutations 
(i.e. are not inherited).  
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Fig 1.1 presents a comparison of estimates of the prevalence of HD with Hoppit et 
al’s (2010) figure of 10 per 100,000 population appearing to mediate between 
extremes, arguably making suggestions of 6,000 people in Britain diagnosed with 
HD realistic. However, the debate seems set to continue, with Sackley et al (2011) 
concluding that while evidence to support Rawlins’ estimate may be lacking, the true 
figure may well be much higher than has been demonstrated thus far.  
Movement disorder 
According to Kremer (2002) chorea occurs in 90% of cases of HD and Louis et al 
(1999) cited two neurologists who reviewed video-tapes of 42 people with HD and 
found that 95% had dystonia of differing severity. For seven (16.7%) of these 
individuals, the dystonia was found to be severe and constant while 24 (nearly 60%) 
were troubled by this in at least one body area more than half of the time. A later 
paper involving 127 patients suggested that for around 12% of the same subjects, 
dystonia was the predominant HD symptom (Louis et al 2000). 
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Fig 1.2 shows that while chorea is the most noted symptom of HD (Ramaswamy et 
al 2007), dystonia is slightly more prevalent in people with HD and is more 
physically disabling (Louis et al 2000).    
 
 
Fig 1.2 Prevalence of movement disorder in people with HD by type, severity 
and predominance, based on studies cited above. 
 
Psychiatric problems 
In a survey of over 4000 carriers of the HD genetic mutation 17.5% reported 
experiencing suicidal thoughts at the time of the survey and 10% had made at least 
one suicide attempt previously (Paulsen et al 2005b). It is difficult to state the 
proportion of people with confirmed HD affected by psychiatric problems with any 
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certainty. Estimates range from between around one third (Cummings 1995) to three 
quarters (Watt and Seller 1993).  These estimates are depicted in Fig 1.3. 
 
1.6 Genetic Inheritance 
The dominant pattern of inheritance in HD means that a person with one mutated HD 
gene will develop HD at some time in life providing she or he does not die earlier of 
some other cause. This is the case despite having one normal copy of the gene in 
nearly all cases. Newly conceived offspring inherit one allele (form of the gene) 
from each parent. Assuming that a partner of a person with this HD mutation has two 
normal alleles, a child of this couple will definitely possess one normal allele coming 
from the mutation-free parent. From the affected parent, the child may have inherited 
the normal copy or the mutated copy, hence the 50% risk. 
HD is described as a single-gene disorder (e.g. Chial 2008; Hormozian et al 2004) 
yet modifying factors are known to play a part in determining the age of onset and 
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the pathogenic process (Swami et al 2009). People with between 27-35 CAG repeats 
on the HD gene (IT15) are said to be within a ‘high normal’ range (Hendricks et al 
2009) and no-one within that range has had a confirmed diagnosis of HD. Yet some 
fathers but not mothers within that range may pass on a penetrant HD genetic 
mutation (more than 40 CAG repeats) to offspring and this means that anyone with 
more than 40 repeats will develop HD at some time in life unless they die of some 
other cause before onset. That is, the expanded gene is fully (100%) penetrant. It 
should be added that despite the established association between higher numbers of 
CAG repeats and earlier HD onset this is merely a trend. Age of onset cannot be 
predicted on the basis of the length of an individual’s CAG count (Squtieri et al 
2009). It seems fair to conclude that a description of HD as a single gene disorder 
may understate the complexity of factors associated with inheritance.  
Predictive testing for HD has been available since 1987 following the identification 
of a genetic marker on the short arm of chromosome four (Creighton et al 2003). The 
linkage test depended on samples from various family members to maximise the 
likelihood of up to 95% accuracy. The Hereditary Disease Foundation (1994) 
reported that many people who wished to be tested experienced difficulty in 
recruiting family members to take part leading to lower confidence in test results or 
to the procedure becoming a non-feasible option. The HD genetic mutation was 
identified in March 1993, a decade after the genetic marker leading to the 
development of a near to 100% accurate genetic test available in the UK from late 
1993 (Harper et al 2000). Most tests in the UK are provided with formal structured 
counselling based on international guidelines (Tibben 2006) at Clinical Genetics 
Departments within the National Health Service. The test can inform people who are 
at risk of HD whether they have the mutation or not. For people who have symptoms 
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akin to those associated with HD the test can rule out the condition or provide 
confirmation of the diagnosis. Prenatal testing can also determine whether an unborn 
child has the genetic mutation for HD (Wolff 1996).  
Decisions about whether to be tested for HD are complex and some of the reasons 
for agreeing to the testing for HD include the wish to reduce anxiety associated with 
uncertainty concerning risk status and to aid decisions about family planning. 
Reasons for turning down the offer of testing for HD might include fear concerning 
loss of health insurance or mortgage opportunities or of confirmation of the presence 
of the mutated gene and its future consequences. Due to the complexity surrounding 
the choice, family members tend to feel strongly about whether or not individuals 
should be tested and often disagree (Klitzman et al 2007).  
1.7 Impact on individuals and families  
Families affected by HD are faced with many challenging dilemmas. For example 
they may have to make decisions such as: who will care for sick family members; 
how and when to tell children about their HD risk status; whether or not to have a 
genetic test; is it useful to be prescribed a particular medication; whether to 
participate in a research study; whether to have a tube inserted into the stomach 
when it is no longer possible to swallow safely; or to donate one’s brain for research 
or education. Choices may place a heavy sense of responsibility onto people already 
struggling to cope with daily activities. 
People diagnosed with HD could face losses such as job prospects and may 
experience loss of control in the form of other people having to manage their 
finances, driving, etc. Family members may also have to manage unusual or 
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sometimes aggressive behaviour from the person with HD who may depend on their 
assistance to get to the toilet, have a bath, eat or dress.    
The complexity of these aspects of the impact of HD on the diagnosed person and 
family members, friends and caregivers are outlined in numerous texts (e.g. 
Aubeeluck and Wilson 2008; Adam and Jankovic, 2008; and Lechich et al 2008). 
The diagnostic label ‘Huntington’s disease’ cannot adequately capture this 
complexity and the particular ways that different individuals and families experience 
the impact of the condition as is true of any other medical diagnostic label.         
Recognising this problem, the World Health Organisation (WHO 2001) promotes 
consideration of the impact of disability on individuals and their families in terms of 
the International Classification of Functioning (ICF). This framework encourages 
health professionals to take into account the impact of the health condition on body 
functioning and body structures, activities and social participation. Although the 
model was developed for the purpose of classifying conditions it is helpful here 
towards contemplating the broad impact of HD on individuals and families as HD 
presents families with complex problems in all of the depicted areas.  
Fig 1.4a illustrates factors that can contribute to a person’s functioning. Tomey and 
Sowers (2009) highlight the inadequacy of attempting to appreciate the impact of 
physical functioning without context. Environmental, social and service provision 
factors tend to be adapted to compensate when functioning is compromised (Tomey 
and Sowers 2009). For example medication, handrails, a hearing aid or adapted 
transport services may prevent a personal function limitation becoming disabling.  
21 
 
Figure 1.4b demonstrates the interactive relationship between the health condition 
(HD) and environmental and personal factors on body function and structure, 
activities and participation (as explained in the introduction).  
Fig 1.4 A &B: The WHO ICF Framework (WHO 2001). 
A:  
 
B: 
 
Source: WHO,  http://www.who.int/classifications/icf/en/  P18, Reproduced with permission.  
The method selected in this thesis to examine what helps people with HD live with 
their condition needs to be capable of facilitating all of ICF components.  The 
justification (in chapter two) for choosing a method known as ‘concept mapping’ 
will demonstrate that this is an inclusive rather than consensus design.  The concept 
mapping method engages participants (who in this case will be people with HD, 
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caregivers and health professionals) in generating statements intended to convey 
factors that are helpful in living with HD. Rather than seek a consensus about what 
factors should be considered concept mapping will ensure that any factor considered 
relevant even by one participant will be represented. In the discussion section at the 
end of this thesis the extent to which the method has enabled people to raise a 
sufficiently broad range of factors will be considered. The ICF is intended as a 
framework capable of capturing the whole impact of a health condition and so a 
successful concept map would be expected to contain some items (statements) 
relating to each of the components of the model.  
1.8  Treatment 
While a range of available interventions are prescribed to improve symptoms 
associated with HD, a systematic review designed to establish whether any 
pharmaceutical treatments have been shown to have consistent control of HD 
symptoms concluded that only one medication was shown to be effective (Mestre et 
al 2009a). The drug ‘Tetrabenazine’ showed clear efficacy for the control of chorea, 
but was reported to be associated with serious adverse effects. Clear effectiveness 
was not demonstrated in trials of any other medications for HD and Mestre et al 
(2009a) called for well-designed randomised controlled trials in this area.  
In another systematic review, Mestre et al (2009b) found that no pharmacological 
treatment was effective as a disease-modifying therapy for HD. Mestre and Ferriera 
(2012) undertook a further review using a systematic approach and found that while 
it is encouraging that many newly developed interventions have been the subject of 
recent and current clinical trials, Tetrabenazine remains the only treatment for HD 
(for chorea only) with efficacy supported by strong clinical evidence. Mestre and 
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Ferriera (2012) suggest that the clinical management of HD needs to rely on 
recommended good practice based on low level evidence and on efficacy 
demonstrated in trials of therapeutic interventions for other disorders in which 
people who are affected may experience similar symptoms and disease impact.   
Experiences of living with HD and with other similar disorders are considered below 
as are the responses to specific problems that have been made by health care 
professionals, caregivers and people directly affected by HD. This is intended to 
provide context for the research question that this thesis will investigate.  
This thesis seeks to add to knowledge and understanding of perspectives of those 
directly affected by HD and their family caregivers and of health professionals with 
experience of caring for people with HD, about what helps people to live with the 
condition. In the absence of a cure it is important to work to assist those who provide 
appropriate treatment, care and services and those who decide the focus for research 
examining effectiveness of interventions for HD to do so with an appreciation of 
priorities from these perspectives. The purpose of the thesis is to contribute to such 
understanding.  
To this end the next chapter examines experiences of people with HD and other 
similar conditions and responses to these experiences.  A rationale for the choice of 
study method- concept mapping- aimed at establishing perspectives of what helps 
people live with HD is provided. Chapter Three explains the methodology, Chapter 
Four presents results and the final chapter discusses the implications of the findings.  
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Chapter Two 
Literature review and rationale for the study 
 
This review of the literature aims to describe the patient experience of Huntington’s 
disease (HD) and also the responses of patients, carers and healthcare professionals 
to these challenges. Evidence concerning the subjective experience of living with 
HD is limited and so it is necessary to consider studies that have investigated patient 
perspectives of living with other diseases that share some features with HD such as 
movement disorders, mental health problems or deteriorating cognition. The 
literature shows that problems identified in studies concerned with subjective 
experiences of people with HD and their family caregivers also feature in 
investigations of experiences of people with other degenerative neurological 
conditions such as Alzheimer’s disease (AD) and other forms of dementia, 
Parkinson’s disease (PD) and multiple sclerosis (MS). Some experiences of people 
who live with impairment resulting from stroke may also be relevant. In the context 
of movement disorder for example, Quinn et al (2013) suggest that while the 
symptoms of Parkinson’s disease and Huntington’s disease are unique the two 
conditions do share aspects that have relevance to rehabilitation. 
The review was informed by a search of literature obtained from AMED, CINAHL, 
MEDLINE, EMBASE, PsychINFO and Cochrane Library databases. Each database 
was searched from inception using the keywords: Huntington’s Disease; 
Neurological; Parkinson’s; Alzheimer’s; Multiple Sclerosis; Stroke; Dementia; Care; 
Carer; Caregiver; Impact; Quality of Life; Experience; Intervention; Treatment.  
Google Scholar® and Google® were also searched, as were the ‘Huntington’s 
Disease Association’ and ‘European Huntington’s Disease Network’ websites. 
Presentations and informal discussion with experts in the field of research in 
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interventions for HD at the following conference proceedings were also part of the 
search strategy:  
 The European Huntington’s Disease Network 6th EHDN Plenary Meeting: 
Roadmap for Effective Therapies in Huntington’s Disease, Prague, 
September 2010. 
 Movement Disorders Symposium, Lund University, Sweden, March 2011. 
 Movement Disorders Society 16th International Congress, Dublin June 2012. 
Papers were examined if the focus was considerd to be concerned with the 
experience of living with a neurological disorder or with patient, caregiver or health 
professional perspectives about what helps people live with these conditions.   
2.1 Responses to experiences of HD diagnosis and genetic testing.  
 
The abnormality that constitutes the genetic basis for HD is an excessive number of 
repeats of the trinucleotides CAG on the short arm of chromosome four. However 
despite the knowledge that more than 40 repetitions cause HD (Novak and Tabrizi 
2010) and more rapid progression is associated with higher repeat numbers, the date 
of onset and the rate of deterioration for individuals cannot be predicted (Paulsen 
2011).  
Erwin et al (2010) reported a high level of perceived stigma and discrimination 
associated with a family history of or genetic testing for HD (46% of 433 
participants in the USA, Canada, Australia) regarding insurance, employment and 
relationships. Anxiety about discrimination and stigma resulting from a diagnosis of 
HD was reported to be a greater problem than the actual negative experiences. The 
extent to which this may deter people from seeking a diagnosis is not known (Erwin 
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et al 2010). Asscher and Koops (2010) defend ‘the right not to know about 
Huntington’s’ in response to a Dutch government decision to prevent couples from 
having preimplantation genetic diagnosis (PGD) without the at-risk parent knowing 
their own HD risk status. Medically it is perfectly possible to select an embryo 
without sharing the diagnosis (whether positive or negative) with the at-risk parent. 
Asscher and Koops (2010) suggest that the importance of the right not to have the 
burdensome knowledge is greatly underestimated. However Novak and Tabrizi 
(2010) report that a HD positive diagnosis can be a relief for some people as this 
removes uncertainty which can be harder to live with than coming to terms with the 
reality.  
Currently diagnosis is founded on neurological assessment confirming associated 
movement disorder in conjunction with a positive genetic test for the HD mutation 
(Paulsen 2011). A positive genetic test in the absence of clinically identifiable motor 
signs indicates that the person is in what is termed a prodromal phase (Paulsen 2011: 
p2). This situation is felt to be unsatisfactory given that the presence of detrimental 
cognitive effects has been established as evident at least 15 years prior to detection 
of motor symptoms (Paulsen et al 2006, Paulsen et al 2007). Revision of the 
diagnostic criteria involving reliable and valid cognitive measures is advocated 
(Paulsen 2011).  
A number of studies focussed on fear and uncertainty related to HD (e.g. Semaka et 
al, 2012; Huniche, 2009; Dufrasne et al, 2011), and this tends to be associated with 
the hereditary nature of the disorder and to problems related to decisions regarding 
whether to undergo predictive testing for HD. Eddy et al (2011) found evidence of 
fear and uncertainty specifically relating to predictive or confirmatory testing.  
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While access to knowledge of genetic status regarding HD can be considered a right 
for at-risk individuals so can the choice not to know (Taylor 2004) and it is argued 
that benefits in terms of relief from uncertainty and informed life options and 
planning override potential disadvantages (Codori and Brandt 1994). From analyses 
of records to date, while genetic testing raises a variety of practical, social and 
ethical problems requiring skilful tact and experience from health and social 
professionals to work with families and individuals to overcome, there is no 
evidence that providing the information has resulted in harm and none to support the 
view that receipt of certain results leads to depression (Broadstock et al 2000, Meiser 
and Dunn 2000, Nanetti et al 2012). This is supported by studies using qualitative 
interview and also self- report questionnaire approaches (e.g. Pakenham et al 2004, 
Rouwer-Dudokdewpith et al 2004).  
Problems with adjusting to the predictive test results and a person’s psychological 
wellbeing appear from this body of evidence to relate to emotional state prior to 
being tested and not to the result received.  
That decision-making is complex (as is the impact of genetic testing on individuals, 
couples and families) seems well established but the evidence for predictive factors 
associated with responses to receiving test results is not strong. There is a need for 
further good quality research in the areas identified above on which to base 
continued revision of international protocol, and the need for counsellors to be well 
trained and experienced, flexible and aware of the complexities raised in the 
accumulated body of evidence so far is called for (Cordier et al 2012). Meanwhile 
new guidance for predictive testing for HD concurs with the view that most 
individuals who undergo the process do not experience negative psychological 
consequences but emphasise the importance of identifying those who may be 
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vulnerable and ensuring adequate counselling is offered and provided (MacLeod et 
al 2013).  
2.2 Responses to experiences of fear and uncertainty regarding disease 
progression 
Eddy et al (2011) reported that the experience of fear in people with HD is reduced 
as the disease progresses. They suggest that changes to fear responses may explain 
increased risk-taking behaviour with potential detrimental personal and social 
consequences. However the method involved subjective ratings of emotional 
responses to pictures and scenarios and as the authors acknowledge, ability to 
appraise pictures and scenarios may have been a confounding factor. Rating fear 
responses to these stimuli may be very different to fear experienced as a result of 
living with a condition with uncertain onset and rate of progression. This literature 
review has found no recent evidence of fear and uncertainty associated with living 
with HD other than that specifically relating to predictive or confirmatory testing but 
that is not to say these emotions are not part of the experience of living with the 
condition. Wexler (1979) describes fears concerning HD symptoms among at-risk 
interviewees and reports a particular dread of losing continence and the ‘horror’ of 
anticipated body changes. Wexler summarises the interviews in terms of ‘fears, 
griefs and hopes of persons coping with an unusual life situation’ (Wexler 1979: 
pp199-200). Since that time, the problem of uncertainty and fear in HD seems un-
investigated but in other degenerative neurological conditions the aspect has been 
researched (Cole and Vaughan 2005, Steeman et al 2007), and there is arguably no 
reason to doubt the relevance of findings across diagnoses.  
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Fear of consequences of changes due to disease manifestation and difficulty living 
with uncertainty are reported to be common experience in PD (Cole and Vaughan, 
2005) and in dementia (Steeman et al 2007). Fear of symptom exacerbation and 
deterioration and uncertainty regarding the future are also major concerns among 
people with multiple sclerosis (MS) (McNulty et al 2004).  
It seems reasonable to assume that similar experiences of fear and uncertainty are 
problematic for people with HD and currently there appears to be a lack of literature 
evaluating any response to this by healthcare professionals, by informal family 
caregivers or indeed by people with HD themselves, and hence this may be an 
important area for future exploration.   
2.3 Responses to experiences of loss associated with neurological disease 
In a recent qualitative study people with HD and family members expressed 
impaired communication in terms of a loss, which was perceived to negatively 
impact on meaningful social participation (Hartelius et al 2010). Other losses 
experienced by families affected by HD have been expressed as loss of personality, 
loss of physical aptitude in affected parents and loss of the usual family structure 
(Smolina  2007). People with PD have also been shown to perceive the impact of the 
condition in terms of losses (Charlton and Barrow  2002). In a qualitative study, 
eight individuals expressed their experience of the impact of having PD in terms of 
the loss of their own personal identity and the loss of the ability to function socially, 
physically and mentally (Charlton and Barrow 2002). Similarly, ‘loss of self’ or 
‘personal identity’ is commonly expressed among people with Alzheimer’s disease 
(AD) (McRae 2011). Seeing the impact of disease as a series of losses was a core 
finding of a recent review of 43 qualitative studies exploring subjective experiences 
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of living with dementia (Steeman et al 2007). These losses were said to threaten 
perceived security, autonomy and of being a useful or meaningful society member. 
Fear of further losses in future, reducing the ability to retain the personal identity, or 
sense of self, were common across the diagnoses in these studies (Charlton and 
Barrow 2002; McRae 2011; Steeman et al 2007).  
A large body of research concerned with older people living alone suggests that 
chronic disease is often experienced in terms of similar losses to those expressed 
above, indicating that the problem is not peculiar to neurological disease but is more 
generic (Haslbeck et al 2012).  This systematic review found that it is widely held 
that these perceived losses can be best compensated for by maintaining control and 
independence and that support towards self-help and self–management can play an 
important role in achieving this (Haslbeck et al 2012).  
The view seems to be shared in the context of neurological disorders and specifically 
HD. Helder et al (2002) found illness perceptions and coping mechanisms adopted 
by people with HD to be predictive of wellbeing in HD. De Boer et al (2007) 
suggested that their research showed that understanding of the way people with 
dementia cope should be encouraged among professionals and service providers as 
the knowledge can help to tailor services and care more appropriately. De Boer et al 
(2007) found that contrary to widely held perceptions people with dementia 
passively deteriorate and are helpless to influence the impact of the disease, coping 
mechanisms are used to confront the effects. De Boer et al (2007) recognised 
emotion-focussed and problem-focussed (considered more effective) mechanisms 
being employed and concluded that the finding emphasised the value of teaching 
effective coping strategies. Given the similar conclusions of Helder et al (2002) 
concerning HD the importance of coping mechanisms in living with neurological 
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decline is arguably not disease-specific as far as implications for service and care 
provision are concerned.  
People with HD, their caregivers and health professionals have reported benefits of 
involvement in self-help support groups in coping with living with the disorder 
(Dawson et al 2004). Self-help group membership, attendance and participation are 
considered a factor related to how well people with neurological disorders cope with 
and adjust to living with the condition. With regard to PD, Charlton and Barrow 
(2002) found that self-help group attendees used different coping strategies to those 
not involved in groups, with group members tending to incorporate PD into their 
lives, embracing the condition, while non-attendees were more likely to cope by 
striving for a ‘normal life’. Ways of coping with PD included adopting a positive 
attitude, maintaining a fighting spirit, avoiding thinking or talking about PD, having 
hope, accepting the disease, and keeping up active social engagement (Charlton and 
Barrow 2002). For non-group attendees, equipment designed to offer practical help 
to overcome physical problems were more likely to be perceived negatively as a 
landmark in their deterioration. Schwartz (1999) found that attending a self-help 
group improved external locus of control for people with MS, although this did not 
improve psychosocial role performance or wellbeing. Those participants in the study 
with affective symptoms of MS benefitted most from peer group support. However, 
Schwartz (1999) concluded that teaching coping skills was more effective than peer 
group involvement.  
Authors of a pilot study examining the feasibility of a patient education programme 
for people with HD based on a programme developed for people with PD reported 
that the self-management approach inherent in the programme can improve quality 
of life in both conditions (Campo et al, 2012). The concept of self-management 
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which involves providing support for people with long-term health conditions to 
manage their symptoms and treatment and the physical, social and psychological 
impact of chronic disease (Department of Health (DoH) 2005a) has become central 
to health policy not only in the UK but also internationally (Coster and Norman 
2009). However, Battersby et al (2010) suggest that while the need to empower 
people with chronic conditions is undisputed, clear information to help professionals 
to decide specifically how to improve patients’ abilities to self-manage is lacking.  
Schneider and Young (2010) concluded that professionals should see their role as 
helping people with MS towards self-management and avoid a tendency to ‘take 
over’. Jones et al (2013) emphasise the importance of self-management in the long-
term care of people post-stroke, and identify a lack of research in this area as 
problematic. Jones et al (2012) report that despite increasing research activity 
focussed on self-management programmes in stroke care many aspects remain 
unexplored and they call for collaboration in this area across chronic diagnoses. De 
Boer et al (2007) also emphasise the importance of working to encourage and 
facilitate self-management as opposed to giving care that amounts to ‘taking over’, 
in their a review of 50 papers concerned with the experiences of people with 
dementia.  
Building on evidence supporting enhanced self-management through home-based 
exercise programmes in stroke (Olney et al 2006) and PD (Lun et al 2005), Quinn et 
al (2010) concluded from a qualitative study investigating client and patient views 
that regular unsupervised exercise may help to meet therapeutic physical outcomes 
among people with HD as well as people with PD. As an approach to facilitating this 
Khalil et al (2012) developed an exercise programme on DVD for home use and 
investigated the experience of people with HD in carrying out the programme 
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(unsupervised) through exercise diaries and semi-structured interviews. Caregiver 
commitment was found to be a key factor in adherence to the programme.  
A self-management rehabilitation programme for people with PD included taught 
mobility and speech exercises, activities of living training on specific tasks, for 
example turning in bed and dressing, and group discussions on a range of topics such 
as talking on the phone and preventing falls (Tickle-Degnen et al 2010). Tickle-
Degan et al (2010) concluded from their randomised controlled trial (n=115) that 
whereas self-management programmes tend to be provided for people after 
significant physical deterioration, greater benefit can result from engagement with 
the activities in early to middle PD stages.   
A novel internet-based programme aimed at facilitating cognitive behaviour therapy-
based self-management for fatigue occurring with multiple sclerosis was reported to 
have demonstrated significant improvement in anxiety and depression contributing 
to fatigue, in a small preliminary trial (Moss-Morris et al 2012). Qualitative data 
indicated that most participants found the programme acceptable and helpful in that 
they came to understand their fatigue better and to find ways to control it.  
Mountain and Craig (2012) identified twelve topic areas for self-help programmes 
based on qualitative interviews with five people with dementia and five carers. 
Having help to understand and rethink dementia, living with dementia (by 
establishing routines and learning memory strategies) and keeping mentally well (by 
recognising and overcoming depression and learning strategies to manage anger and 
anxiety) were among priorities for participants.  
Techniques to help self-manage frustration and fatigue, pain and isolation, 
exercising, communicating, use of medications, nutrition and how to evaluate new 
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treatments are taught as part of a ‘chronic disease self-management programme’ 
(Hirsch et al 2011). Sessions involve participants in developing their own action 
plans through discussions and problem-solving activities. Relevance of this approach 
to professionals engaged with people with neurological conditions more broadly has 
been suggested (Whitehead 2011).  
The body of literature concerned with self-management in neurological disease and 
specifically HD is relatively new and limited but the growing interest in 
investigating strategies to empower this group is encouraging. Training in activity of 
living tasks, strategies to limit the impact of symptoms, innovative exercise 
programmes and use of information technology resources such as internet and DVD 
to facilitate unsupervised therapeutic activity seem promising avenues for 
exploration.  
A view that researchers and professionals should seek to understand and consider 
patient and family member perspectives in striving to alleviate the impact of disease 
experienced as losses is well represented in research focussing on HD (e.g. Ho and 
Hocaoglu 2011; Aubeeluck and Buchannan 2007). De Boer et al (2007) make the 
same point with regard to care for people with dementia. Kouzoupis et al (2010) 
reviewed literature to consider a psychosocial perspective of the impact of multiple 
sclerosis (MS) and suggest that a narrow, medical view of the condition and of 
chronic disease generally is often taken by professionals who frequently ignore 
family members and leave them to feel isolated. They stressed the importance of 
including family caregiver perceptions of the impact of chronic illness.    
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2.4 Responses to the experience of motor symptoms associated with HD 
HD presents as a complex movement disorder characterised by chorea coexisting 
with bradykinesia (Thompson et al 1988). More recently Gudesblatt and Tarsy 
(2011) have suggested involuntary movement as the most common initial symptom 
of HD and ‘restlessness’ as the most visible motor sign. As the disease progresses 
motor impairment becomes increasingly proximal. Dystonia, postural imbalance and 
tics as well as oculomotor problems are common features but chorea is more 
noticeable to casual onlookers than more subtle but potentially disabling effects 
(Gudesblatt and Tarsey, 2011). It is reported that many people with HD are 
untroubled by chorea personally and that the tendency for health professionals and 
caregivers to wish the symptom to be treated can be misplaced (e.g. Phillips et al 
2008; Thompson 2009 in Stevens et al 2009, p156-163). Quinn et al (2013) indicate 
that dystonia may occur in up to 90% of people with HD and share the view of 
Phillips et al (2008) that this can be more disabling than chorea.  
However Zeef et al (2011) cite examples of severe and disabling chorea and Poon et 
al (2010) report that severe chorea can cause social embarrassment, impaired ability 
to carry out activities of living and suggest that patients experience increasingly 
extensive disability as chorea becomes more pronounced. Ho and Hocaoglu (2011) 
found in a qualitative semi-structured interview study examining patient perspectives 
(n=80) that problems associated with physical function that included chorea were a 
more dominant concern in mid stages of the disease than were concerns associated 
with other identified themes such as cognition, emotion, and social aspects.  
Bradykinesia is a commonly disabling feature in HD (Phillips et al 2008) and is one 
of the cardinal motor symptoms of PD along with rigidity which is also seen in 
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advanced HD, (Quinn et al 2013), resting tremor and postural instability (Haahr et al 
2010). As is true for some people with HD patients with PD experience movement 
disorder as a predominant feature of their condition and consequently have 
difficulties with tasks such as reaching, grasping and fine motor coordination (Quinn 
et al 2013). In both conditions the motor disorder occurs in conjunction with 
psychiatric and cognitive symptoms (Quinn et al 2013). Much of the focus of Health 
Care Professional (HCP) interventions for HD is on the control of these motor 
symptoms.  
The only medication demonstrated to be consistently effective in the treatment of 
chorea is tetrabenazine (TBZ) (Huntington’s Study Group (HSG) (Tetra-HD) 2006, 
Frank et al 2008) and in the United States TBZ remains the only pharmacological 
treatment for chorea in HD approved by the Food and Drug Administration 
(Videnovic 2013). Tetrabenazine was also associated with improved clinical global 
impression scoring (HSG Tetra-HD 2006). The Huntington’s Study Group suggests 
that apprehension among physicians regarding TBZ as a drug of choice for the 
treatment in chorea in HD is due to reported serious adverse events in the treated 
group, but not in the placebo group (HSG Tetra-HD 2006). The concern may be 
unjustified: the review for this thesis found no convincing evidence to inform 
conclusions regarding the causality of these events. However some concern has been 
expressed regarding dosage where TBZ is prescribed with antidepressants such as 
Paroxetine and Fluoxetine. TBZ is metabolized by an enzyme in the body known as 
Cytochrome P4502DS (CYP2D6) and these antidepressant drugs inhibit CYP2D6 
(Suchowersky 2013). Armstrong and Miyasaki (2013) agree with Suchowersky’s 
assertion that for patients with HD taking these antidepressants a TBZ dosage should 
be reduced by 50% but add that whether this advice is adopted clinically is unknown.  
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Prior to availability of TBZ neuroleptic medications were used to reduce chorea in 
HD but as these were strongly associated with extrapyramidal effects it is argued that 
TBZ offers a substantial improvement to quality of life (Hayden et al 2009).  
There is evidence of a negative impact of chorea on quality of life whether resulting 
from HD (Carlozzi and Tulski 2013) or from other causes such as unwanted effects 
of treatment for PD (Manson et al 2012). This tends to be related to associated 
mobility impairment (Carlozzi and Tulski 2013) and social embarrassment resulting 
from chorea in HD and can be justification for treatment with TBZ (Cha 2007). This 
seems to support the view by Hayden et al (2009) of the potential for TBZ to 
improve quality of life in HD but counter concerns that TBZ may aggravate 
psychiatric symptoms including depression (Novak and Tabrizi 2010) and that 
embarrassment and social impact of chorea is often more a problem for family 
members and others than for the patient (Carlozzi and Tulski 2013) and this should 
be considered in any decision-making process about whether treatment with TBZ is 
appropriate. It should be added that a recent study found TBZ to be effective in 
reducing chorea with no increase in depression among participants who were taking 
antidepressants although the authors acknowledge the trial was small and larger trials 
are needed (Dorsey et al 2011).   
Patient satisfaction with the benefits of the drug and cost effectiveness were reported 
in a small questionnaire survey involving 23 respondents with HD, 39 with Tourettes 
syndrome and 34 with tardive dyskinesia despite reports of unwanted effects by 82% 
of participants including drowsiness (54%), slow movement (32%), restlessness 
(14%) and depression or mood change (12%) (Palao et al 2010). Generally trials of 
the effectiveness of tetrabenazine for the treatment of Huntington’s disease were 
restricted to investigating movement disorder, particularly chorea and while some 
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studies such as a recent open label withdrawal pilot project (Fekete et al 2012) 
measure broader outcomes including cognition, depression, behaviour and other 
functional scales none found in this review investigate impairment or caregiver 
outcomes. The limited body of research concerned with wider aspects of the impact 
of HD and of the effects of the only treatment for the disorder that is demonstrated as 
effective in rigourous randomised controlled trials emphasises the need for more 
studies that explore patient and caregiver and other perspectives to enhance 
understanding of subjective experiences of living with HD and of what is helpful 
towards doing so.  
Other drugs evaluated for their efficacy in treating HD were Amantadine, 
Apomorphine, Aripiprazole, Atomoxetine, Baclofen, Cannabidiol, Clozapine, 
Coenzyme Q10, Creatine, D-alpha-tocopherol, Donepezil, Ethyl-EPA, Fluoxetine, 
Idebenone, Ketamine, L-acetyl carnitine, Lamotrigine, Latrepirdine, Minocycline, 
Mixed oral unsaturated fatty acids, Modafinil, OPC-14117, Piracetam.Prodipodine, 
Remacemide, Riluzole, Rivastigmine, Sulpiride, Terguride and Tiapride. Although 
some of these drugs have shown initial promise none of the studies evaluating their 
efficacy have had sufficient numbers of participants, duration of follow-up, or 
methodological quality to ensure that the results are robust and reliable enough to be 
able to claim efficacy (Mestre and Ferreira 2012). 
The findings of some fairly recent studies offer hope for the future. The ‘HART’ 
study (n=22) (Tedroff  2010) and the ‘MermaiHD’ study (n=437) (Garcia de 
Yebenes et al 2011) have generated optimism regarding Pridopidine for improving 
motor function in HD. A trend towards improvement in affective symptoms was 
reported in a small scale study of Pridopidine (Lundin et al 2010) but none of these 
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trials have so far demonstrated significant improvement on any primary outcomes. 
The potential for Pridopidine to improve life for people with HD has yet to be 
established.  
Potential value of some medications for some HD patients cannot be ruled out. 
Apomorphine may benefit carefully selected individuals with HD (Vitale et al 2007; 
Albanese et al 1995) but the evidence for this is low.  
The conflicting findings from the various trials of effectiveness of ethyl-EPA are 
tantalising with one trial involving 316 people with HD showing no significant effect 
on motor function (Trend-HD 2008) while another smaller study involving 30 
patients with advanced HD demonstrated significant reduction in cerebral atrophy 
rate particularly in localised brain regions associated with movement disorder in HD 
(Puri et al 2008). Ethyl-EPA looks set to remain a focus for investigation.  
Zeef et al (2011) point out that so far patients included in studies of deep brain 
stimulation (DBS) for HD have been selected based on having motor problems with 
minimal emotional disturbance. This is in keeping with practice in studies of DBS 
for Parkinson’s disease where dementia and depression are excluded due to poor 
outcomes for patients with these co-morbidities (Fasano et al 2010). For this reason 
while encouraging, results cannot be generalised. Establishing DBS as a treatment 
option seems set to be a long-term future project, with some promise for a limited 
group within the HD population. 
The only study to convincingly demonstrate efficacy for neural transplantation for 
HD is that carried out in Créteil, France (Bachoud-Lévi et al 2000a & b, Bachoud-Lévi 
et al 2006). The study aims and efficacy demonstrated were concerned not only with 
movement disorder but also cognitive deterioration associated with HD. With the 
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low number in the trial and only three of five patients showing improvement, and the 
potential for bias due to the non-blinded design, as Dunnett and Rosser (2007) 
advised, cautious interpretation is appropriate even for this most rigorous of trials so 
far undertaken. As they suggest while some optimism for the future may be 
appropriate, reliability and generalisability have not been established.  
In any case it should be noted that foetal neuron transplantation, while useful in 
research seeking to establish proof of concept, can never become widely adopted as a 
treatment. The ethical ‘minefield’ of using foetal tissue aside, practical difficulties in 
supply would be insurmountable as Dunnet and Rosser point out (2007). Whether 
the future will bring to prominence embryonic stem cells, foetal neuronal precursors 
or adult stem cells is a debate beyond the scope of this review.  
Bilney et al (2003) and Quinn and Rao (2002) point out that the low-level evidence 
that exists does support the use of physiotherapy for treating balance and muscle 
strength problems and ability to carry out daily activities. Busse and Rosser (2007) 
highlight the need for valid and reliable assessment tools to aid evaluation of the 
effectiveness of rehabilitation interventions for HD. In PD a recent Cochrane 
systematic review (Tomlinson et al 2012) concluded that physiotherapy provides 
short term benefits in this disease, and that little difference was shown in treatment 
effects between a wide range of techniques. A comparable body of evidence is 
needed to evaluate similar therapeutic input for people with HD.  
One within-subjects design study (Zinzi et al, 2006) (n=40) examined the effect of a 
three-week intensive therapy programme for people with HD. The result of ‘no 
change’ between baseline and the follow-up two years later was proposed to 
demonstrate maintenance of function and motor performance. This pilot study needs 
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to be followed with a study that has a comparator group, larger numbers, uses 
independent blinded assessment and reports on whether or not people who miss 
some sessions benefit from their partial involvement in the programme.  
Conflicting results suggest that the use of ECT to treat chorea in HD cannot be 
supported (Leroi and Michalon 1998; Beale et al 1997; Lewis et al 1996). ECT is 
also discussed below in the context of treatment for psychiatric HD symptoms. 
While there are many pharmacological and non-pharmacological interventions that 
may have an important place in reducing motor symptoms in HD, evidence in 
support of this is lacking and the only treatment for which there is robust evidence- 
Tetrabenazine for chorea- does not have support for a positive effect on the wider 
impact of the symptoms on patients and their caregivers. A lack of evidence does not 
mean that interventions are not effective and therefore robust research in a range of 
therapies aimed at treating motor symptoms in HD utilising broad outcome measures 
must be supported.   
2.5 Responses to the experience of psychiatric symptoms associated with HD 
Psychiatric disorders, particularly major depressive disorder have been demonstrated 
to be a common experience among people with HD (Redeeker et al 2012). 
Uncertainty surrounds the incidence and prevalence of psychosis in HD (Crooks and 
Rickards 2012). In their data-mining study involving data sets from 998 participants, 
prevalence was 6.5% and incidence was 2.8 new cases per 100 patients per year 
(Crooks and Rickards 2012). However these authors concluded that further 
validation of the measure used (UHDRS) to identify hallucinations and delusions is 
necessary before these results can be considered meaningful.  
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Fifty two consecutive people with HD recruited from a clinical research programme 
at two US locations were interviewed using standardised measures of psychological 
impairment (Paulsen et al 2001). In 98% neuropsychiatric symptoms were identified 
with dysphoria, agitation, irritability, apathy and anxiety most prominent.   
Estimates of the prevalence of depression in people with HD vary from 9% to 63% 
and several sources suggest an occurrence of nearly 50% (Paulsen et al 2005b). De 
Souza et al (2010) highlight difficulties in diagnosing depression in HD because 
indicators such as weight loss, sleep problems, loss of concentration and fatigue are 
inherent in HD. This potentially leads to incorrect diagnosis of depression in people 
who are showing the first signs of HD. Additionally the diagnosis of depression can 
be missed as a co-morbidity of HD where the symptoms of depression are readily 
dismissed as core features of HD. Ho et al (2004) identify depression in HD as 
associated with impaired quality of life and Paulsen et al (2005)b cite evidence to 
suggest depression and other psychiatric symptoms can be the presenting complaint 
and may be present up to 20 years prior to a diagnosis of HD.  
The experience of people with HD regarding psychiatric symptoms is arguably 
similar to that of people with other degenerative neurological conditions. In a study 
comparing the frequency of neuropsychiatric symptoms in people with PD with and 
without dementia to patients with dementia with Lewy bodies (DLB), delusions and 
hallucinations occurred in all three groups, most commonly in DLB, and least in PD 
without dementia (Aarsland et al 2001). In all three groups the presentation of these 
symptoms was similar. The negative impact of psychiatric symptoms on the quality 
of life of people with PD is well documented (e.g. Barone et al 2009, Gómez-
Esteban et al 2011). Anxiety disorders are reportedly common but under-investigated 
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in PD and in a case-series study (n=79) a 14% occurrence of comorbid anxiety and 
depression was observed (Dissanayaka et al 2010). Depression is said to affect up to 
50% of people with PD (similar to estimates of depression in HD) and to be 
associated with poor outcomes for individuals and their families (Menza et al 2009). 
One study found a higher prevalence of PD among hospital patients who had 
depression than among those without depression (Miu and Chan 2011). They 
demonstrated that depression was associated with a higher prevalence of functional 
decline and mortality. Depression in PD is regarded as one of the most disabling 
aspects of PD (Hemmerle et al 2012).  
The prevalence of anxiety and depression in association with HD is greater than 
among the general population (Dahl et al 2009). This has also been found in other 
neurological conditions such as MS and PD. Burns et al (2013) identified an 
association between exacerbations of MS (both pseudo and confirmed) and anxiety 
and depression. Giordano et al (2011) noted an association between anxiety and 
depression and found anxiety to be prevalent and persistent during the period leading 
up to and around the time of diagnosis in MS patients. Levels of anxiety were not 
influenced by the diagnostic result and Giordano et al (2011) concluded that 
recognition and intervention for anxiety in the early period may reduce the likelihood 
of long term depression. Depression is established as a common complication of PD 
(Reijnders et al 2008) and anxiety in PD is reported to be under-recognised and 
undertreated (Pontone et al 2009). 
In a systematic review Mitchell et al (2010) found that across a range of neurological 
conditions including HD, PD, MS, stroke, epilepsy, head injury and motor neuron 
disease, cognitive impairment often occurs and is frequently overlooked by 
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clinicians and suggest that earlier recognition might reduce the negative impact of 
disease on quality of life. Mitchell et al (2010) concluded that in spite of awareness 
of the importance of profound cognitive decline amounting to dementia the broad 
spectrum of impairment including subclinical, subtle cognitive changes are 
increasingly becoming recognised as significant factors affecting quality of life in all 
of these diagnoses.   
An association between behaviour problems in HD and earlier admission to 
residential care has been demonstrated (Fisher et al 2012). In a considerable minority 
of people with PD challenging behaviour poses problems for caregivers (Leeman et 
al 2012). A systematic review and meta-analysis investigating the prevalence of 
behavioural problems in multiple sclerosis concluded that behaviours such as 
aggression, apathy, euphoria and lack of insight are problematic and under-
recognised in this condition (Rosti-Otajarvi and Hämäläinen 2013). Behaviours that 
lead to distress among family members frequently occur in dementia suggesting that 
caregivers would benefit if these symptoms were targeted and addressed (Gitlin et al 
2010).  
It is clear then that psychiatric symptoms and related problems with management of 
behaviour cause distress and disability across diagnoses but while hallucinations and 
delusions have been found to be the strongest predictors of admission to nursing 
homes in PD (Aarsland et al 2000; Goetz and Stebbins 1993), physical factors have 
been claimed as more commonly the reason for institutionalization in HD 
(Rosenblatt et al 2011). Fisher et al (2012) dispute this however, and refer to 
potential bias acknowledged by Rosenblatt et al relating to high prevalence of 
psychosocial and behavioural problems among participants lost to follow-up as a 
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possible explanation for underestimating the relationship between psychiatric 
problems in HD and institutionalisation. Reduction or delay in institution admissions 
associated with community interventions to improve psychosocial and behavioural 
factors such as counselling for carers, behaviour management strategies and case 
management has been demonstrated with regard to dementia (Brodaty et al 2003, 
Mittelman et al 2006) and it is suggested that similar approaches could alleviate 
caregiver duress and avoid unnecessary admissions to long term care in HD (Fisher 
et al 2012).  
Currently there appears to be no evidence to support physicians looking for effective 
pharmacological management strategies for psychosis in HD (Mestre and Ferreira 
2012). One case study (n=1) evaluated cognitive behaviour therapy (CBT) for 
effectiveness in treating depression and anxiety relating to a positive genetic test for 
HD (Silver 2003). The subjectivity within the discussion of reported benefit for this 
individual does not indicate that CBT is not effective for HD, but currently there 
appears to be no substantial evidence in support.  
The small number of case studies examining the effect of electroconvulsive therapy 
(ECT) for HD (Leroi and Michalon 1998; Beale et al 1997; Lewis et al 1996) are 
accounts of despair demonstrated by some harrowing suicide attempts. Although the 
impact of HD is frequently described as devastating, these extreme cases are 
fortunately atypical. ECT has been seen as an option worth trying despite uncertainty 
regarding effectiveness. The resulting evidence is little more than anecdotal but 
appears to be the best available. The generally favourable reports regarding treatment 
for depression in HD are likely to be valuable support for discussion in cases where 
every other attempt to relieve despair have failed.  
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There is no good quality evidence to help inform clinical teams of the best 
pharmacological option for the treatment of anxiety and depression in HD. 
Latrepirdine shows some promise with regard to improved cognition on the mini 
mental state examination, although no benefit compared to placebo was 
demonstrated on the UHDRS or the Alzheimer’s Disease Assessment Scale-
cognitive subscale (ADAS-cog) (Kieburtz et al 2010).  
One randomised controlled study examined the effects of multisensory stimulation 
environment (MSE) on rehabilitation, behaviour and mood disturbance and motor 
assessment (Leng et al 2003). The small study (n=10) found an unsustained benefit 
of improved mood and behaviour in the treatment group. 
Three studies sought to explore or evaluate music therapy as a treatment for HD 
(Magee 1995; Davis and Magee 2001; Daveson 2007). Improvisation techniques 
were reported to benefit people in early to middle stages, and more structured and 
familiar music benefits people in advanced stages of HD (Magee 1995). Music 
therapy was said to bring about improved mood associated with positive changes in 
levels of interaction and to provide an alternative means of communication for 
people with HD (Davis and Magee 2001).   
2.6 Responses to the experience of stigma associated with HD  
Historically social stigma associated with HD has led many families to keep the 
diagnosis a secret and stigma continues to add to suffering (Wexler 2010). 
According to Wexler although enlightenment through scientific knowledge can 
reduce stigma it can also exacerbate the problem as occurred when science 
underpinned the eugenics movement; the view that the problem of HD might be 
eradicated through ensuring people with HD do not procreate, may not yet be 
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extinct. Nevertheless stigma is generally understood to result from ignorance (lack of 
knowledge of the condition) (Wexler 2010). Hence the value of knowledge families 
have gained through their experiences, a principle adopted in the 1977 by the USA 
Congressional commission for the Control of Huntington’s Disease which had 
extensive input from family members and along with newly forming lay groups was 
reportedly instrumental in influencing research to avoid seeking eugenic solutions 
(Wexler 2010).  
Apart from the issue of social stigma, HD is a complex condition that requires 
knowledge in a variety of areas in order to optimally manage it. Patients and their 
carers gain knowledge of their condition through a variety of sources, and familial 
expertise in this genetic disorder is not to be overlooked (Simpson and Rae 2012). 
Simpson and Rae suggest that this point has been embraced by the European 
Huntington’s Disease Network (EHDN) Standards of Care working group whose 
aim is to develop internationally approved guidance for HD care based on 
understandings of the condition informed by family expertise (Simpson and Rae 
2012).  
A lack of knowledge of HD among health professionals has been identified as an 
issue of concern in literature relating to HD as this can negatively impact on the 
organisation and delivery of care and services. Unintentional stigmatisation may 
result from a lack of knowledge or ‘ignorance’ (Wexler 2010).  Dawson et al (2004) 
highlight a need for disease-specific training among staff in hospitals and residential 
care settings providing for people with HD and found that poor knowledge of the 
condition among staff caused a lack of trust in the standard of care. This point has 
been raised with regard to MS by Schneider and Young (2010) who found a need for 
physicians to have a greater knowledge of MS, so that they were able to give clear 
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guidance. The commonly reported inability of physicians to do so was a cause of 
frustration among participants in that study.  
One paper investigated online support for people affected by HD (Coulson et al, 
2007). The authors undertook a content analysis study of messages on one social 
network site concerned with HD. The authors highlighted the potential value for 
health professionals of using the facilities to understand discrepancies between 
evidence-based practice and consumer beliefs, behaviour and expectations. Of 
course this does pre-suppose expertise on the part of the HCPs informing the 
debates. Concern among professionals for the wellbeing of people who have 
experienced a stroke or transient ischaemic attack (TIA) and do not seek medical 
attention led to a study to determine whether people who seek information about 
these conditions online can be targeted (Kim et al 2012). An advertisement placed on 
a website designed to be reached by people searching for information on TIA and 
stroke led to 251 (1%) of over 25,000 visitors over 122 days completing an online 
questionnaire and phone contact between professionals and people identified as 
consenting to and in need of professional input. Although Kim et al (2012) were 
concerned with providing emergency medical intervention the study does 
demonstrate a tendency for some people with neurological symptoms to seek 
information via the internet rather than direct initial contact with health professionals 
and there may be implications for the importance of providing good information 
online for people seeking to gain knowledge about degenerative neurological 
disorders.  
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2.7 Conclusions regarding responses to experiences of living with HD  
There are then many aspects to the experience of living with HD and despite some 
unique characteristics of the condition it appears that to some extent people with 
other neurological disorders also face similar challenges. Research activity 
concerned with effectiveness of interventions for HD has been most intensive with 
regard to the problem of the movement disorder and has resulted in identifying the 
only treatment for any symptom so far demonstrated as effective, Tetrabenazine. 
Interventions that are frequently adopted as responses to other aspects of the 
experience of HD may be effective also but to date substantial evidence for this is 
lacking. The seemingly disproportionate engagement in research concerned with 
movement disorder (Gudesblatt and Tarsey 2011) compared to investigations of 
effectiveness of responses to non-motor problems emphasises the importance of 
being guided by the perspectives of individuals with HD and their families. It can be 
argued that they are in a far better position to identify the aspects of HD that have the 
greatest impact on their lives and so their opinions should drive the prioritisation of 
research into interventions.  
This need to understand subjective experience of those who live with long term 
neurological conditions including HD is increasingly appreciated and some of the 
methods adopted to enhance insight in this area are considered below.  
2.8 Methods used to understand living with neurological disorders 
The studies considered in this review that have reported on the prevalence of disease 
or of symptoms associated with specific diagnoses adopt a quantitative survey design 
as is appropriate for these purposes (Abramson and Abramson 2011) and those that 
examined the effectiveness of interventions generally used a quantitative 
experimental design which is also suitable to meet the aims of such studies 
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(Abramson and Abramson 2011). The studies investigating the experience of lving 
with the conditions, the impact on quality of life and any that seek to aid 
understanding of subjective perspectives that are discussed in the review used 
qualitative approaches and these methods are much more suited to questions of this 
nature (Bowling 2009). The body of knowledge is informative with regard to 
understanding of what it is like to live with HD, the range of experiences and 
problems that are associated with the condition and of what is known so far about the 
effect and experience of the many interventions aimed at alleviating some of the 
specific challenges that HD poses. None of the work within the reviewed literature 
investigates perspectives of HD patients, their caregivers and the health professionals 
providing their care and treatment about what is helpful towards living with HD in a 
way that would enable participants to make a broad range of suggestions including 
for example, therapeutic interventions, social or politico-economic factors or any 
other aspect they might consider to be important. This is an identified gap that this 
thesis is intended to address. The topic area concerns subjective opinions drawn from 
experience of HD and therefore methods that have been used in qualitative studies 
discussed in the review should be considered in the process of determining the 
approach most suited to answering research question.  
One common approach to gaining insight into patient and/or caregiver perspectives 
about some aspect of living with a neurological condition is through questionnaires. 
The development of suitable questionnaires aimed at understanding patient and 
caregiver quality of life with regard to Huntington’s disease is ongoing (Hocaoglu et 
al 2012; Aubeeluck et al, 2012). Recent examples of this approach in other 
neurological conditions include a study of the experience of fatigue in PD (Beiske et 
al, 2010); a self-report survey examining employment changes and the importance of 
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symptom management in relation to living with multiple sclerosis (Simmons et al 
2010) and identifying personal factors that influence the experience of living with 
motor neurone disease (Ng and Kahn 2011).  
However, a questionnaire approach is suited to studies in which the questions are 
‘straight-forward and simple’ and less suited to addressing complex issues (Bowling 
2009) such as the broad question that this current study poses: ‘What helps people 
with HD live with their condition?’ On the other hand, self-reported questionnaire 
methods, especially postal, have the benefit over interview approaches of being more 
likely to reduce researcher bias through social engagement that may lead respondents 
to give answers they perceive as pleasing to the researcher (Bowling 2009).  
Qualitative interview methods have been adopted for example to understand the 
subjective family experience of stigma associated with Alzheimer’s disease (Werner 
et al, 2010) and to explore the experience of living with a partner with Parkinson’s 
disease who is undergoing deep brain stimulation treatment (Haahr et al, 2013). 
Whether the interview format is structured or unstructured, this approach does have 
the advantage of enabling the interviewer to explore any uncertainties and to prompt 
if necessary, reducing the likelihood of missing data particularly if the interviewer is 
friendly and motivating. Bowling (2009) suggests that qualitative interviews pose a 
low burden on respondents as they do not need writing skills and can speak 
naturally.   
Quinn et al (2010) interviewed patients with PD and HD and suggested this approach 
had an advantage over focus groups in allowing participants the convenience of 
being more freely able to choose the time and location to take part. However they did 
also use a focus group method in their study examining views on exercise 
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programmes for these conditions and indicated that focus groups are compatible with 
other qualitative data collection methods and often result in a broader scope of topics 
arising as a result of engagement in discussion. For some participants focus group 
activities may provide a greater sense of security than interview methods (Webb and 
Doman 2011).  
Mixed-methods (qualitative and quantitative) are becoming increasingly recognised 
as valuable in health research because of the capacity to draw on the strengths of 
each (Curry et al 2009). Curry et al (2009) point out the potential to identify rich 
subjective data via a qualitative component, and examine this further through 
quantitative means. This has appeal with regard to the current study because it could 
accommodate exploring what helps people live with HD using qualitative methods 
akin to focus group and interview approaches, and then consideration of what is most 
important through a quantitative component.  
2.9 Selection of the Concept Mapping method 
To answer the question: ‘What helps people with HD live with their condition?’ the 
traditionally dominant positivist approach to the acquisition of knowledge was 
rejected due to both the nature of the question and also to the primary investigator’s 
personal and professional history of involvement with the topic area. Positivism 
assumes an external and concrete reality and requires that research is concerned with 
objective methods designed to uncover truth (Brown 2003). This study is concerned 
with subjective views and opinions about what participants believe is helpful and 
with how they conceptualise and prioritise the factors perceived to help. There is no 
concrete ‘truth’ in the positivist sense to uncover.  
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Interpretivism views the social world as actively constructed by human beings, and 
the qualitative methods generally associated with it are broadly concerned with 
investigating how people make sense of their contextual situations and circumstances 
(Parahoo 1997). This seemed a closer fit to the current inquiry, and a number of 
qualitative approaches associated with the interpretivist paradigm were considered.  
For example, a grounded theory approach could involve gathering statements or 
recording dialogue from individuals and/or groups, and constructing a theory from a 
thematic analysis. The current study does seek to be inductive rather than deductive, 
that is, to draw conclusions derived from data rather than test any hypothesis. But the 
aim is to represent opinions of participants, not to investigate the social processes 
that may underlie how the opinions came to be, or to build a theory of how these 
processes work.  
Another approach that initially seemed as though it might be suitable for this study 
was a ‘Delphi study’ which it was felt could have been adopted to obtain and analyse 
rich, contextual qualitative data (Mason 1996). It is a method that involves engaging 
in discussions with participants in natural settings (Cresswell 1994) and would 
facilitate consideration of what helps people to live with HD by distilling the 
judgements of carefully chosen experts (Adler and Ziglio 1996), in this case the 
people who do live with the condition, the caregivers and the health professionals. 
However, the tendency to force a ‘middle of the road consensus’ as a way of dealing 
with views that might be considered extreme by most participants, is inherent in 
Delphi studies (Barnes 1987) and would be a disadvantage here as there is a need to 
represent the whole range of views in this current project.  
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A phenomenological approach was also considered because it would provide insight 
into the lived experience of participants. Pringle et al (2011) for example discuss the 
challenges of using phenomenological approaches to exploring the experiences of 
people who have survived a stroke. Qualitative methods involving focus groups or 
individual interviews are examples of means for achieving this kind of insight. But it 
was felt that the aims of this current study could not be entirely met by exploring the 
lived experience of being or caring for someone with HD. The purpose was to obtain 
opinions about what helps, and to learn how people conceptualise and prioritise 
factors that are perceived to be helpful.  
Concept mapping is designed to obtain statements of opinion, prioritise them and 
graphically represent the way that participants conceptualise the relationships 
between the statements. The concept mapping method was selected for reasons 
explained below.  
The concept mapping method involves participants in a brainstorming activity in 
which statements are generated that capture answers to the research question. This 
tends to be done in groups arriving at the statements through discussion of aspects of 
the problem being considered but the method allows for some participants to 
generate statements individually (Kane and Trochim 2007).  A statement reduction 
process by the researchers eliminates duplicate statements and those that do not 
answer the research question. The reduction process also in some cases involves 
creating one single statement that the steering group and validation group (these 
groups are defined in the next chapter) agree sums up several original statements. 
The developers of the concept mapping method (Trochim and Linton 1986) suggest 
that it tends to be possible to capture the points arising from brainstorming sessions 
within no more that 100 statements. In a separate activity, participants organise the 
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statements (each printed separately onto a numbered card) into ‘clusters’ or 
groupings indicating their individual subjective view of which statements seem to 
belong together for some reason. Then the participants each prioritise the statements 
by placing each into one of five stacks numbered one to five, five being the stack 
containing the perceived most important statements and stack one containing the 
perceived least important statements. The stacks should be distributed so that each 
contains a similar number of statements. The data collection process is explained in 
more detail in Chapter Three. 
Specialised computer software (‘Ariadne’®) is used in the analysis to determine how 
often participants placed any two statements together in a cluster, and to calculate a 
mean priority score for each statement based on which priority stack (1-5) each 
participant placed each statement. The mean priority score for each cluster could 
then be calculated.  
The reason for analysing the way the statements are grouped by participants into 
clusters is to be able to derive more meaning from the data than would be achievable 
through a list of stand-alone statements. Kane and Trochim (2007) point out that 
creating graphic maps is an inate human activity that allows us to make sense of 
where we are and what choices we may have about moving from one place or 
situation to another. The clustering of statements onto a map facilitates a view of 
how the thoughts of groups of participants are organised, and how in this case some 
statements are perceived to relate closely to each other while others may be more 
distant, separate issues. The reason for prioritising the statements that will be 
grouped into clusters is to enable calculation of mean priority scores to determine 
which clusters are perceived by the participants as a group to be most important. It is 
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also valuable to note which particular statements stand out as having high 
importance among participants.    
Based on a study involving four GP groups from different demographic areas, 
concept mapping was reported to be a very useful method with the ability to 
capitalise on the advantages of both qualitative and quantitative research approaches 
(Southern et al 1999). Ryan et al (2001) found it similar to using focus groups but 
attribute concept mapping with the quality of ensuring that all participants have an 
equal opportunity to express opinions, avoiding what they describe as the problems 
group dynamics can cause. Trochim and Linton (1986) suggest that the method is 
suited to informing decision-making and prioritising, which fits well with the aims of 
this current study. The difference between informing decision-making and helping to 
reach decisions (the latter lending itself towards a consensus method) should be 
noted. These factors form the rationale for the choice of this method. Qualitative data 
is gathered in the form of statements agreed by participants that answer the question 
(in this case ‘what helps people with HD live with their condition?’). Quantitative 
analysis is used to prioritise statements enabling the consensus among participants 
about which statements are more important than others, and also to calculate the 
frequency with which participants group particular statements together so that the 
software can present a visual map of ‘clusters’ of statements, demonstrating how 
statements are conceptualised into groupings. Because both qualitative and 
quantitative elements are inherent in the process Trochim and Linton (1986) 
described their approach as ‘mixed methods’.  
Applications of concept mapping  
The term ‘concept mapping’ here refers to the structured method developed by 
Trochim and Linton (1986) as opposed to methods of setting out ideas designed to 
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be used by individuals, as the term is often used (Trochim and Kane 2005). Since its 
introduction the approach has been used in a diverse variety of social research 
projects beyond a direct health context.  
For example Ridings et al (2008) used concept mapping to steer a community 
building project by a large non-profiting organisation with a grant provided to 
benefit African Americans in a metropolitan area of Chicago. Phang and Lee (2009) 
studied the experience of social support among working mothers. Community 
relations in Northern Ireland were studied by Knox (1995) using this method. Its use 
towards steering projects, investigating experience and evaluating policy 
demonstrated in these three examples highlights the adaptability of concept mapping. 
Health research adopting concept mapping embraces a broad range of topic areas 
such as beliefs about chronic back pain held by patients (Knish and Calder 1999), 
determining an optimum treatment location (home versus centre) for community 
rehabilitation (Barker and Ziino 2010) understanding patient perspectives of breast 
cancer care (De Kok et al 2007) and facilitating job retention for chronically ill 
employees (Haafkens et al 2011). 
Trochim et al (2004) used the method to inform a state-wide health improvement 
initiative for one USA state with a need to quickly and appropriately disseminate 
unanticipated funds arising from a tobacco settlement agreement. The method was 
considered particularly suitable due to the ability to facilitate the complexity of the 
undertaking, the speed with which results were needed to help reach decisions and 
the importance of incorporating multiple stakeholder perspectives (Trochim and 
Kane 2005).  
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De Ridder et al (1997) used concept mapping to elicit perspectives of patients on 
ways of coping with illness and with the healthcare system. One of the co-authors 
(Peter Severens) went on to develop the ‘Ariadne®’ software used for analysis in this 
thesis. The experience of depression among college students was studied by 
Daughtry and Kunkel (1993). Daughtry and Kunkel (1993) found concept mapping 
particularly useful in helping to clarify the constituent elements and underlying 
structure of depression as experienced by the college students.  
In a study by Valentine (1989) views of three participant subgroups (nurses, patients 
and nurse theorists/ researchers) were presented in separate concept maps to depict 
how ‘caring’ was perceived in a nursing context. Another study comparing subgroup 
perceptions was carried out to shed light on differences between patient and medical 
specialist perspectives of preferences of aspects of care in relation to quality of care 
with regard to chronic diseases, namely chronic obstructive pulmonary disease, 
rheumatoid arthritis and diabetes mellitus (van Der Waal et al 1996).  
Summary of advantages of utilising concept mapping for this question 
The concept mapping method then can accommodate study into wide-ranging health 
and social care issues where stakeholder views are sought to establish what is 
important and how the identified factors can be conceptualised and prioritised to 
inform decision-making regarding practice, service provision and policy. The 
method facilitates handling of complex issues and relatively speedily provides results 
that can inform decision-making (Trochim et al 2004). Kikkert et al (2006) 
suggested that because the ‘clustering’ task enables participants as opposed to 
researchers to decide which grouped factors emerge from the data and how these 
‘clusters’ of statements are related, interpretation of the qualitative data may be less 
susceptible than other qualitative approaches to researchers’ preconceptions. 
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Concept mapping is useful when stakeholder perspectives are important to 
understand (De Ridder et al 1997). The approach can clarify the structure and 
constituent elements of perceived phenomena (Daughrty and Kunkel 1993) and so 
for example if ‘social inclusion’ were identified as helpful towards living with HD it 
may be possible to see specific components of the concept of ‘social inclusion’ and 
how these are organised. 
Comparison of perspectives between participant subgroups is supported by concept 
mapping (van der Waal et al 1996; Valentine 1989) and therefore the intention to 
compare views of people with HD, caregivers and professionals in the current study 
can be accommodated. Valentine (1989) highlighted the high level engagement of 
participants in stages of the process and their tendency to enjoy participation as 
advantages for the method. A further advantage pointed out by Valentine (1989) that 
is particularly attractive for the current study is the visual representation of results. It 
was felt that this could enhance dissemination, enabling people with HD and 
caregivers as well as professionals to readily understand results when presented at 
conferences and small group meetings.  
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Chapter Three 
Methods 
3.1 Introduction 
A mixed methods participatory approach known as Concept Mapping was adopted to 
enable exploration of the views of participants representing three stakeholder groups: 
people with Huntington’s disease (PwHD), family caregivers (Carers) and health 
professionals who work with patients (or clients) with HD (HP). A rationale for this 
choice of method is provided in the previous chapter.  
3.2 Preparation 
3.2.1 Project Monitoring 
Project monitoring was carried out through monthly meetings between the primary 
investigator and PhD supervisors. Day to day progress was also reviewed through 
this process.  
3.2.2 Steering group 
Quarterly ‘steering group’meetings involved the above project monitors and also two 
PhD students, (HF and AM) who were both also using concept mapping 
methodology in their projects. These meetings informed the study design.  
3.2.3 Validation group 
Inclusion of people with HD and caregivers in the steering group was intended but 
discussions with potential candidates led to the conclusion that this was not practical. 
Instead the principal investigator met with members of a branch of the Huntington’s 
Disease Association at key stages: to agree the protocol; to discuss the ethics 
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application prior to submission; to validate the process of statement reduction 
following generation of statements at brainstorming sessions; to discuss and validate 
(or contest) results; to validate (or contest) draft discussion and conclusions prior to 
thesis submission. The intention to ensure this ‘validation group’ included at least 
two of each of health professionals, people with HD and family caregivers at each 
meeting was achieved. This ‘service user’ involvement in research design is in 
keeping with National Research Ethics Service recommendations (NRES 2011). In 
addition the draft protocol was summarised in presentations by the primary 
investigator to health professionals with an interest in HD and/or other neurological 
disorders with a view to noting comments given as feedback, and where appropriate 
adjusting the protocol.  
3.2.4 Project focus 
In line with the concept mapping process the steering group decided on the research 
question which would form the basis for construction of the concept map (Novak 
and Canas 2008). This question ‘What helps people with HD live with their 
conditions is…’ was displayed prominently in the room during statement generation 
and sorting activities to aid participants in remaining focussed on their task. 
3.2.5 Ethical Issues  
Ethical permission for this project was granted by the NHS National Research 
Committee, Cambridge 2, on September 25th 2009. The key issue of concern for the 
committee was safeguarding the rights and wellbeing of people with HD, especially 
those with advancing disease, who may not have capacity to give informed consent 
in accordance with the Mental Capacity Act (2005). On the other hand, the 
committee members were appreciative of concerns raised by the ‘validation group’ 
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referred to above, that the views of people with advanced HD are important and that 
they should not be excluded.  
The Research Ethics Committee commended the plan for dealing with this issue. The 
plan involved identifying a ‘consultee’ to assist me as primary investigator, in 
deciding whether a participant without capacity to give informed consent, who 
indicated willingness to take part, should be enrolled, and whether a person who 
appeared to lose capacity and who wished to continue taking part should be allowed 
to do so.  
As agreed with the Research Ethics Committee, care was taken to avoid disclosure of 
factors that might have identified participants in the following way. The reply slips 
and consent forms and signed information sheets were (are) kept securely in a locked 
filing cabinet within a locked room within the School of Nursing Sciences at the 
University of East Anglia. Personal details were held on a university computer with 
password security, in a document with further password security. Apart from contact 
details, the personal information recorded for the purpose of analysing data was:  
All participants: Gender; date of birth;  
People with HD:  Length of time since clinical HD diagnosis.  
Caregivers: Relationship to the person they care for; length of time caring for a 
person or persons with HD. 
Health Professionals: Name of profession. Number of patients with HD on current 
client list; length of time involved with care for people with HD.  
Personal identities were not made known to others- summaries of results used in any 
publications ensured anonymity. The forms that contain the data referring to the way 
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each participant prioritised and clustered the generated statements, contained a code 
number relating to the personal information held on the consent forms and reply 
slips. 
3.3  Recruitment 
The originally planned method for recruitment, agreed by the Research Ethics 
Committee entailed recruiting three groups that had been identified as key 
stakeholders with a high level of expertise in relation to the topic (people with HD, 
caregivers and health professionals) each of between 10-20 participants, accessed 
through a neurology department database in Cambridge, UK. Trochim (1989) 
suggests that there is no strict limit concerning numbers of participants in groups. He 
highlights successful concept generation involving one lone participant, and also 
groups of 75-80 people. Typically he reported using groups of 10-20 and found this a 
workable number. Whatever the group sizes, conceptualising is best according to 
Trochim (1989) when it involves a wide variety of relevant people.  
The inclusion criteria for members of the three stakeholder groups, as agreed by the 
steering and validation groups were: 
PwHD: Clinically diagnosed HD confirmed by genetic testing. 
Family Caregivers: Identified by the PwHD as his or her primary informal caregiver 
(unpaid). 
Health professional: current experience of providing care, services or treatment for at 
least one person with HD.  
Initially recruiting participants from groups via the Huntington’s Disease 
Association (HDA) seemed a practical option because groups already meet, negating 
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the need to bring strangers together, find a venue and arrange refreshment facilities. 
But recruitment from a clinic database was decided on as an attempt to reduce 
potential selection-bias because people who take part in support groups may tend to 
self-select and may be unrepresentative of others affected by HD who do not.  
Health professionals were recruited from attendance lists from professional meetings 
with an HD focus, accessed via the European Huntington’s Disease Association 
Network at various locations in England.  
The recruiting method needed to be revised after attempts to recruit from the clinic 
database were largely unsuccessful. An amendment agreed by the Research Ethics 
Committee allowed in addition to the initial procedure, enrolment of people with HD 
and their caregivers via branches of the HDA, and of people with advanced HD, 
caregivers and health professionals at a named specialist Huntington’s Disease care 
facility within a large neurodisability hospital in London. This second part of the 
amendment was requested as it had been realised that the initial plan seemed 
unlikely to be very successful in gaining access to participants for whom the context 
of living with or caring for a person with HD is based in a long-term care setting 
rather than in the community. Local Research and Development (R&D) approval 
was obtained to recruit within their specialist HD wards.  
The potential problem referred to earlier - that people who attend Huntington’s 
Disease Association branch meetings may not be representative of other people with 
HD - is acknowledged. It is also recognised that the large specialised long-term care 
facility is not typical of long-term care facilities caring for people with HD, many of 
which may be smaller nursing or residential homes, and may not be specialised, 
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caring for example, for elderly people. Copies of ethics approval documents 
including the amendment are included in Appendix 3.1. 
Potential participants with HD were contacted initially by telephone (prior to 
recruitment amendment) and those who accepted the invitation were sent a postal 
package containing a letter of invitation, an information document, a consent form, a 
reply slip and a second pack labelled ‘Carer Pack’. Potential participants were 
advised not to complete any of the documentation prior to attending the first activity, 
the brainstorming session. The letter of invitation asked if the person with HD would 
kindly hand the ‘carer pack’ to the person they regard as their main carer. The carer 
pack also contained a letter of invitation, an information document, a consent form 
and a reply slip. The pack sent to potential health professional participants contained 
similar documentation (Appendix 3.2).  
A follow-up phone call aimed to establish the time and place of the brainstorming 
session. Signed consent was obtained at the brainstorming session venue, prior to 
commencing the activity. Participants were reminded that they were not obliged to 
take part and that they were free to discontinue at any time, without the need to give 
any reason. In the case of participants recruited via Huntington’s Disease 
Association branches, the material described above was given to the HDA branch 
leader, in envelopes, to hand to people with HD, who in the same way, were asked to 
decide who to hand the enclosed ‘carer pack’ to.  
Fig 3.1  Flow Chart- Recruitment method 1: 
 
 
  
 
 
 
 
 
Phone unobtainable:     6  
Not known at address:     3 
Moved away:               5 
Died:                       2 
              -------- 
Total not contacted:  16 
 
Recruited by 
original method: 
PwHD:  2  
(+Carers: 2) 
 
 
Contacted: 18  Declined:  16 
PwHD wished to avoid 
meeting others with HD: 6 
PwHD didn’t wish to  
discuss HD:     3 
Too ill     2 
No reason given:    5 
Note- no reason was sought 
Contact details obtained from clinic database and invitations sent: 34 (16 of 
which sent to Nursing home addresses) 
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Fig 3.2  Flow chart- recruitment method 2. 
 
 
 
 
 
 
Fig 3.3  Flow chart- Health Professional Recruitment. 
 
  
 
 
 
 
 
Invitation to take part advertised to branch leaders by HDA.  
 
Principal investigator contacted by six group leaders expressing a 
wish for branch members to take part. 
 
Principal investigator recruited volunteers (37 pwHD and 46 
caregivers) who took part at the six centres.    
 
Invitation to take part advertised at four bases of attendees at 
professional Huntington’s Disease related meetings.  
 
Principal investigator contacted by professional volunteers and 
invited to run the sessions at four bases.    
 
A total of 39 health professional volunteers recruited. 
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3.4 Demographic distribution 
Not all participants chose to complete the few demographic details requested on the 
reply slip accompanying the information sheet sent out with the invitation. The 
following details concerning demographic distribution are derived from the 
information volunteered from the 126 participants.  
Table 3.1 Demographic distribution of participants 
Subgroup  Male Age 
(years): 
Mean 
(range) 
Time since 
diagnosed/ 
duration of 
caregiving or 
professional 
experience 
with HD 
(years): 
range  
Number of 
patients seen 
in past two 
years by 
professionals 
Relationship to care 
receiver with HD/ 
Profession  
People with 
HD (n=39) 
31%  50.5 
(27-66) 
<1 to 8* N/A N/A 
Caregivers 
(n=48) 
38% 60.2 
(39-80) 
1- 20+* N/A  Relationship 
information from 45 
caregivers (I am a …. 
to the person I care 
for).         
Spouse/ partner  23(51 
%)     
Sibling:                 
5(11%) 
Parent                    
6(13%) 
Son/ daughter        
5(11%) 
Uncle/ Aunt           
3(7%) 
Granparent             
1(2%)        
Grandchild             
1(2%) 
Step parent             
1(2%) 
Health Care 
Professionals 
(n=39) 
 
( nursing= 
58%;  
 
Medical= 18% 
 
31% No data <1-25 (mean 
= 9.4). 
1-200 (mean 
= 27). 
Community  
Nurse:              6(15%) 
Pract. nurse:     1(3%) 
Mental health   
Nurse:              5(13%) 
Hosp/ n.home 
Adult field N: 11(28%) 
Ph. Therapist:   3(8%) 
Occ. therapist:  2(5%) 
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Allied Health 
Profs= 19% 
 
Social Work= 
5%) 
Spch & Language       
Therapist:         3(8%) 
Soc. Worker:    2(5%) 
Neurologist:     2(5%) 
Psychiatrist:      1(3%) 
Clin Psychol:   2(5%) 
Other medical: 2(5%)         
*Mean not calculated due to some vague responses -e.g. 20+ years- Carers and pwHD 
found estimating duration difficult due to subtle early signs and insidious progression.  
 
Table 3.2 below provides a summary of the numbers of participants taking part in 
each of the 3 activities- brainstorming, prioritizing and clustering. In total, 126 
participants took part in at least one aspect of the study: 39 people with HD; 48 
caregivers; and 39 health professionals. 
Table 3.2:  Summary of Participant involvement in the 3 activities 
 Brainstorming Prioritising Clustering Total Did both 
prioritising 
and 
clustering 
tasks 
Did All 
three 
activities 
PwHD       29        19    9 39          9 6 
Carers       31        26  20 48 9 9 
HPs       30        20  20 39 11 11 
Total       90        65   49 126 29 26 
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3.5 Data Collection – detailed explanation. 
The concept mapping method involves four stages of data collection, as shown in fig 
3.4, and explained in more detail below. 
Fig 3.4   Data collection flow chart. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Brainstorming 
sessions: People 
with HD 
Brainstorming 
sessions: 
caregivers 
Brainstorming 
sessions: Health 
professionals 
Stage One: Participants carried out a ‘brainstorming’ activity, mostly in groups, some 
individually, but the three subgroups (people with HD, caregivers, health professionals) 
were kept apart. They agreed statements that answered the question: “What helps people 
with HD live with their condition?”  
Stage Two: The steering group carried out ‘statement reduction’. They 
examined the statements and reduced them by deleting duplicates, reducing where the 
meaning of a number of statements could be captured in a single statement, and 
deleting those that did not answer the question or fit the criteria for included 
statements. The team produced less than 100 refined statements. These were validated 
by the validation group, involving people with HD, caregivers and health professionals 
Stage Three: The participants carried out a ‘prioritising activity’. Each 
statement was printed onto a small numbered card. Each participant had a full set of 
cards (statements). Each participant sorted them evenly into five stacks, least 
important statements on the left, most important on the right. The researcher noted 
which stack each participant placed each card. 
Stage Four: Participants carried out a ‘clustering activity’, whereby they 
sorted the cards again, this time into groupings (or clusters) that seemed to belong 
together for some reason. Again, the researcher noted where each participant placed 
each card for this activity. 
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Brainstorming sessions were carried out between October 2009 and August 2010. 
Clustering and prioritising sessions were carried out between September 2010 and 
June 2011. 
People with HD, caregivers and health professionals took part in the ‘brainstorming’ 
sessions separately. The sessions were carried out at locations in eight geographic 
areas of England, spread between the mid-South Coast to North Lancashire, and the 
Essex Coast to the East, (Table 3.3).  
Table 3.3: Numbers of participants at brainstorming sessions by geographic 
location. 
Area  PWHD Carers Professionals Total 
Centre 1  2 2 12 16 
Centre 2 6 8  14 
Centre 3 5 6  7 18 
Centre 4 6 5  11 
Centre 5    7  7 
Centre 6 4 5   9 
Centre 7    4  4 
Centre 8 6 5  11 
Total 29 31 30 90  
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The largest (and mean) group sizes were: people with HD, n=6, (1.8); caregivers, 
n=8, (3.4); professionals, n=8, (3.0). The five people with advanced HD were seen 
individually, to encounter problems in communicating associated with the condition, 
which would inevitably make group participation difficult. Otherwise two people 
with HD, one caregiver and six health professionals took part individually, and the 
remainder took part within groups.  
Participants’ answers to the question ‘What helps people with HD live with their 
condition?’ were written onto a flipchart by the principal investigator or an assistant 
(member of the steering group). Comments made by the participants to explain or 
illustrate the statements were noted.  
Fig 3.5 Proportion of total statements (1358 prior to the reduction process) 
contributed     by each subgroup (people with HD; caregivers and 
health professionals) 
 
PwHD 29.2%
Carers 39.2%
HPs 31.5%
 
The steering group carried out the statement reduction process in which they 
analysed the statements, and eliminated duplicates where more than one statement 
had essentially the same meaning, and also any that did not fit the necessary criteria. 
Where it was decided that a number of statements could be reduced to a single 
statement that captured their essence, this was done with the intention of capturing 
what all of the ‘legitimate’ statements (those meeting the criteria) had been intended 
to convey, within 100 statements or less. Kane and Trochim (2007) suggest a 
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reduction to less than 100 statements by these methods if this is possible while 
ensuring all points that participants intend to make are captured. Their rationale is 
that the following tasks (prioritising and clustering) may be too onerous for 
participants if there are more than 100 statements.  
The validation group were in general agreement with the reduction process 
undertaken by the steering group but initiated two changes. The steering group had 
reduced a number of separate statements about treatment for chorea, to one single 
statement: 
What helps people with Huntington’s disease live with their condition 
is…Medication against chorea to help the person with HD do activities such as 
sleep, have a sex life, reduce distress, reduce fatigue and carry out activities of 
living. 
The validation group were happy to accept the grouping of most of these activities, 
but wished to keep separate the statement:  
What helps people with Huntington’s disease live with their condition 
is…Medication against chorea. 
They felt that this statement was a different issue; separating treatment to reduce 
chorea as an end in itself from treating chorea to enable a range of activities. 
There was divided opinion among the steering group about whether smoking could 
be grouped together with having alcohol and a range of other social activities said to 
help people live with HD. The validation group settled this and opted for smoking, 
and having alcohol to be addressed in two distinct statements, separate from other 
social activities. 
The final reduction exercise resulted in 94 statements. While further reduction would 
make the sorting sessions more manageable for participants, it was unanimously 
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agreed that the consequence of doing so would be to sacrifice a point that 
participants had intended to raise, or combine statements that raised separate issues, 
which would be unacceptable. 
Each of the 94 statements was allocated a randomly allocated number (1-94) and was 
then printed onto a separate card in preparation for the prioritising and clustering 
exercises (Fig 3.6). 
 
Fig 3.6 Example of a 
statement card (not 
an actual statement 
produced in the 
study) 
 
 
 
In the prioritising task, each participant was given a pack of 94 cards, shuffled to 
ensure variation in the order in which each statement was viewed. Participants 
ranked the statements in ascending order of importance by arranging the cards into 
five stacks. The relatively least important were placed in the first stack, furthest left 
(stack one) and the most important (in the participant’s opinion) were placed in the 
furthest right stack (stack five). Participants were advised that each of the five stacks 
of cards should contain at least 17 and a maximum of 21 statements (to avoid people 
rating nearly all statements as either most important or least important).  
After a 15 minute break the second task was to group the cards into stacks, so that all 
the statements in a particular stack seemed in one way or another, to belong together, 
22 
     What helps people with 
Huntington’s disease live with their 
condition is: having a hammock instead 
of a bed to sleep on.  
 
       
 
12 
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that is, had to do with the same aspect. These groups of statements were called 
‘clusters’.  
Participants were told that clustering can be done in any way that the individual 
thought sensible as long as the clusters comprise statements that according to the 
participant somehow belong together. The fact that there is no ‘right’ or ‘wrong’ way 
to do this was emphasised, the participants were advised to avoid having a 
‘miscelaneous’ cluster in which statements felt to be unrelated might be put together. 
even if one single statement was felt not to belong with any others it should be 
placed in its own ‘stack’ to identify it as having a separate theme.   
Participants then completed data sheets (appendix 3.3) identifying how individuals 
had prioritised each statement and which statements had been grouped together to 
form clusters, and suggesting a name for each cluster, that could best capture the 
theme of the statements within it.   
3.6 Data Entry 
The data were entered onto computer using the Ariadne® programme (NcGv/Talcott, 
Utrecht, The Netherlands, 1995; Severens, 1995). A code for each participant who 
undertook the prioritising and / or the clustering activities was loaded into the 
programme by the primary investigator, as was the information from data sheets 
depicting how each individual prioritised and clustered each statement. Where more 
than one item shared a mean score, highest priority rating was given to the score with 
the narrowest standard deviation. 
The coding system only identied whether the participant was a person with HD, a 
caregiver or a health professional. That is, a randomly selected person with HD was 
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coded as HD1, another as HD2 etc; a randomly selected caregiver was coded as C1, 
and a randomly selected health professional was coded as P1. To protect 
confidentiality, only the principle investigator kept access to documents linking 
participants to codes. Participants who only undertook the brainstorming sessions 
were not entered into the Ariadne® programme because those data were not needed 
for that part of the analysis.  
As a way of checking the accuracy of the data entry process, another steering group 
member (HF) randomly selected 10% of participant code numbers, and also entered 
the data into a copy of the Ariadne® programme. We then compared the entries in 
both versions to check that they matched. Both sets of entires were found to be 
accurate and similar. 
It is acknowledged that double entry (whereby two researchers each load all data into 
the programme, and the programme identifies any discrepancy between the two) 
would have been more ideal. The Ariadne® programme does not accommodate this, 
and the method we used to check was considered by the steering group to be 
acceptable as a method of verification of the process.  
3.7 Data analysis 
The purpose of data analysis was to capture the themes identified collectively by 
participants, that is, how their generated answers to ‘what helps people with HD live 
with their condition?’ had been conceptualised; and to determine the perceived order 
of importance for those themes. Analysis was also aimed at identifying any 
similarities or differences between PwHD, Carer and HP perceptions.  
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The Ariadne® software uses multidimensional scaling (MDS) and cluster analysis to 
depict a graphic portrayal of ‘distances’ between items (statements) by plotting their 
position on a two-axis matrix, resulting in production of graphic conceptual maps. 
This approach in health related research using Ariadne® has been adopted by a 
number of researchers (e.g. de Kok et al 2007; Varekamp et al 2005; Roeg et al 
2005). 
Strictly, analysis should treat the rating of items as ordinal. The activity of placing 
cards into five stacks according to importance is in essence the same as using a 
Likert scale. While stacks 1-5 indicate an increasing level of importance to the 
participants, we cannot assume that the difference say, between stacks 2 & 3 is the 
same as the distance between stacks 4 & 5. Jamieson (2004) stresses risks inherent in 
mishandling data that is ordinal by attributing a scale quality. Jamieson (2004) 
maintains that calculation of mean scores is appropriate to scale data, whereas 
median scores are more suited to ordinal data. However, Norman (2010), while 
acknowledging that this is strictly true, refutes Jamieson’s implication that therefore 
it is inappropriate to use parametric tests to analyse data derived from a Likert scale. 
Norman emphasises the robustness of parametric methods. He demonstrated that 
results from a survey using a 10-point Likert scale, analysed as though the data were 
interval, correlated extremely closely with results after reducing the Likert 
instrument to 4-point, by grouping together some of the original points so that 0 = 1; 
1 and 2 = 2; 3, 4, and 5 = 3; and 6, 7, 8, 9, and 10 = 4. This ensured that the ordinal 
data was extremely skewed- the concern for Jamieson (2004), being that because 
distances between points may vary, results may not be accurate. Norman holds that 
critics who raise this point fail to suggest how inaccurate, and overlook the 
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robustness of parametric methods in their ability to accommodate ‘problems’ such as 
low participant numbers, non-normal distribution, and as discussed here, ordinal 
data.  
It seems justifiable in the light of the above debate to calculate means and standard 
deviations in this current study given that the results will be far more informative 
than if median scores were calculated. For example, where the median item score for 
people with HD and for health professionals might be 3, a mean score might be 3.2 
for one of the subgroups and 3.6 for another, demonstrating that there is a calculable 
difference in the item’s importance between the subgroups.  
Developers of specialised concept mapping programmes (Kane and Trochim, 2007; 
Severens 1995) clearly adopt this view, as both Ariadne® and the ‘Concept Systems’ 
software (www.conceptsystems.com) do calculate mean scores and standard 
deviations. The practice is well established, with many examples of published 
research in health based on calculations obtained through the use of either of these 
two concept mapping programmes (e.g. Nijman et al 2011; Anderson et al 2011; 
Scahill et al 2010: van Bon-Martens et al 2011).  
Norman (2010) suggests that the widely adopted stance that parametric tests are 
based on assumptions of normality tends to be misunderstood. The means, not the 
data have to be normally distributed and he points out that the Central Limit 
Theorem demonstrates that for sample sizes of more than five or ten per group, the 
means are ‘approximately normally distributed regardless of original distribution’.  
Nevertheless, the broadly held view (e.g. Field 2009) would demand that in order to 
consider whether any differences between subgroups were statistically significant 
regarding how specific variables were prioritised it was first necessary to establish 
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whether data were normally distributed to determine whether parametric or non-
parametric testing would be more appropriate and this was complied with. 
SPSS™ software (SPSS inc. Chicago Illinois) was used to carry out the 
Kolmogorov-Smirnov and Shapiro-Wilk tests for normality. The latter is suggested 
as more appropriate for small samples (Field 2009). For both tests the null 
hypothesis is that the data are normally distributed and so a significance value of 
<0.05 means that the null hypothesis can be rejected and that the data are therefore 
not normally distributed.  
Appendix 3.4 provides results of the test for normality carried out. The table shows 
that significance for each subgroup regarding almost all variables (i.e. except for 
12.5%, or 24 of 192 values) was <0.05 indicating that data were not normally 
distributed. Visually on the quartile-quartilie (q-q) plots deviation from the line 
expected if data were normally distributed appears only slight in nearly all cases, but 
in view of the small numbers of participants in this study, it was considered 
appropriate to rely only on numeric results for the test for normality and therefore 
reporting is based on non-parametric tests.  
Reported statistics comparing scores between subgroups, unless otherwise stated 
were derived from the Kruskall-Wallis test, a non-parametric equivalent of the one-
way ANOVA. However, in line with suggestions by Norman (2010) the one-way 
ANOVA test was also run and produced similar results.  
It is possible to calculate confidence intervals from mean scores and standard 
deviations but this is felt to be unjustified as it would not add value amd so was not 
done. The concept mapping method is developed to calculate mean priority scores 
and the position of statements on an NxN matrix on the basis of frequency with 
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which a given statement was placed in a cluster stack along with another given 
statement. Reliance on mean scores is widely accepted and consensus among 
researchers who employ the method seems to be against reporting confidence 
intervals (e.g. Roeg et al, 2005; de Kok et al 2007; Nijmen et al, 2011). 
Selecting subgroups for analysis 
The study aimed to generate statements about what helps people live with HD from a 
broad range of perspectives and obtain an overall inclusive priority order and 
grouping of statements. The concept mapping method is designed for this, but can 
also facilitate comparison of subgroups. There is no justifiable rationale for 
comparing data from groups separated according to gender or age. Each group that 
generated statements included both genders (though as shown male representation is 
relatively low) and an age range encompassing mid to late life in keeping with the 
general pattern of HD duration.  
However, people with HD, family caregivers and health professionals generated 
statements separately as subgroups at the outset and as these are different ‘roles’ 
with regard to living with HD, comparing and contrasting the three perspectives was 
considered to be legitimate. Ho et al (2006) suggest that comparison of perspectives 
between patients with HD and those of carers can provide valuable insight into 
management approaches most likely to succeed. Understanding of similarities and 
differences between patient, carer and professional perspectives more generally can 
help to improve the working relationship and clarify needs (Walters et al 2000).  
Living with and providing for people with HD in the context of a nursing home 
during the advanced stages of disease, where a paid team provide 24 hour care in 
facilities dedicated to that purpose must intuitively be different to managing at home 
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in the community where family members gradually assume a role as disease 
symptoms insidiously develop. This perceived difference is the justification for 
drawing a distinction between the nursing home and community contexts. For these 
reasons analysis was undertaken for patient, carer, health professional, community-
based and nursing home-based subgroups.  
Cluster Analysis 
The Ariadne® programme forms a visual 2 dimensional matrix and plots the 
statements according to ‘distances’ representing the frequency with which statements 
had been grouped together by participants. The graphic rectangular representation 
produced is divided into four equal quadrants by two axes, and allows the researcher 
to name the axes. Each end of each axis was given a name intended to sum up the 
content of statements situated near to that area of the concept map (see Fig 3.7). The 
steering group verified the name given to each end of each axis on the concept map.  
Fig 3.7:  Matrix with labelled axes 
Medical 
 
  Individuals         Health System 
    Care 
To clarify, it was decided that the statements the software plotted near to the top 
centre of the rectangle tended to relate to medical input. Those statements positioned 
near the far right tended to relate to the health care system whereas those at the far 
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left were mostly to do with living as an individual. Statements that Araidne® located 
on the lower part of the rectangle tended to relate to some aspect of care. 
The number of clusters that group the statements meaningfully tends to be a 
minimum of eight and a maximum of 20 (Jackson and Trochim 2002). Using the 
Ariadne® programme and beginning with six clusters the number of clusters was 
increased until, conceptually, this seemed to make sense, in that natural groupings of 
the statements, according to their location on the matrix, seemed to be optimally 
captured by nine clusters. At this point, reducing the number of clusters by one 
seemed to fail to acknowledge distance between some items from others on the 
matrix that are forced into the same cluster. Increasing the number of clusters by one 
separated out items that, according to their position on the matrix, seemed to belong 
with items in a neighbouring cluster. The process was checked and verified by the 
steering group and the validation group and all agreed that a nine-cluster solution 
should be adopted. The results section shows that when the data for subgroups (e.g. 
people with HD, caregivers, health professionals, and also participants with HD 
experience in a nursing home context and in a community-based context) were 
analysed a different number of clusters was agreed (in most cases a ten-cluster 
solution). In each case the number of clusters was agreed through the process 
described above.  
The element of subjectivity in this process is acknowledged, and is considered to be 
appropriate in this research method (Jackson and Trochim 2002).   
Latent preferences 
The Ariadne® programme is also able to present maps that plot a relationship 
between individual participants and the matrix. This also uses multi-dimensional 
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scaling. For example, a participant who frequently prioritises statements that relate to 
care, will be plotted near to the lower end of the vertical axis on the map (the care-
medical axis). The participant would be considered to have a ‘latent preference’ 
towards prioritising statements concerned with care.  
3.8  Summary 
 
In the absence of good quality evidence for the effectiveness of interventions for HD, 
it is valuable towards planning provision of services, care, support and treatments for 
people affected by the disorder to understand what helps to live with the condition 
from the perspectives of key stakeholders- patients, family caregivers and health 
professionals. This study aims to address this need by generating a graphic, 
conceptual map.  
Various qualitative approaches to determine what is most helpful towards living with 
HD were considered but the inclusivity of ideas, the generation of concepts or 
themes based on groupings of specific statements and the quantified relative 
importance of those themes accommodated by the concept mapping method in 
addition to the resulting visual conceptual map were factors that contributed to 
choosing the concept mapping method. 
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Chapter Four 
Results 
 
The study aims were first to identify factors that help people with HD live with their 
condition from the combined perspective of people with HD, caregivers and health 
professionals, and second to generate a graphic map illustrating how these factors are 
conceptualised by the participants, using concept mapping. The third aim was to 
establish a perceived order of importance for conceptual clusters of factors that help 
and the fourth was to compare and contrast perspectives of participant subgroups. 
In order to meet these aims I collected statements generated in brainstorming 
sessions in which participants agreed ways to complete the semtence ‘What helps 
people with HD live with their condition is…’. Participants then prioritised the 
statements by allocating to each a score of 1-5 (1=least important, 5= most 
important) and grouped the statements according to their similarity (clustering).  
To avoid unnecessary repetition results regarding numbers of participants recruited 
and their characteristics were reported in the previous ‘methods’ chapter. This 
chapter presents the results from the prioritising and clustering exercises.    
The Ariadne® software uses multidimensional scaling to represent the data 
graphically on concept maps. Fig 4.1 is a point map that depicts the way the 
participants sorted the 94 statements. Each numbered point represents a single 
statement and the distance between statements on the map indicates the frequency 
that statements were grouped together in clusters. Statements placed together into the 
same cluster by many of the participants appear close together on the map whereas 
statements less often grouped into the same cluster are further apart. The statements 
that each numbered data point on the map relates to are listed in appendix 4.1.  
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Fig 4.1a Concept map for all participants depicting statement locations in 
relation to matrix 
 
In Fig 4.1a each numbered point on the map depicts the positioning of individual 
statements in relation to each other and to the two axes (individuals – health care 
system; and medical – care). That is, statements that participants often grouped 
together in cluster stacks are represented close together. The statements and 
corresponding numbers are listed in appendix 4.1.   
 
4.1 Clusters  
Analysis of the clustering of the 94 statements using Ariadne® software resulted in 
the formation of nine clusters for 65 participants representing the three stakeholder 
subgroups (people with HD, Carers and professionals). The process by which a nine-
cluster solution was arrived at is explained in the methods chapter. Table 4.1 
presents the clusters in priority order (cluster 1= most, cluster 9= least important). A 
high mean score indicates that on average statements within a cluster had been 
prioritised highly by participants. The maximum possible score would be five, which 
would have indicated that all participants had given all statements within the cluster 
highest priority; the lowest possible mean score would be one (neither of these 
extremes occurred). The table shows the number of statements within each cluster. 
The highest scoring cluster contained only one statement: ‘what helps people with 
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HD live with their condition is if there is expert assessment and treatment of mental 
health problems (e.g. depression, anxiety) occurring along with HD’.  
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Table 4.1  Cluster table for All 
Participants 
Fig 4.1b Cluster map for all participants 
 
The statements that make up each of these nine clusters are identified and discussed below.  
 
Cluster Name (numbered according 
 to priority order 1= most important)  
Mean 
importance 
rating 
No. of 
state- 
ments 
1   Co-morbid mental health problems 3.72   1 
2   Appropriate flexible care 3.32   7 
3   Timely integrated expertise 3.28 17 
4   Help to independence  3.15   8 
5   Practical engagement 3.15   2 
6   Longer term care issues 3.12   8 
7   Medical input 2.93 18 
8   Social living 2.90 29 
9   Insight  2.77   4 
7 Medical 
 1 Mental health   
2 Flexible Care 
8 Social 
9 Insight 
6 Longer term care 
4  Independence 
 3 
Expert 
5 
Pract
ical 
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Cluster analysis.  
 
Tables 4.1.1 to 4.1.9 below show the statements that make up each cluster in the 
order of the mean importance rating for all participants (that is, the three subgroups- 
people with HD, carers and health professionals combined).  
 
Cluster 1, Co-morbid mental health problems 
 
The identification of assessment and treatment for mental health issues as the highest 
priority among factors that help in living with HD as rated by the combined 
subgroups (people with HD, carers and health professionals) is the key finding of 
this study. The cluster contains only one singles statement. Mental health problems 
were discussed in every brainstorming session and in the reduction process the 
statement was formed to capture the essence of many original statements about 
living with a variety of co-morbid mental health conditions.   
Table 4.1.1  Content of cluster 1, Co-morbid mental health problems. 
Cluster 1 
 
Statement 
Mean 
importance 
rating 
If there is expert assessment and treatment of mental health problems 
(e.g.depression, anxiety) occurring along with HD 
3.72 
 
 
Cluster 2, Appropriate flexible care 
The second highest priority cluster referred to the importance of ‘appropriate flexible 
care’. One tale told by a caregiver during a brain storming session seemed to typify 
the perceived problems that underpin the seven statements within the cluster: ‘She 
[paid Health Care Assistant] came to the house one morning and said she’d come to 
help wash and dress my husband. I told her it took me years to get the routine right 
so he doesn’t go into a tantrum. If you do up the shirt buttons top down instead of 
bottom upwards, or shave him the wrong way, he’ll become aggressive. So I asked 
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her to help get the children ready for school, to free me to help him. She took that to 
mean I refused the help she’d been sent to offer. No help’s better than inflexibility’.  
Being offered care that is regarded by recipients as inappropriate or inflexible seems 
to be the cause of much angst in families affected by HD.  
 
Table 4.1.2  Content of cluster 2, Appropriate flexible care 
Cluster 2  
 
Statements 
Mean 
importance 
rating  
If family carers are believed when they report reaching a tipping point, where care at home 
is no longer manageable. 
3.86 
If care is available where the person with HD needs it. 3.75 
Not being cared for in an inappropriate setting (e.g. psychiatric or elderly setting where 
staff don't know about HD). 
3.72 
If informal carers have training in HD 3.17 
If a care home environment is made to feel as home should feel 3.02 
If visiting carers are flexible regarding the specific type of care they provide 2.98 
If professional carers are flexible about who they help in the household (for example, 
being  prepared to help children, so that the spouse  can help the person with HD, if the 
person with HD  doesn't want help from the professional carer). 
2.71 
 
 
 
Cluster 3, Timely integrated expertise 
 
Expertise is clearly a highly important issue for participants. Having access to 
professionals who are expert in HD was the highest scoring individual statement 
overall and in brainstorming sessions it was noted that dealing with GPs, nurses and 
neurologists who do not appear to understand the condition well can cause families 
enormous frustration. Those who had been referred to a national specialist HD centre 
were considered highly fortunate and invariably commented that living with HD 
became very much more manageable following the first visit. Many participants 
commented that they would be prepared to travel to access integrated 
interdisciplinary specialist expertise. Timeliness of assessment, interventions and 
receipt of equipment was seen as a natural benefit of access to experts who know 
HD, and know the family well and can plan ahead as opposed to responding to 
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crises. This explains the importance of continuity of staff, also highlighted within 
cluster three.  
Table 4.1.3   Content of cluster 3, Timely integrated expertise. 
Cluster 3 
 
Statements 
Mean 
importance 
rating 
Access to professionals who are expert in HD 4.12 
If care is available when the person with HD needs it 3.92 
Access to a multi-disciplinary team that is expert in HD 3.82 
Having good quality healthcare professionals and carers who are good 
communicators; share information; stay calm and avoid confrontation 
3.80 
Being referred to a specialist National HD centre 3.52 
Having continuity of care staff, (e.g., professional carers in homes or that visit at 
home). 
3.52 
Regular and timely access to health and social care assessment 3.46 
When service provision is planned for when it will be needed, rather than thought 
about  once things have already got difficult 
3.43 
Continuity of health and social care professionals 3.31 
If there is information about HD for health professionals in general medical settings 3.11 
If there is information about HD for health professionals in general medical settings 3.11 
Effective multi-disciplinary working 3.09 
If professionals help the person with HD to get a life 2.91 
Effective interagency working 2.83 
If professionals follow up patients who do not keep appointments 2.63 
If people with HD know the role of each professional 2.63 
Timeliness in access to care homes 2.54 
 
 
 
Cluster 4, Help to independence 
 
The central themes for cluster three of timeliness and expertise also feature in cluster 
four in the context of having help towards independence. Aids and adaptations were 
seen as important so long as they are provided at the right time (when needed) and 
with regular assessment to ensure continued suitability. For people with HD for 
whom tube-feeding is regarded as helpful the introduction of this intervention needs 
to be timely and participants commented that this would avoid a crisis-led approach 
in which unhelpful decisions can be made hurriedly. A timely approach can 
empower people with HD to maximise independence by being enabled to make 
choices about this issue (Simpson 2007). The involvement of speech and language 
therapists was a factor associated with independence not only for their part in 
helping to overcome swallowing problems but also for help with communicating. 
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Early assessment and a responsive approach to changes in ability to initiate and take 
part in communication throughout the various stages of HD progression are called 
for in recently formulated European guidance concerning speech and language 
therapy for people with HD and their families (Hamilton et al 2012). The guidance 
recognises that communicating problems associated with HD challenge families, not 
only individuals.  
The importance of having the right level of information about HD at the right time 
was stressed within this cluster.  This was often seen as provided by family support 
workers from the HDA. Another aspect of choice grouped into the cluster concerned 
with help to independence was that of deciding whether to see a male or a female 
GP. 
Cluster four presents an important theme for professionals to bear in mind.The loss 
of independence is associated with a higher risk of suicide among people with HD 
(Novak and Tabrizi 2010). Independence can be seen as integral to the aims of 
rehabilitation generally and specifically for people with HD (Ciancarelli 2013).  
Table 4.1.4 Content of cluster 4, Help to independence 
Cluster 4 
 
Statements 
Mean 
importance 
rating 
Speech and language therapy involvement to help with swallowing problems 3.92 
Speech and language therapy involvement in maintaining ability to communicate 3.62 
Having support from the Huntington's Disease Association. 3.58 
Having timely access to appropriate aids and adaptations 3.28 
Having access to the right level of information about  HD at the right time 3.22 
Regular timely assessment for aids and adaptations 3.18 
Timely introduction of tube feeding 2.55 
Having a choice about seeing a male or a female GP 1.85 
 
 
 
Cluster 5, Practical support 
 
There was considerable discussion within the steering and validation groups about 
why the analysis process had led to the two statements in table 4.1.5 (below) being 
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grouped together and apart from other clusters. It was generally agreed that this had 
occurred because of a tendency among the participants to avoid grouping ‘having 
support from the HDA’ with ‘being involved in a HDA support group’, and also 
avoid grouping ‘advice on foods and textures’ with issues to do with ‘swallowing’ in 
cluster four. Active involvement in a local branch of the HDA was evidently seen as 
a separate and much more practical issue than being a member of the national 
organisation. Rosenblatt et al (1999) suggest that people with HD are often reported 
by family caregivers as disengaged. According to Rosenblatt et al (2009) this is 
largely due to lack of internal initiation and can be countered by external initiation 
which can re-engage the person with HD in work and social activities. It seems 
reasonable that membership of a national organisation may not necessarily stimulate 
drive whereas involvement in a local branch might. This appears to be the point 
identified by participants in this study.  
 Although speech and language therapy can address problems with communicating 
and with swallowing, it was felt that having practical advice on textures and kinds of 
food to eat may have seemed to participants to go beyond problem-solving and to be 
a more proactive way of being supported to live, in common with having an active 
role within a support group. Indeed, Aubeeluck et al (2011) cite the importance of 
food being of appropriate size and texture as an example not only of safeguarding 
against or reducing dysphagia but as a means of improving quality of life.  
Table 4.1.5   Content of cluster 5, Practical support. 
Cluster 5 
 
Statements 
Mean 
importance 
rating 
Being involved in a Huntington's Disease Association support group 3.48 
Practical advice on specific foods and textures 2.83 
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Cluster 6, Longer term care issues 
 
 
In cluster six, eight statements brought together issues such as enabling daily living 
through the provision of bathroom aids and aids for communication and falls-
prevention; having training to use the aids and being able to make choices about 
ongoing and end of life care. Aspects of life in institutional long term care such as 
being able to go out and engage in the community while a nursing home resident and 
having meaningful relationships with other nursing home residents were included in 
this cluster as were concerns about family caregivers: having a break from caring 
and being listened to and believed. In a care of the elderly context Wolff (2013) 
found that satisfaction with life can be enhanced and depression reduced more 
effectively among nursing home residents by activities such as frequent in-house 
social events aimed at fostering friendships between fellow residents than by visits 
from family which are of course also positively influential.  
Anderson and Dabelko-Schoeny (2010) report emotional and physical benefits for 
civic engagement among older adults but found that opportunities to do so once 
admitted to a nursing home are limited. Social and practical barriers (for example 
ageism and transportation) are identified as reasons for this and the authors call for 
social work action to overcome these obstacles. This study supports a need for such 
action on behalf of a younger cohort also: nursing home residents with HD.  
Table 4.1.6 Content of cluster 6, Longer term care issues 
Cluster 6 
 
Statements  
Mean 
importance 
rating 
If the family carer has a break from looking after him or her. 3.80 
Having aids to enable daily living (eg. aids that help with communication, mobility, 
furniture, bathroom and falls prevention). 
3.63 
Making choices about care including end of life care in advance and having the 
choice respected 
3.59 
If carers are listened to as an adult and believed and respected 3.49 
Having assistance to eat and drink 3.35 
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Being able to go away from the care home to engage in community activities 2.78 
Having appropriate training to use equipment 2.35 
Having meaningful relationships with other care home residents 2.00 
 
 
Cluster 7, Medical input 
Within this cluster partipants highlighted that medication can be helpful in reducing 
chorea, particularly if doing so is aimed at improving ability to carry out activities 
such as sleeping and having a sex life and to reduce stress and fatigue. In a separate 
statement the value of medication to help sleep was reiterated. Timely reviews of 
medication were called for and having the goal of a normal life when prescribing 
medicines was situated in this cluster. Participants cautioned against prescribing 
sedative medication for the sole purpose of managing behaviour and stressed that the 
effects of medication vary from patient to patient and that side effects can be 
seriously detrimental to living with HD. Assessment for aggressive behaviour was 
seen as helpful and recognition that behavioural problems and impulsivity are 
serious aspects of HD was called for. Availability of genetic testing and pre-
implantation diagnosis were viewed as part of medical input.  
A wish to be able to try medicines experimentally as individuals, without waiting to 
find out if there will be a trial was expressed within the cluster.  
Table 4.1.7   Content of cluster 7, Medical input 
Cluster 7 
 
Statements 
Mean 
importance 
rating 
Medication against chorea to help the person with HD do activities such as sleep, have 
a sex life, reduce distress, reduce fatigue and carry out activities of living. 
3.75 
Medication against chorea 3.48 
A prompt diagnosis 3.32 
Having appropriately timed reviews of medication 3.22 
Having medicines to help sleep 3.22 
Having the goal of a normal life when considering the use of medication 3.13 
Pre-test and post-test counselling 3.11 
Assessment of management of aggression if it occurs 3.06 
The availability of a genetic test 3.03 
If obsessive behaviour and impulsivity are recognised as serious symptoms of HD 3.02 
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Recognition that antipsychotic medication can be helpful in HD 2.85 
Having the opportunity to be involved in research 2.83 
Availability of pre-implantation diagnosis 2.62 
Access to experimental treatments (not as part of research, but to find a treatment that 
works for the person with HD). 
2.57 
Knowing that sedative medication will not be given solely to manage behaviour 2.51 
Knowing that side effects of drugs for HD can be serious 2.45 
Knowing that the effects of medications for HD are variable 2.42 
Recognition that facial and neck pain can be a problem in HD. 2.13 
 
Cluster 8, Social living 
This was the largest cluster in terms of the number of included statements. The 
importances of supportive family and friend networks and of a stable partner 
relationship were expressed as was being able to talk freely about HD in the home 
situation. Being able to drive, smoking cigarettes and drinking alcohol were grouped 
among the statements concerned with social living. Other factors included in this 
cluster were having hobbies and pastimes, having meaningful conversations, 
maintaining a positive outlook, being able to get out and about, accessible transport 
facilities and having strategies to enable eating out without embarrassment. People 
with HD were felt to need to be able to engage in intellectual as well as physical 
activities and there was a call for employers to make reasonable adjustments to 
enable continued working after diagnosis. Contrasting approaches to money 
management are suggested as helpful. 
Table 4.1.8  Content of cluster 8, Social living   
Item Mean 
importance 
rating 
Having a supportive network of family and friends 4.09 
Having a familiar daily routine. 3.95 
Having family and friends who offer practical support 3.88 
Having a stable relationship with a partner 3.82 
If the person with HD has help to be able to get out and about 3.62 
Having a positive outlook on life 3.49 
If he or she is able to talk freely and openly about HD within the family 3.57 
Having opportunities for meaningful conversation 3.49 
Having help to socialise 3.35 
If there is availability of food that is appetising and manageable 3.17 
Living for today 3.08 
Participating in physical activities 3.05 
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Having someone to sort out his or her access to financial benefits 3.03 
Knowing in advance the detailed plans for what will happen today and / or at 
forthcoming events 
2.83 
Being able to take up hobbies and pastimes 2.83 
Having practical strategies to enable him or her to eat out without embarrassment 2.78 
Having community understanding 2.77 
Having accessible town, transport and shop facilities 2.71 
If employers make reasonable adjustments to enable continued employment 2.66 
Direct access to cash benefits to spend on what is needed now 2.63 
Participating in intellectual activities 2.60 
Being able to undertake domestic activities such as cooking, gardening and 
cleaning 
2.55 
If they are enabled to maintain the roles that they feel suit their gender 2.51 
Still being able to drive. 2.28 
Spending money while he or she is able to 2.12 
Having alcohol 1.89 
Having cigarettes 1.83 
Being prudent with money 1.68 
Having a smoking aid 1.66 
 
 
Cluster 9, Insight 
The issue of the extent to which a person with HD might posess insight is the subject 
of further tension between perspectives that is also discussed below with regard to 
subgroup differences. This cluster contained four statements to do with the person 
with HD being able to accept his or her diagnosis, and being listened to and believed; 
and also knowing and not knowing if family members have a positive HD diagnosis. 
Insight proved to be a controversial issue. All participants appeared to see value in 
knowing the genetic status of family members regarding HD but some also placed 
some value on not knowing. One parent described the one consolation felt by him 
and his wife after their 20+ year-old son died in an accident. They shared a sense of 
relief that they had kept the family legacy of HD a secret from their son and that he 
had been able to enjoy living as long as he did without ever having been troubled 
with the knowledge of his at-risk status.  
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Table 4.1.9    Content of cluster 9, Insight 
Item Mean 
If they are listened to as an adult and believed and respected. 3.72 
If they accept the diagnosis. 3.26 
Knowing if other family members are genetically positive for HD 2.23 
Not knowing whether other family members are genetically positive for HD 1.86 
 
 
Comparison between perspectives of the three subgroups  
Some differences in how the statements were prioritised and clustered were found 
when the data from subgroups (people with HD, caregivers, health professionals, 
participants with HD experience from a nursing home context / community-based 
context) were analysed separately and compared.  
People with HD 
The priority order of the 94 statements for this subgroup is shown in Appendix 4.3. 
A ten-cluster solution was arrived at following the process and Table 4.2 below 
demonstrates that the highest scoring cluster for people with HD was ‘Being 
Trusted’. Appendix 4.3 shows the content of each of the clusters for this subgroup. 
. 
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Fig 4.2 Cluster map for People with HD  
 
 
The highest scoring cluster contains five statements including ‘what helps people with HD live with their condition is if they are 
 listened to as an adult and believed and respected’ and ‘…still being able to drive’ as shown in Table 4.2.1 below. Tables 4.2.1 to  
4.2.10 show the statements that make up each cluster in the cluster map for people with HD.  
  
 
Rank order and cluster name (1=most important) Mean 
importance 
rating 
1  Being trusted to take part 3.29 
2  Medical input  3.27 
3  Social network 3.22 
4  Expertise 3.19 
5  Attitudes and participation  3.13 
6  Care  2.95 
7  Choice & help to continue normal living 2.94 
8    Being understood and supported  2.94 
9    Care homes  2.29 
10  Coping by avoiding  1.84 
1 Trusted 
2 Medical 
3 Social Network 
5 
Attitudes/Participatio
n 
 
4 Expertise 
5 Care 
8 
Understood/ 
Supported 
7 Choice / 
Normal 
Living 
10 
Avoid 
3 Social 
Network 
Table 4.2: Clusters for people with HD in priority order based 
on mean score (Cluster 1 = most important). 
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Cluster 1 for people with HD: being trusted to take part.  
For people with HD the cluster rated as most important emphasises their wish to be 
trusted to say what the need and don’t need and determine what they are able to do. 
During the generation of the statements in this cluster in brainstorming sessions 
some people with HD expressed resentment about family members and professionals 
reaching conclusions about whether they should still be able to the shops or continue 
driving. The participants were mostly support group members and valued 
involvement in the groups, especially when this enabled them to engage in activities 
they would not manage without the group such as gliding, absailing and camping.  
Participation in research gave some a feeling that despite their own deterioration, 
they can contribute to preventing their children from sharing the same fate.    
Table 4.2.1,  Cluster 1, Being trusted to take part (PwHD) 
 
Statements (1= most important). 
Mean 
importance 
rating 
If they are listened to as an adult and believed and respected. 3.79 
Still being able to drive. 3.42 
Being involved in a Huntington's Disease Association support group 3.32 
Having the opportunity to be involved in research 3.21 
Having accessible town, transport and shop facilities 2.74 
 
 
Cluster 2 for people with HD, Medical input. 
 
This cluster of statements mostlty concerned with interventions such as medical 
treatments, genetic testing and counselling was rated highly by people with HD, with 
a score very close to that of cluster 1 (mean rating =3.27 compared to 3.29). In 
brainstorming sessions people with HD were frequently noted to express frustration 
at experiencing symptoms of HD despite going to see consultants. The hope for a 
cure was mentioned only among this subgroup. Some keenly expressed willingness 
to try experimental medications and the purpose of treatments was frequently noted 
as being enabled to continue or return to enjoying ‘normal’ life activities. 
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Expectations that medical expertise should be able to improve life seem to be 
stronger among people with HD than among carers or professionals.     
 
Table 4.2.2  Cluster 2, Medical input (PwHD) 
 
Rank order and name of statements (1= most important). 
Mean 
importance 
rating 
 If there is expert assessment and treatment of mental health problems (e.g. depression,  
 anxiety) occurring along with HD 
3.79 
Medication against chorea to help the person with HD do activities such as sleep, have a 
sex life, reduce distress, reduce fatigue and carry out activities of living. 
3.68 
Having support from the Huntington's Disease Association. 3.68 
The availability of a genetic test 3.58 
Medication against chorea 3.53 
If obsessive behaviour and impulsivity are recognised as serious symptoms of HD 3.32 
A prompt diagnosis 3.21 
Having the goal of a normal life when considering the use of medication 3.17 
Access to experimental treatments (not as part of research, but to find a treatment that    
works for the person with HD). 
3.16 
Having access to the right level of information about  HD at the right time 2.84 
 Pre-test and post-test counselling 2.84 
 Knowing that side effects of drugs for HD can be serious 2.42 
 
 
 
Cluster 3 for people with HD, Social network 
 
People with HD often referred to the importance of family and friends, of a stable 
relationship, familiar routines in the home and other aspects of social living 
identified in table 4.2.3 during brainstorming sessions. Some voiced the opinion that 
life with HD would be very much more difficult for people without a strong social 
network and a limitation to this study acknowledged earlier is failure to recruit many 
participants in that situation, the overwhelming majority being support group 
members. One participant said that stability was so important that it over-rode the 
importance of staying with her husband: ‘I told him to think about the future when 
I’ll be as ill with HD as my father was, and decide if you’re going to stay the course- 
if not leave now… I’ll cope with you or without you, but not with the disruption of 
you changing your mind at a later stage and leaving home then. He told me he’d 
stay, but I said, no, think about it some more and tell me in a month- then you have 
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to promise to stick to your decision however difficult my behaviour becomes. He did 
decide to stay.’ 
Table 4.2.3  Cluster 3,  Social Network (PwHD) 
 
Statements 
Mean 
importance 
rating 
Having a supportive network of family and friends 4.11 
Having a stable relationship with a partner 4.00 
If the family carer has a break from looking after him or her 3.89 
Having help to socialise 3.63 
If carers are listened to as an adult and believed and respected 3.63 
Having a familiar daily routine. 3.47 
Having opportunities for meaningful conversation 3.26 
Having assistance to eat and drink 2.89 
Being able to undertake domestic activities such as cooking, gardening and cleaning 2.89 
Knowing if other family members are genetically positive for HD 2.58 
If they are enabled to maintain the roles that they feel suit their gender 2.37 
Being prudent with money 1.95 
 
 
 
Cluster 4 for people with HD, Expertise 
 
The fourth most important cluster for people with HD is ‘Expertise’ and the statements within that 
cluster are listed below in table 4.15. The statements about expertise specific to HD for professionals 
and teams of professionals scored highest in the cluster. 
 
Table 4.2.4  Cluster 4, Expertise (PwHD) 
 
Statements 
Mean 
importance 
rating 
Access to professionals who are expert in HD 4.32 
Access to a multi-disciplinary team that is expert in HD 3.58 
If there is information about HD for health professionals in general medical settings 3.58 
Being referred to a specialist National HD centre 3.21 
Recognition that antipsychotic medication can be helpful in HD 3.05 
Having medicines to help sleep 2.89 
Having appropriately timed reviews of medication 2.79 
Knowing that the effects of medications for HD are variable 2.74 
Knowing that sedative medication will not be given solely to manage behaviour 2.58 
 
 
Cluster 5, Attitudes and participation. 
 
In this cluster the statements (as listed in table 4.2.5) link attitudes such as having a positive outlook 
and accepting the diagnosis, living for today and talking openly and freely about HD; to having the 
support and help to participate- this aspect of taking part is different to that highlighted in cluster one 
where the emphasis was on being trusted to shop and drive. Here, areas where there may be more 
dependence on others to enable participation are grouped together.  
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Table 4.2.5  Cluster 5, Attitudes and participation (PwHD) 
 
Statements 
Mean 
importance 
rating 
Having a positive outlook on life 4.11 
Having family and friends who offer practical support 3.84 
If they accept the diagnosis. 3.47 
If the person with HD has help to be able to get out and about 3.42 
If there is availability of food that is appetising and manageable 3.32 
Participating in physical activities 3.26 
Being able to take up hobbies and pastimes 3.26 
Having someone to sort out his or her access to financial benefits 3.21 
Living for today 3.11 
Participating in intellectual activities 3.00 
Practical advice on specific foods and textures 2.89 
If he or she is able to talk freely and openly about HD within the family 2.89 
Having practical strategies to enable him or her to eat out without embarrassment 2.84 
Spending money while he or she is able to 2.58 
Direct access to cash benefits to spend on what is needed now 2.58 
Knowing in advance the detailed plans for what will happen today and / or at 
forthcoming events 
2.32 
 
 
 
Cluster 6 for people with HD, Care. 
 
‘Care’ was identified as the theme connecting the 18 statements in the sixth most important cluster for 
people with HD (Table 4.2.6). As will be demonstrated in later sections of this thesis, care aspects 
generally held a higher priority among family caregivers and health professionals who tended not to 
attribute participation and autonomy with as high priority as people with HD did.    
Table 4.2.6  Cluster 6,  Care (PwHD) 
 
Statements 
Mean 
importance 
rating 
Having good quality healthcare professionals and carers who are good communicators; 
share information; stay calm and avoid confrontation 
3.67 
Not being cared for in an inappropriate setting (e.g. A psychiatric or elderly setting 
where staff don't know about HD). 
3.58 
Having continuity of care staff, (e.g., professional carers in homes or that visit at home). 3.58 
If care is available when the person with HD needs it. 3.58 
Continuity of health and social care professionals 3.47 
If family carers are believed when they report reaching a tipping point, where care at 
home is no longer manageable. 
3.47 
When service provision is planned for when it will be needed, rather than thought about  
once things have already got difficult 
3.32 
Regular and timely access to health and social care assessment 3.16 
If professionals work with all members of the family 3.05 
If a care home environment is made to feel as home should feel 2.79 
If people with HD know the role of each professional 2.63 
If professionals follow up patients who do not keep appointments 2.53 
Regular timely assessment for aids and adaptations 2.47 
Effective interagency working 2.42 
Having timely access to appropriate aids and adaptations 2.37 
Recognition that facial and neck pain can be a problem in HD. 2.37 
Timeliness in access to care homes 2.32 
Timely introduction of tube feeding 2.26 
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Cluster 7 for people with HD, Choice & help to continue normal living 
 
A statement about being able to make choices about aspects of care including end of 
life care tended to be placed by people with HD into the same cluster as the other 10 
statements shown in table 4.2.7 most of which are about having help- including 
training to use equipment- to overcome problems associated with HD such as 
swallowing and communicating difficulties, and be able to get on with ordinary daily 
activities and carry on in employment as far as possible.  The statement about 
availability of pre-implantation diagnosis also emphasises the importance of being 
enabled to make choices. The validation group in agreement with the research team 
concluded that the theme binding these statements making up the 7th most important 
cluster for people with HD was being able to continue making choices while being 
helped to live as normally as possible. 
Table 4.2.7  Cluster 7, Choice & help to continue normal living 
 
Statements 
Mean 
importance 
rating 
Speech and language therapy involvement to help with swallowing problems 3.95 
Speech and language therapy involvement in maintaining ability to communicate 3.74 
Making choices about care including end of life care in advance and having the choice 
respected 
3.58 
If visiting carers are flexible regarding the specific type of care they provide 3.28 
Having aids to enable daily living (eg. aids that help with communication, mobility, 
furniture, bathroom and falls prevention). 
3.11 
If professional carers are flexible about who they help in the household (for example, 
being  prepared to help children, so that the spouse  can help the person with HD, if the 
person with HD doesn’t want help from the professional carer). 
2.95 
Availability of pre-implantation diagnosis 2.53 
If employers make reasonable adjustments to enable continued employment 2.47 
Having alcohol 2.32 
Having appropriate training to use equipment 2.26 
If professionals help the person with HD to get a life 2.21 
  
 
Cluster 8, for people with HD, Being understood and supported 
 
The steering and validation groups agreed that the theme running through six 
statements in this eighth priority cluster for people with HD was the need to feel 
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understood and supported.  Some overlap between some clusters was acknowledged, 
for example, the issue of choice also appears here, as it does in cluster seven.  But it 
was felt that the main emphasis demonstrated by people with HD in frequently 
grouping the statements in Table 4. together, and apart from statements in other 
clusters was focussed on ways in which they could be helped by being understood- 
for example through training for informal carers, by having aggressive behaviour 
carefully assessed and by there being greater awareness about HD in the community; 
and supported by effective multi-disciplinary working and having care provided 
where needed. Notes taken in brainstorming sessions suggest many people with HD 
felt care often needed to be given at home but accepted that it can become preferable 
to have care in a nursing home, and if so this should be near home so that family 
may visit and day visits back home are manageable. While prepared to travel 
distances for expertise to assess and treat, and arrange and organise care (see cluster 
3 all participants, Table 4.1.3), people with HD did not appreciate receiving care 
long distances from home. In the context of the statement being set into this cluster, 
the choice regarding GP gender was taken by the steering and validation groups to 
mean that this would help facilitate a comfortable, open and supportive dialogue.   
 
Table 4.2.8  Cluster 8, Being understood and supported (PwHD) 
 
Statements 
Mean 
If care is available where the person with HD needs it. 4.05 
Effective multi-disciplinary working 3.05 
If informal carers have training in HD 3.00 
Assessment of management of aggression if it occurs. 2.79 
Having community understanding 2.74 
Having a choice about seeing a male or a female GP 2.00 
 
 
 
Cluster 9 for people with HD, Care Homes.  
 
Two statements specifically relating to living in care homes shown in Table 4.2.9 
comprised the ninth most important cluster for people with HD.  
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Table 4.2.9   Cluster 9, Care homes (Pw HD) 
 
Statements 
Mean 
importance 
rating 
Being able to go away from the care home to engage in community activities 2.68 
Having meaningful relationships with other care home residents 1.89 
 
 
 
Cluster 10 for people with HD, Coping by avoiding. 
 
The grouping of statements concerned with smoking together with the suggestion 
that it is helpful not to know whether other family members are genetically positive 
for HD (Table 4.2.10) suggested to the steering group and validation group that 
people with HD regarded these as ways to cope by avoiding having to think about 
HD and its impact on the family. This was supported by notes from brainstorming 
sessions that recorded comments from some people with HD suggesting that 
smoking is an important factor in ‘taking your mind off all these problems’. 
 
 
Table 4.2.10  Cluster 10, Coping by Avoiding (Pw HD) 
 
Statements 
Mean 
importance 
rating 
Not knowing whether other family members are genetically positive for HD 2.00 
Having cigarettes 1.89 
Having a smoking aid 1.63 
 
 
 
Caregivers 
The priority order of the 94 statements for the caregiver subgroup is shown in 
appendix 4.4. A ten-cluster solution was agreed and Fig 4.3 and Table 4.3 below 
demonstrate that the highest scoring cluster for caregivers was ‘Long term planning’.  
Tables 4.3.1 to 4.3.10 present the statements making up the content of each caregiver 
cluster. 
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Fig 4.3 Concept map for caregivers                
 
The highest scoring cluster for caregivers, Long term planning’ contains five statements referring to issues including support from the  
Huntington's Disease Association and choices about end of life care, as shown in Table 4.3.1 below. Tables 4.3.1 to  
4.3.10 show the statements that make up each cluster in the cluster map for caregivers.  
  
 
 
Table 4.3  Clusters for caregivers in 
priority order based on mean score 
(Cluster 1 = most important). 
Mean 
importance 
rating 
1 Long term planning 3.41 
2 Carers  3.40 
3 Integrated expertise 3.31 
4 Accepting aids, advice and assistance 3.25 
5 Access to innovations 2.99 
6 Social living 2.93 
7 Continuing active engagement 2.88 
8 Medical input 2.76 
9 Timely aids and communication 2.70 
10 Smoking 1.46 
 10 Smoking 
1 Long 
Term 
Planning 
2 Carers 
3 Integrated 
Expertise 
5 
Innovations 
6 
Social Living 
4 Aids, 
advice, 
assistance 
7 Active 
engagement 
8 Medical 
9 Timely aids 
and 
communication 
106 
 
Cluster 1 for caregivers, Long term planning 
The theme for the most important cluster for caregivers is long term planning. This 
links having support form the Huntington’s Disease Association with statements 
relating to therapy to help with swallowing difficulties (a feature of advanced 
disease), regular assessment for aids and adaptations and training to use equipment, 
and choices about end of life care (Table 4.3.1).  
Table 4.3.1   Cluster 1 for caregivers: Long term planning. Mean 
importance 
rating 
Having support from the Huntington's Disease Association. 3.88 
Speech and language therapy involvement to help with swallowing problems 3.88 
Regular timely assessment for aids and adaptations 3.38 
Making choices about care including end of life care in advance and having the 
choice respected 
3.16 
Having appropriate training to use equipment 2.73 
 
 
 
 
Cluster 2 for caregivers, ‘Carers’. 
 
This second most important cluster for family carers consists of three statements 
directly relating to the treatment of carers- being listened to and being able to take a 
break; to having help from visiting carers, paid and unpaid; and to suitability of a 
care home (Table 4.3.2). Incorporating the concern about quality of care homes into 
this cluster was considered by the validation group to infer that knowing a loved one 
is receiving good residential care helps carers to live with not having the person at 
home.  
 
Table 4.3.2  Cluster 2 for caregivers ‘Carers’.  Mean 
importance 
rating 
If family carers are believed when they report reaching a tipping point, where care 
at home is no longer manageable. 
4.19 
If the family carer has a break from looking after him or her. 3.88 
If carers are listened to as an adult and believed and respected 3.58 
If a care home environment is made to feel as home should feel 3.15 
If visiting carers are flexible regarding the specific type of care they provide 3.08 
If professional carers are flexible about who they help in the household (for 2.54 
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example, being  prepared to help children, so that the spouse  can help the person 
with HD, if the person with HD doesn’t want help from the professional carer). 
 
 
 
 
Cluster 3 for caregivers, Integrated expertise 
 
Twenty three statements make up the third most important cluster for caregivers 
within which the steering and validation groups agreed the central theme is 
integrated expertise (Table 4.3.3).  
 
Table 4.3.3  Cluster 3 for caregivers, Integrated expertise 
 
Statements 
Mean 
importance 
rating 
If care is available when the person with HD needs it. 4.23 
Being referred to a specialist National HD centre 4.12 
Access to professionals who are expert in HD 4.04 
Having good quality healthcare professionals and carers who are good 
communicators; share information; stay calm and avoid confrontation 
4.00 
Having continuity of care staff, (e.g. professional carers in homes or that visit at 
home). 
3.88 
Access to a multi-disciplinary team that is expert in HD 3.77 
Not being cared for in an inappropriate setting (e.g. A psychiatric or elderly 
setting where staff don't know about HD). 
3.69 
Having access to the right level of information about  HD at the right time 3.62 
If care is available where the person with HD needs it 3.62 
If there is expert assessment and treatment of mental health problems (eg. 
depression, anxiety) occurring along with HD 
3.58 
If informal carers have training in HD 3.38 
Continuity of health and social care professionals 3.35 
Regular and timely access to health and social care assessment 3.27 
If professionals help the person with HD to get a life 3.23 
When service provision is planned for when it will be needed, rather than 
thought about  once things have already got difficult 
3.23 
If professionals work with all members of the family 3.08 
If there is information about HD for health professionals in general medical 
settings 
3.08 
Effective interagency working 2.77 
If people with HD know the role of each professional 2.77 
If professionals follow up patients who do not keep appointments 2.73 
Effective multi-disciplinary working 2.65 
Timeliness in access to care homes 2.50 
Having a choice about seeing a male or a female GP 1.50 
 
 
 
 
Cluster 4 for caregivers, Accepting aids, advice and assistance 
 
The fourth most important cluster for caregivers contains five statements relating to 
the person with HD accepting aids, advice and assistance (Table 4.3.4). In 
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brainstorming sessions caregivers frequently mentioned that coping with HD is 
much easier if the person with the diagnosis accepts the need for help and advice and 
aids and equipment if these are needed. 
 
 
Table 4.3.4   Cluster 4 for caregivers, Accepting aids, advice and 
assistance 
 
Statements 
Mean 
importance 
rating 
Having aids to enable daily living (e.g. Aids that help with 
communication, mobility, furniture, bathroom and falls prevention). 
3.73 
Having assistance to eat and drink 3.38 
If they accept the diagnosis 3.27 
If there is availability of food that is appetising and manageable 3.12 
Practical advice on specific foods and textures 2.72 
 
 
 
 
Cluster 5 for caregivers, Access to innovations 
 
The theme of the fifth most important cluster for caregivers is having access to a 
broad range of innovations such as diagnosis, pre-implantation diagnosis, medication 
reviews, management of aggression, genetic counselling, and experimental 
treatments (Table 4.3.5). 
 
Table 4.3.5  Cluster 5 for caregivers, Access to innovations Mean 
importance 
rating 
A prompt diagnosis 3.38 
Having appropriately timed reviews of medication 3.20 
Assessment of management of aggression if it occurs. 3.15 
Having the opportunity to be involved in research 3.00 
Pre-test and post-test counselling 3.00 
Access to experimental treatments (not as part of research, but to find a 
treatment  that works for the person with HD). 
2.65 
Availability of pre-implantation diagnosis 2.58 
 
 
 
 
Cluster 6 for caregivers, Social living 
 
Cluster 6, sixth most important for caregivers (Table 4.3.6) is large in terms of the 
number of included statements (27) and is concerned with many aspects of social 
living.   
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Table 4.3.6   Cluster 6 for caregivers, Social living Mean  
Having a familiar daily routine. 4.19 
Having a supportive network of family and friends 4.15 
If the person with HD has help to be able to get out and about 4.04 
Having a stable relationship with a partner 4.04 
Having family and friends who offer practical support 4.04 
If he or she is able to talk freely and openly about HD within the family 3.81 
Having a positive outlook on life 3.62 
Having help to socialise 3.46 
Having opportunities for meaningful conversation 3.46 
Participating in physical activities 3.31 
Having someone to sort out his or her access to financial benefits 3.19 
If they are listened to as an adult and believed and respected. 3.19 
Living for today 3.00 
Being able to take up hobbies and pastimes 2.92 
Knowing in advance the detailed plans for what will happen today and / 
or at forthcoming events 
2.77 
Having accessible town, transport and shop facilities needed now 2.77 
Having community understanding 2.69 
Having practical strategies to enable him or her to eat out without 
embarrassment 
2.54 
Participating in intellectual activities 2.50 
If they are enabled to maintain the roles that they feel suit their gender 2.35 
If employers make reasonable adjustments to enable continued 
employment 
2.31 
Being able to undertake domestic activities such as cooking, gardening 
and cleaning 
2.27 
Spending money while he or she is able to 2.00 
Having alcohol 1.88 
Still being able to drive. 1.77 
Having cigarettes 1.58 
Being prudent with money 1.50 
 
 
 
 
Cluster 7 for caregivers, Continuing active engagement. 
 
The seventh most important cluster for caregivers is concerned with people with HD 
being able to actively engage within Huntington’s Disease Association support 
groups, the community and within care homes (Table 4.3.7).  
 
ITable 4.3.7   Cluster 7 for caregivers, Continuing active engagement Mean  
Being involved in a Huntington's Disease Association support group 3.85 
Being able to go away from the care home to engage in community 
activities 
2.65 
Having meaningful relationships with other care home residents 2.15 
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Cluster 8 for caregivers, Medical input 
 
Table 4.3.8 groups together 11 statements relating to various aspects of what the 
steering and validation groups saw as perceived by caregivers as medical input. This 
was rated the eighth most important cluster for caregivers.  
 
Table 4.3.8   Cluster 8 for caregivers, Medical input.  Mean  
Medication against chorea to help the person with HD do activities such 
as sleep, have a sex life, reduce distress,  
reduce fatigue and carry out activities of living 
3.50 
Having medicines to help sleep 3.23 
Medication against chorea 3.12 
If obsessive behaviour and impulsivity are recognised as serious 
symptoms of HD 
3.04 
Having the goal of a normal life when considering the use of medication 3.00 
The availability of a genetic test 2.92 
Knowing that side effects of drugs for HD can be serious 2.54 
Recognition that antipsychotic medication can be helpful in HD 2.42 
Knowing that sedative medication will not be given solely to manage 
behaviour 
2.31 
Knowing that the effects of medications for HD are variable 2.27 
Recognition that facial and neck pain can be a problem in HD. 2.00 
  
 
 
Cluster 9 for caregivers, Timely aids and communication. 
 
The ninth most important cluster for caregivers links five statements concerned with 
timely access to aids and with communication (Table 4.3.9).  
 
Table 4.3.9   Cluster 9 for caregivers, Timely aids and communication  
 
Statement  
Mean 
importance 
rating 
Having timely access to appropriate aids and adaptations 3.58 
Speech and language therapy involvement in maintaining ability to 
communicate 
3.54 
Timely introduction of tube feeding 2.46 
Knowing if other family members are genetically positive for HD 2.00 
Not knowing whether other family members are genetically positive for HD 1.92 
 
 
 
 
Cluster 10 for caregivers, Smoking 
 
The statement about having a smoking aid was isolated within its own cluster by 
caregivers, and rated as the least important cluster for this subgroup (Table  4.3.10). 
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Table 4.3.10    Cluster 10 for caregivers, Smoking 
 
Statement 
Mean 
importance 
rating 
Having a smoking aid 1.46 
 
 
Health professionals 
The priority order of the 94 statements for the health professional subgroup is shown 
in Appendix 4.5. A ten-cluster solution was agreed (see Fig 4.4 and Table 4.4). The 
highest scoring cluster for health professionals was ‘Later stages’ and Tables 4.4.1 to 
4.4.10 below present the statements making up each cluster in priority order.  
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Fig 4.4   Cluster map for Health Professionals 
 
 
 
 
 
 
 
1  Later stages  3.95 
2  Co-morbid mental health problem  3.85 
3  Care setting 3.33 
4  Expertise 3.33 
5  Practical support 3.31 
6  Timely, flexible, appropriate care 3.20 
7  Medical input  2.99 
8  Decision-making   2.91 
9  Social living 2.88 
10 Family implications 1.92 
  2 Mental 
Health  
 
Table 4.4  Clusters for health professionals in priority order 
based on mean score (cluster 1 = most important). 
 
 
10 Family 
Implications 
9 Social Living 
1 Later 
Stages 
3 Care setting 
 
7 Medical 
Input 
8 
Decision 
Making 
5 Practical Support 
 
6 Appropriate Care 
4 Expertise 
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The statements that make up each of the health professional clusters are shown in 
Tables 4.4.1 to 4.4.10. 
Cluster 1 for health professionals, Later Stages. 
The highest priority cluster for health professionals contains two statements that both 
relate to later stages of HD: end of life care and having assistance to eat and drink 
(Table 4.4.1).  
Table 4.4.1    Cluster 1 for health professionals, Later Stages. 
 
Statement 
Mean 
Importance 
Rating 
Making choices about care including end of life care in advance and having the 
choice respected 
4.15 
Having assistance to eat and drink 3.75 
 
 
 
Cluster 2 for health professionals, Mental health. 
 
For health professionals the second highest rated cluster is made up of a single 
statement and is identical to the most highly rated cluster for combined subgroups, 
which prioritises having expert assessment and treatment of mental health problems 
occurring with HD (Table 4.4.2).  
 
Table 4.4.2   Cluster 2 for health professionals, Mental Health. 
 
Statement 
Mean 
priority 
rating  
If there is expert assessment and treatment of mental health problems (e.g. 
Depression, anxiety) occurring along with HD 
3.85 
 
 
 
 
Cluster 3 for health professionals, Care setting 
 
The cluster rated as third priority for health professionals contains three statements 
suggesting the importance of a care environment in which staff members have 
knowledge of and traing about HD and which is made to feel like home. Notes from 
brainstorming sessions recorded participants from all subgroups mentioning that 
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placement for people with HD in general psychiatric or elderly care settings was 
inappropriate (Table 4.4.3).  
 
Table 4.4.3  Cluster 3 for health professionals, Care setting. 
 
Statement 
Mean 
priority 
rating 
Not being cared for in an inappropriate setting (eg. A psychiatric or elderly 
setting where staff don't know about HD). 
3.90 
If informal carers have training in HD 3.05 
If a care home environment is made to feel as home should feel 3.05 
 
  
 
Cluster 4 for health professionals, Expertise 
 
The eleven statements making up the fourth priority cluster for health professionals 
highlights the importance of access to integrated team working among professionals 
with specialist HD expertise (Table 4.4.4).  
Table 4.4.4   Cluster 4 for health professionals, Expertise.  Mean 
priority 
rating 
Access to a multi-disciplinary team that is expert in HD 4.10 
Access to professionals who are expert in HD 4.05 
Regular and timely access to health and social care assessment 4.00 
Effective multi-disciplinary working 3.70 
Having good quality healthcare professionals and carers who are good 
communicators; share information; stay calm and avoid confrontation 
3.65 
Effective interagency working 3.30 
Being referred to a specialist National HD centre 3.05 
Continuity of health and social care professionals 3.05 
If there is information about HD for health professionals in general medical 
settings 
2.70 
If professionals follow up patients who do not keep appointments 2.60 
If people with HD know the role of each professional 2.45 
 
 
 
Cluster 5 for health professionals, Practical support. 
The steering and validation groups agreed that the theme of practical support is 
central to the twelve statements making up the fifth highest priority cluster for health 
professionals (Table 4.4.5).  
 
Table 4.4.5   Cluster 5 for Health professionals, Practical support Item 
 
Statement 
Mean 
priority 
rating 
Having aids to enable daily living (e.g. aids that help with communication, 
mobility, furniture, bathroom and falls prevention). 
4.00 
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Speech and language therapy involvement to help with swallowing problems 3.95 
If family carers are believed when they report reaching a tipping point, where 
care at home is no longer manageable. 
3.80 
Having timely access to appropriate aids and adaptations 3.75 
Regular timely assessment for aids and adaptations 3.60 
Speech and language therapy involvement in maintaining ability to 
communicate 
3.60 
If the family carer has a break from looking after him or her. 3.60 
If professionals help the person with HD to get a life 3.15 
Having support from the Huntington's Disease Association. 3.10 
Having access to the right level of information about  HD at the right time 3.05 
Having a choice about seeing a male or a female GP 2.15 
Having appropriate training to use equipment 1.95 
  
 
 
Cluster 6 for health professionals, Timely flexible, appropriate care. 
 
The importance of timeliness and flexibility and the appropriateness of care for 
people with HD is expressed in the sixth highest rated cluster for health 
professionals, containing eight statements (Table 4.4.6). 
Table 4.4.6   Cluster 6 for  health professionals, Timely, flexible, 
appropriate care 
Mean  
If care is available when the person with HD needs it 3.85 
When service provision is planned for when it will be needed, rather than 
thought about  once things have already got difficult 
3.80 
If care is available where the person with HD needs it. 3.65 
If professionals work with all members of the family 3.20 
Having continuity of care staff, (e.g., professional carers in homes or that visit 
at home) 
3.00 
Timeliness in access to care homes 2.80 
If professional carers are flexible about who they help in the household (for 
example, being prepared to help children, so that the spouse  can help the person 
with HD, if the person with HD  doesn't want help from the professional carer). 
2.70 
If visiting carers are flexible regarding the specific type of care they provide 2.60 
 
 
 
Cluster 7 for health professionals, Medical input. 
 
The theme of medical input was not given as high a priority rating by health 
professionals (seventh highest rated cluster) as by people with HD for whom it was 
the second highest aspect of what helps to live with the condition.  
 
Table 4.4.7  Cluster 7 for health professionals, Medical input 
 
Statement 
Mean 
priority 
rating 
Medication against chorea to help the person with HD do activities such as sleep, 
have a sex life, reduce distress, reduce fatigue and carry out activities of living. 
4.15 
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Medication against chorea 3.90 
Having appropriately timed reviews of medication 3.65 
Having medicines to help sleep 3.50 
Having the goal of a normal life when considering the use of medication 3.25 
Recognition that antipsychotic medication can be helpful in HD 3.20 
Assessment of management of aggression if it occurs. 3.20 
Knowing that sedative medication will not be given solely to manage behaviour 2.70 
If obsessive behaviour and impulsivity are recognised as serious symptoms of HD 2.70 
Knowing that side effects of drugs for HD can be serious 2.35 
Knowing that the effects of medications for HD are variable 2.30 
Recognition that facial and neck pain can be a problem in HD. 2.05 
Access to experimental treatments (not as part of research, but to find a treatment  
that works for the person with HD). 
1.90 
 
 
 
 
 
Cluster 8 for health professionals, Decision-making. 
 
This eighth most important cluster from the health professional viewpoint brings 
together issues such as diagnosis, genetic testing and related counselling, whether to 
take part in research, and whether to introduce tube feeding in response to 
swallowing problems, that can often present people with HD and their families and 
also health professionals with diffcult choices that must be made (Table 4.4.8).   
 
Table 4.4.8    Cluster 8 for health professionals, Decision-making.  
 
Statement 
Mean  
Pre-test and post-test counselling 3.50 
A prompt diagnosis 3.35 
Timely introduction of tube feeding 2.95 
Availability of pre-implantation diagnosis 2.75 
The availability of a genetic test 2.65 
Having the opportunity to be involved in research 2.2 
 
 
 
 
Cluster 9 for health professionals, Social living. 
 
Health professionals formed one very large (36 statements) cluster which they rated 
ninth most important, the themes of which was agreed by the steering and validation 
groups to be social living (Table 4.4.9).  
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Table 4.4.  9 Cluster 9 for health professionals, Social living 
 
Statement 
Mean 
importance 
rating 
If they are listened to as an adult and believed and respected. 4.35 
Having a familiar daily routine. 4.10 
Having a supportive network of family and friends 4.00 
If he or she is able to talk freely and openly about HD within the family 3.90 
Having opportunities for meaningful conversation 3.75 
Having family and friends who offer practical support 3.70 
Knowing in advance the detailed plans for what will happen today and / or at 
forthcoming events 
3.40 
Having a stable relationship with a partner 3.35 
If employers make reasonable adjustments to enable continued employment 3.30 
If the person with HD has help to be able to get out and about 3.25 
If carers are listened to as an adult and believed and respected 3.25 
Living for today 3.15 
Being involved in a Huntington's Disease Association support group 3.15 
If there is availability of food that is appetising and manageable 3.10 
If they accept the diagnosis. 3.05 
Having practical strategies to enable him or her to eat out without 
embarrassment 
3.05 
Being able to go away from the care home to engage in community activities 3.05 
Having a positive outlook on life 3.00 
Having help to socialise 2.95 
Having community understanding 2.90 
Practical advice on specific foods and textures 2.90 
If they are enabled to maintain the roles that they feel suit their gender 2.85 
Having someone to sort out his or her access to financial benefits 2.65 
Having accessible town, transport and shop facilities 2.60 
Being able to undertake domestic activities such as cooking, gardening and 
cleaning 
2.60 
Direct access to cash benefits to spend on what is needed now 2.55 
Participating in physical activities 2.50 
Participating in intellectual activities 2.35 
Being able to take up hobbies and pastimes 2.30 
Having cigarettes 2.10 
Having a smoking aid 1.95 
Having meaningful relationships with other care home residents 1.90 
Spending money while he or she is able to 1.85 
Still being able to drive. 1.85 
Being prudent with money 1.65 
Having alcohol 1.50 
 
 
Cluster 10, Family implications. 
 
Two polarised statements concerned with whether knowing or not knowing if other 
family members are genetically positive for HD is helpful were grouped together by 
health professionals in the cluster they rated as least important (Table 4.4.10). 
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Table 4.4.10  Cluster 10 for health professionals, Family 
implications. 
 
Statement 
Mean 
importance 
rating 
Knowing if other family members are genetically positive for HD 2.20 
Not knowing whether other family members are genetically positive for HD 1.65 
 
 
Nursing home-based subgroup 
The nursing home-based subgroup consisted of 19 Caregivers and eight health 
professionals who identified themselves as having their main involvement with HD 
relating to a person with the condition who resides at a nursing home or similar long 
term care facility. Each of the people with HD who resided at a nursing home and 
who participated in brainstorming was unable to underetake the more onerous tasks 
of prioritising and clustering statements. The priority order of the 94 statements for 
the ‘nursing home-based subgroup’ is shown in Appendix 4.6. An eight-cluster 
solution was agreed and Table 4.5 below demonstrates that the highest scoring 
cluster for the nursing home-based subgroup was ‘Care’.  
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Fig 4.5 Cluster map for the nursing home-based subgroup          
 
 
Table 4.5  Clusters for the Nuring home-based 
subgroup, Care  
 
 
 
Cluster Name  
Mean 
importance 
rating 
(cluster 1 = 
most 
important) 
1 Care 3.30 
2 Expertise 3.29 
3 Accepting innovations 3.27 
4 Interaction with a supportive network 3.21 
5 Assessment by informed professionals 3.12 
6 Medical input  3.00 
7 Social living  2.75 
8 Choices about diagnosis & consulting 2.68 
5 
Assess
ment 
6 
Medical  
4 Medic Supportive 
network   
7 Social living  
1 Care   
2 
Expertise   
8 Choices  
3 Accepting 
Innovationsl  
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The statements that make up each of the nursing home-based clusters are shown in 
Tables 4.5.1 to 4.5.8. 
Cluster 1 for the nursing home-based subgroup 
Fourteen statements make up the highest scoring (most important) cluster (‘care’) for 
the nursing home-based subgroup (Table 4.5.1). 
 
Table 4.5.1  Cluster 1 for the nursing home-based subgroup, Care. 
 
 
Mean 
importance 
rating 
If care is available where the person with HD needs it. 3084 
If care is available when the person with HD needs it. 3.84 
If family carers are believed when they report reaching a tipping point, 
where care  at home is no longer manageable. 
3.84 
Not being cared for in an inappropriate setting (eg. A psychiatric or 
elderly setting where staff don't know about HD). 
3.63 
Being involved in a Huntington's Disease Association support group 3.58 
If the family carer has a break from looking after him or her. 3.58 
Having continuity of care staff, (e.g. professional carers in homes or that 
visit at home). 
3.42 
Having support from the Huntington's Disease Association. 3.32 
If professionals help the person with HD to get a life 3.26 
If a care home environment is made to feel as home should feel 3.16 
If informal carers have training in HD 2.84 
If visiting carers are flexible regarding the specific type of care they 
provide 
2.84 
If professional carers are flexible about who they help in the household 
(for example, being  prepared to help children, so that the spouse  can 
help the person with HD, if the person with HD  doesn't want help from 
the professional carer). 
2.58 
Timeliness in access to care homes 2.47 
  
 
 
Cluster 2 for the Nursing Home-based subgroup, Care. 
Expertise is the central theme of the twelve-statement cluster rated as second most 
important for the nursing home-based subgroup (Table 4.5.2).  The aspects rated as 
most important within the cluster are having access to a multidisciplinary team and 
to individual professionals with HD expertise, and referral to a national HD centre.  
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Table 4.5.2 Cluster 2 for the nursing home-base subgroup, 
Expertise.  
Mean  
Access to a multi-disciplinary team that is expert in HD 4.32 
Access to professionals who are expert in HD 4.21 
Being referred to a specialist National HD centre 3.74 
When service provision is planned for when it will be needed, rather than 
thought about  once things have already got difficult 
3.58 
Having good quality healthcare professionals and carers who are good 
communicators; share information; stay calm and avoid confrontation 
3.53 
Having access to the right level of information about HD at the right 
time 
3.42 
Effective multi-disciplinary working 3.00 
Continuity of health and social care professionals 3.00 
Effective interagency working 2.84 
If professionals work with all members of the family 2.84 
If professionals follow up patients who do not keep appointments 2.63 
If people with HD know the role of each professional 2.42 
 
 
Cluster 3 for the nursing home-based subgroups, Accepting innovations.  
 
The steering and validation groups found the theme of this cluster, that is the factor 
that caused members of this subgroup to frequently place these six statements 
together to be less obvious than was the case for most clusters, but they agreed that 
acceptance by people with HD of a variety of innovations could be seen as a 
common thread (Table 4.5.3).  
 
Table 4.5.3  Cluster 3 for the nursing home-based subgroup, Accepting 
innovations.  
Mean  
If they accept the diagnosis. 3.68 
Speech and language therapy involvement in maintaining ability to 
communicate 
3.58 
Having timely access to appropriate aids and adaptations 3.42 
Regular timely assessment for aids and adaptations 3.37 
Timely introduction of tube feeding 3.16 
Having the opportunity to be involved in research 2.42 
 
 
Cluster 4 for the nursing home-based subgroup, Interaction with a supportive 
network. 
 
The grouping of the fourteen statements in cluster 4 was more easily understood by 
the steering and validation groups (see comments, cluster 3, above), and the theme of 
interaction with a supportive network was identified (Table 4.5.4).  
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Table 4.5.4   Cluster 4 for the nursing home-based subgroup, Interaction 
with a supportive network. 
Mean 
importance 
rating 
Having a supportive network of family and friends 4.05 
Speech and language therapy involvement to help with swallowing problems 3.95 
If he or she is able to talk freely and openly about HD within the family 3.89 
Having aids to enable daily living (eg. aids that help with communication, 
mobility, furniture, bathroom and falls prevention). 
3.89 
Having assistance to eat and drink 3.79 
If they are listened to as an adult and believed and respected. 3.63 
Having family and friends who offer practical support 3.58 
If carers are listened to as an adult and believed and respected 3.53 
Making choices about care including end of life care in advance and having 
the choice respected 
3.11 
Practical advice on specific foods and textures 3.00 
Knowing if other family members are genetically positive for HD 2.32 
Having appropriate training to use equipment 2.11 
Having meaningful relationships with other care home residents 2.11 
Not knowing whether other family members are genetically positive for HD 1.95 
 
 
 
Cluster 5 for the nursing home-based subgroup, Assessment by informed 
professionals.  
 
Two statements concerned with the value of assessment which should be regular and 
timely, and by experts; and a third promoting the importance of professionals being 
informed about HD make up this cluster ranked as fifth priority for the nursing 
home-based subgroup (Table 4.5.5).  
 
Table 4.5.5   Cluster 5 for the nursing home-based subgroup, 
Assessment by informed professionals.  
 
Statement 
Mean 
importance 
rating 
Regular and timely access to health and social care assessment 3.42 
If there is expert assessment and treatment of mental health problems (e.g. 
depression, anxiety) occurring along with HD 
3.32 
If there is information about HD for health professionals in general medical settings 2.63 
 
 
 
 
Cluster 6 for the nursing home-based subgroup, Medical input. 
 
Thirteen statements with various aspects of medical input were combined in the sixth 
most important cluster for the nursing home-based subgroup (Table 4.5.6). 
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Table 4.5.6  Cluster 6, for the nursing home-based subgroup, Medical 
input. 
 
Mean 
importance 
rating. 
Medication against chorea to help the person with HD do activities such as sleep, 
have a sex life, reduce distress, reduce fatigue and carry out activities of living. 
4.11 
Medication against chorea 3.89 
Having medicines to help sleep 3.42 
Recognition that antipsychotic medication can be helpful in HD 3.42 
Having the goal of a normal life when considering the use of medication 3.32 
Having appropriately timed reviews of medication 3.26 
Assessment of management of aggression if it occurs. 3.16 
If obsessive behaviour and impulsivity are recognised as serious symptoms of HD 2.74 
Knowing that sedative medication will not be given solely to manage behaviour 2.63 
Knowing that the effects of medications for HD are variable 2.32 
Access to experimental treatments (not as part of research, but to find a treatment  
that works for the person with HD). 
2.32 
Recognition that facial and neck pain can be a problem in HD. 2.26 
Knowing that side effects of drugs for HD can be serious 2.21 
 
 
 
Cluster 7 for the nursing home-based subgroup, Social living.  
 
The seventh most important aspect of help for people living with HD from the 
nursing home-based perspective is captured in a large cluster of 27 statements with 
social living as a central theme (Table 4.5.7). 
 
Table 4.5.7 Cluster 7 for the nursing home-based subgroup, Social living 
 
Statement 
Mean 
importance 
rating 
Having a familiar daily routine. 4.26 
Having a stable relationship with a partner 3.68 
If the person with HD has help to be able to get out and about 3.63 
Having opportunities for meaningful conversation 3.37 
Having help to socialise 3.21 
Knowing in advance the detailed plans for what will happen today and / or at 
forthcoming events 
3.21 
If there is availability of food that is appetising and manageable 3.16 
Participating in physical activities 3.16 
If employers make reasonable adjustments to enable continued employment 3.05 
Being able to go away from the care home to engage in community activities 3.05 
Having a positive outlook on life 2.94 
Living for today 2.89 
Having accessible town, transport and shop facilities 2.84 
Having practical strategies to enable him or her to eat out without 
embarrassment 
2.74 
Having someone to sort out his or her access to financial benefits 2.68 
Having community understanding 2.63 
If they are enabled to maintain the roles that they feel suit their gender 2.63 
Being able to take up hobbies and pastimes 2.63 
Direct access to cash benefits to spend on what is needed now 2.53 
Being able to undertake domestic activities such as cooking, gardening and 
cleaning 
2.37 
Participating in intellectual activities 2.32 
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Having cigarettes 2.11 
Still being able to drive. 2.11 
Spending money while he or she is able to 1.84 
Having a smoking aid 1.84 
Being prudent with money 1.79 
Having alcohol 1.68 
 
 
 
Cluster 8 for the nursing home-based subgroup, Choices about diagnosis and 
consulting. 
 
The theme within the cluster rated eighth and least important by the nursing home-
based subgroup consists of five statements that combine factors relating to making 
choices about diagnosis and counselling.  
Table 4.5.8   Cluster 8 for the nursing home-based subgroup, Choices about 
diagnosis & consulting 
 
Statement 
Mean  
A prompt diagnosis 3.05 
Pre-test and post-test counselling 3.00 
Availability of pre-implantation diagnosis 2.89 
The availability of a genetic test 2.26 
Having a choice about seeing a male or a female GP 2.21 
 
 
Community-based subgroup 
Seven caregivers and 12 health professionals identified their involvement with HD 
as community-based as opposed to nursing-home based. It is acknowledged that the 
distinction is imperfect as within one family there may be close members living at 
home and in a nursing home. The priority order of the 94 statements for the 
‘community-based subgroup is shown in Appendix 4.6. A ten-cluster solution was 
agreed and Fig 4.6 and Table 4.6 below demonstrate that the highest scoring cluster 
for the community-based subgroup was ‘avoiding crises’.  
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Fig 4.6 Concept map for the community-based subgroup  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.6   Clusters for the community-based 
subgroup in priority order based on mean score 
(cluster 1 = most important). (N=26; caregivers-
17; HPs-9) 
 
Cluster Name  
Mean 
importance 
rating 
1  Avoiding Crises 3.59 
2  Longer Term Aspects  3.46 
3  Care 3.40 
4  Information About HD 3.36 
5  Psychological Assessment and Support 3.27 
6  Expert Professionals   3.20 
7  Social living 2.86 
8  Medical input 2.82 
9  Outings 2.80 
10 Family implications 1.86 
10 Family 
8 Medical input 
5 Psychological 
Assessment and 
support 4 HD Info 
7 Socialising 
9 Outings 
10 Family 
2 Long Term 
aspects 1 Avoiding Crises 
3 Care 
3 Experts 
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The statements that make up each of the community-based clusters are shown in 
tables 4.6.1 to 4.6.10 
Cluster 1 for the community-based subgroup, Avoiding crises. 
The highest scoring (most important) cluster for the community subgroup contains 
nine statements concerned with avoidance of problems such as carers reaching a 
tipping point beyond which they cannot cope and swallowing problems in people 
with HD; and with accessing assessment and aids and adaptations at a time when 
they are needed. The theme was considered by the steering and validation groups to 
be ‘avoiding crises’ (Table 4.6.1).  
 
Table 4.6.1   Cluster 1 for the community-based subgroup, Avoiding crises  Mean 
importance 
rating 
If family carers are believed when they report reaching a tipping point, where 
care  at home is no longer manageable. 
4.15 
Speech and language therapy involvement to help with swallowing problems 3.96 
If the family carer has a break from looking after him or her. 3.88 
Having timely access to appropriate aids and adaptations 3.85 
Having aids to enable daily living (eg. aids that help with communication, 
mobility, furniture, bathroom and falls prevention). 
3.77 
Regular timely assessment for aids and adaptations 3.58 
Speech and language therapy involvement in maintaining ability to 
communicate 
3.54 
If a care home environment is made to feel as home should feel 3.12 
Having appropriate training to use equipment 2.50 
 
 
 
 
Cluster 2 for the community-based subgroup, Longer term aspects. 
 
The second most important cluster for the community-based subgroup draws 
together factors determined by the steering and validation groups as ‘longer term 
aspects’ such as end of life care choices, support from the Huntington’s Disease 
Association, carers being believed and listened to and having assistance to eat and 
drink (Table 4.6.2). 
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Table 4.6.2   Cluster 2 for the community-based subgroup, Longer term aspects. 
Statements 
 
Mean 
Importance 
rating                                                                                                                                          
Making choices about care including end of life care in advance and having the 
choice respected 
4.00 
Having support from the Huntington's Disease Association. 3.69 
If carers are listened to as an adult and believed and respected 3.42 
Having assistance to eat and drink 3.31 
Practical advice on specific foods and textures 2.72 
 
 
 
 
Cluster 3 for the Community-based subgroup, Care.  
 
Cluster 3 for the community-based subgroup combines 12 statements relating to 
assessment for, access to and provision of care (Table 4.6.3). 
 
Table 4.6.3 Cluster 3 for the Community-based subgroup, Care.  
 
Statement 
Mean 
priority 
rating 
If care is available when the person with HD needs it. 4023 
Not being cared for in an inappropriate setting (e.g. A psychiatric or elderly setting 
where staff don't know about HD). 
3.96 
Regular and timely access to health and social care assessment 3.77 
Having continuity of care staff, (e.g. professional carers in homes or that visit at 
home). 
3.58 
If informal carers have training in HD 3.54 
When service provision is planned for when it will be needed, rather than thought 
about  once things have already got difficult 
3.46 
If care is available where the person with HD needs it. 3.46 
If professionals work with all members of the family 3.42 
Effective multi-disciplinary working 3.27 
If visiting carers are flexible regarding the specific type of care they provide 2.85 
Timeliness in access to care homes 2.81 
If professional carers are flexible about who they help in the household (for example, 
being  prepared to help children, so that the spouse  can help the person with HD, if 
the person with HD doesn’t want help from the professional carer). 
2.62 
 
 
 
 
 
Cluster 4 for the Community-based subgroup, Information about HD. 
 
A single statement about having access to an appropriate level of information about 
HD constitutes the fourth priority cluster for the community-based subgroup (Table 
4.6.4). 
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Table 4.6.4    Cluster 4 for the Community-based subgroup, Information about 
HD 
 
StatementItem 
Mean 
priority 
rating 
Having access to the right level of information about  HD at the right time 3.38 
 
 
 
 
Cluster 5 for the community-based subgroup, Psychological assessment and 
support. 
 
The fifth priority cluster for the community-based subgroup contains 4 statements 
that refer to expert assessment of mental health problems, pre-and post genetic test 
counselling, management of aggression if this occurs and to timeliness of the 
introduction of tube feeding as helpful factors in living with HD (Table 4.6.5). The 
cluster was named ‘Psychological assessment and support. 
 
 
Table 4.6.5   Cluster 5 for the community-based subgroup, Psychological 
assessment and support. 
 
Statement 
Mean 
priority 
rating 
If there is expert assessment and treatment of mental health problems (e.g. 
Depression, anxiety) occurring along with HD 
3.96 
Pre-test and post-test counselling 3.38 
Assessment of management of aggression if it occurs. 3.19 
Timely introduction of tube feeding 2.38 
 
 
 
 
Cluster 6 for the community-based subgroup, Expert professionals.  
 
 
Eleven statements combine various aspects of expertise and also some of the 
attributes considered particularly helpful among professionals and underline the 
importance of access to this (Table 4.6.6).  This cluster was rated as sixth most 
important for the community-based subgroup. 
 
Table 4.6.6   Cluster 6 for the Community-based subgroup, Expert professionals 
 
Statement  
Mean 
importance 
rating 
Having good quality healthcare professionals and carers who are good 
communicators; share information; stay calm and avoid confrontation 
4.04 
Access to professionals who are expert in HD 3.88 
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Access to a multi-disciplinary team that is expert in HD 3.73 
Being referred to a specialist National HD centre 3.62 
Continuity of health and social care professionals 3.38 
Effective interagency working 3.19 
If professionals help the person with HD to get a life 3.12 
If there is information about HD for health professionals in general medical settings 3.08 
If people with HD know the role of each professional 2.85 
If professionals follow up patients who do not keep appointments 2.77 
Having a choice about seeing a male or a female GP 1.46 
 
 
 
 
Cluster 7 for the Community-based subgroup, Social living 
 
This large cluster for the community-based subgroup was rated as seventh most 
important, containing 32 statements all seen by the steering and validation groups to 
relate to some aspect of social living (Table 4.6.7).  
 
Table 4.6.7   Cluster 7 for the Community-based subgroup, Social living  
 
Statement 
Mean 
priority 
rating 
Having a familiar daily routine. 4.12 
Having family and friends who offer practical support 4.12 
Having a supportive network of family and friends 4.08 
Having a stable relationship with a partner 3.88 
If he or she is able to talk freely and openly about HD within the family 3.88 
If they are listened to as an adult and believed and respected. 3.81 
If the person with HD has help to be able to get out and about 3.69 
Having opportunities for meaningful conversation 3.69 
Having a positive outlook on life 3.58 
Being involved in a Huntington's Disease Association support group 3.50 
Having help to socialise 3.19 
Living for today 3.12 
Having someone to sort out his or her access to financial benefits 3.12 
If there is availability of food that is appetising and manageable 3.12 
If they accept the diagnosis. 2.88 
Having community understanding 2.81 
Having practical strategies to enable him or her to eat out without embarrassment 2.77 
Participating in physical activities 2.73 
Direct access to cash benefits to spend on what is needed now 2.65 
Having accessible town, transport and shop facilities 2.58 
If they are enabled to maintain the roles that they feel suit their gender 2.58 
If employers make reasonable adjustments to enable continued employment 2.58 
Being able to take up hobbies and pastimes 2.58 
Being able to undertake domestic activities such as cooking, gardening and cleaning 2.50 
Participating in intellectual activities 2.42 
Having meaningful relationships with other care home residents 2.00 
Spending money while he or she is able to 1.92 
Having alcohol 1.73 
Having cigarettes 1.62 
Still being able to drive. 1.62 
Having a smoking aid 1.58 
Being prudent with money 1.38 
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Cluster 8 for the community-based subgroup, Medical input 
 
 
The central theme for the eighth most important cluster for the community-based 
subgroup is ‘Medical input’ and is made up of 16 statements (Table 4.6.8). 
 
Table 4.6.8  Cluster 8 for the Community-based subgroup, Medical input  
 
Statement 
Mean 
priority 
rating 
A prompt diagnosis 3.62 
Medication against chorea to help the person with HD do activities such as sleep, 
have a sex life, reduce distress, reduce fatigue and carry out activities of living. 
3.50 
Having appropriately timed reviews of medication 3.48 
Having medicines to help sleep 3.23 
The availability of a genetic test 3.19 
Medication against chorea 3.08 
If obsessive behaviour and impulsivity are recognised as serious symptoms of HD 3.00 
Having the goal of a normal life when considering the use of medication 3.00 
Having the opportunity to be involved in research 2.77 
Knowing that side effects of drugs for HD can be serious 2.65 
Availability of pre-implantation diagnosis 2.42 
Knowing that sedative medication will not be given solely to manage behaviour 2.38 
Recognition that antipsychotic medication can be helpful in HD 2.31 
Knowing that the effects of medications for HD are variable 2.27 
Access to experimental treatments (not as part of research, but to find a treatment  
that works for the person with HD). 
2.23 
Recognition that facial and neck pain can be a problem in HD. 1.80 
 
 
 
 
Cluster 9 for the community-based subgroup, Outings 
 
Table 4.61 shows two statements concerned with going out within one cluster rated 
by the community-based subgroup as ninth in importance. Knowing plans in 
advance and being able to go out from a nursing home to engage in the community 
are highlighted helpful factors towards living with HD.  
  
Table 4.6.9   Cluster 9 for the Community-based subgroup, Outings 
 
Statement 
Mean 
importance 
rating 
Knowing in advance the detailed plans for what will happen today and / or at 
forthcoming events 
2.96 
Being able to go away from the care home to engage in community activities 2.62 
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Cluster 10 for the Community-based subgroup, Family implications. 
 
The cluster rated as least important for the community-based subgroup contains two 
statements indicating that both knowing and not knowing if other family members 
are genetically positive for HD can be helpful towards living with HD (Table 
4.6.10).  
 
Table 4.6.10   Cluster 10 for the Community-based subgroup, Family 
implications 
 
Statement 
Mean 
priority 
rating 
Knowing if other family members are genetically positive for HD 1.96 
Not knowing whether other family members are genetically positive for HD 1.73 
 
 
Comparing Subgroups 
To further assist comparison of the clusters formed and prioritised by people with 
HD, caregivers and health professionals Fig 4.7 presents the clustering by all 
participants and by each of these three subgroups within one diagram, highest 
prioritised cluster for each subgroup is uppermost and numbered ‘1’.  
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Fig 4.7: Diagrammatic representation of cluster names for ‘all participants’ and 
for three subgroups 
People with HD
1 Being trusted to take part
2 Medical Input
3 Social Network
4 Expertise
5  Attitude Participation
6 Care
7 Choice & normal life
8 Understood & supported
9 Care Homes
10 Disengaging
Caregivers
1  Long term plan
2  Carers
3  Integrated expertise
4  Acceptance & assistance
5 Access to Innovations
6 Social Living
7 Continuing active engagement
8 Medical Input
9 Timely aids & communication
10  Smoking
All Participants
1 Co-morbid mental health 
Problems
2 Flexible care
3 Timely integrated expertise 
4 Help to independence
5 Practical support
6 Long term care
7 Medical Input
8 Social living
9  Insight Health Professionals
1 Later stages
2 Co-morbid mental health 
problems
3 Care setting
4 Expertise
5  Practical support
6 Timely, flexible care
7 Medical Input
8 Decision-making
9 Social living
10  Family Implications
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Contrasting values identified by the primary investigator, and ratified by the steering 
group and validation group were considered to capture similarities and differences 
between three subgroups: people with HD, caregivers and health professionals (see 
Table 4.7). 
Table 4.7 Contrasting values between subgroups  
 
Carers / Professionals 
Forward planning 
 PWHD 
Living for today 
PWHD / Professionals 
Trusting the patient 
Confidentiality between 
Patient and Professional 
 
 
 
 
 
Carers 
Recognising impaired 
insight 
Professionals liaising with 
carer 
Carers  
Patient acceptance of 
condition 
Patient provided for 
Patient submission to care 
Professionals 
The professional 
perspective regarding 
these aspects seems to be 
positioned between carer 
and people with HD 
perspectives 
PWHD 
Patient autonomy 
Normal living 
Making choices 
Being understood 
Supported, not controlled 
PWHD 
Medical solution emphasis 
 Carers / Professionals 
Care solution emphasis 
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Latent preferences 
Figs 4.8-4.10 show latent preferences for people with HD, caregiver and health 
professional groups respectively to allow comparison (see methods, 3.10.8).  
Fig 4.8  Concept map showing latent preferences for people with HD 
  
 
Fig 4.9  Concept map showing latent preferences for caregivers 
 
 
Fig 4.10  Concept map showing latent preferences for health professionals. 
 
Fig 4.8 demonstrates a tendency for people with 
HD to prioritise statements relating to medical 
input, the health system and the individual and not 
to those relating to care.  
In contrast to Fig 4.8, Fig 4.9 demonstrates a 
greater tendency among caregivers to prioritise 
statements relating to care and the health system 
rather than to medical input or the individual. 
 
Fig 4.10 shows that with the exception of two outliers 
(coded P4 and P5) prioritising among health care 
professionals places greater emphasis on care than is 
placed by people with HD and greater emphasis on 
medical input than caregivers. The only professionals 
tending to prioritise statements concerned with 
individuals are the only two social workers who both also 
own and manage care homes. 
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Significant Differences 
Results from the Kruskall Wallis H non-parametric ANOVA test showed that of the 
94 items three were associated with a significant difference in how they were rated 
by subgroups as presented below in tables 4.8. 
Table 4.8   Statements associated with significant difference in rating by 
subgroups at p=0.01  
Statement Most valued by Least valued by Subgroup mean 
importance 
rating   
Kruskall-
Wallis result 
for 
significance 
at p<0.01. 
Having timely 
access to 
appropriate aids 
and adaptations 
Professionals People with HD Profs:   3.75,  
Carers: 3.58  
PwHD: 2.37 
 
P=0.002 
Still being able to 
drive 
People with HD Caregivers PwHD: 3.42 
Profs:   1.85 
Carers: 1.77 
P=0.001 
Access to 
experimental 
treatments (not as 
part of a research 
study) 
People with HD Professionals PwHD: 3.16 
Carers: 2.65 
Profs:   1.90 
P=0.008 
 
 
 
Nursing Home-Based and Community-Based Subgroup Comparison 
Of the 94 statements, statistical difference (p<0.01) in ranking between the 
community-based and the nursing home-based subgroups occurred in one case, that 
of the statement ‘What helps people with Huntington’s disease live with their 
condition is recognition that antipsychotic medication can be helpful in HD.’ This 
statement was given a higher (more important) rating by nursing home-based 
caregivers and health professional participants (3.42) than by caregivers and health 
professionals in the community-based subgroup (2.31). 
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Caution should be exercised in interpreting this difference given that there are close 
to 100 statements making the 1% probability of occurrence in one case likely purely 
by chance. Table 4.16 shows the table produced by SPSS analysis using the Mann 
Whitney U test comparing distribution between independent samples. Two other 
statements were highlighted as associated with significant difference at p<0.05, but 
this higher probability of these results occurring by chance means they cannot be 
accepted as significant.  
Having a positive outlook, and availability of genetic testing were given a higher 
mean rating by community-based (3.58 and 3.19 respectively) compared to nursing 
home-based participants (2.94 and 2.26 respectively) but the difference was not 
significant at p=<0.01 (Table 4.9). 
Table 4.9 Differences between nursing home-based and community-based 
ratings of three statements  
Statement 
‘What helps people with 
HD live with their 
condition is… 
Level of significance 
(difference between nursing 
home-based and community-
based subgroup responses) 
Context  
(where rated as more 
important) 
…recognition that 
antipsychotic medication 
can be helpful in HD’. 
P=0.008* Nursing home 
…having a positive 
outlook on life’. 
P=0.049 Community 
…availability of a genetic 
test’. 
P=0.047 Community 
Three statements in Table 4.16 were identified as ‘significant’ using Mann Whitney at p<0.05. For 
reasons explained above only significance at p=<0.01 is considered acceptable and therefore only the 
statement concerning recognition that antipsychotic medication can be helpful in HD, at (p=0.008) is 
viewed as significant. 
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Chapter Five 
Discussion 
 
5.1  Introduction 
This is the first study providing a concept map based on quantitative analysis of 
qualitative statements generated by people with HD, family caregivers and health 
professionals with HD experience, in answer to the question ‘what helps people with 
HD live with their condition?’ The labels of the concept map axis are in keeping 
with findings of others who have used concept mapping to elicit, conceptualise and 
quantitatively rate subjective opinions of people with long term conditions, carers 
and professionals. Flaherty (2014) studied coeliac disease, and found that the process 
of plotting statements on the matrix tended to polarise issues to do with medical 
input versus aspects of care or management, and personal, individual factors from 
those to do with accessing the healthcare system.  
5.2 Discussion of findings 
The principle result is a combined opinion that ‘expert assessment and treatment for 
co-morbid mental health problems occurring with HD’ is what helps most in living 
with HD. A criticism of this finding might be that the rating for the isolated 
statement constitutes the mean importance rating for the cluster, whilst other clusters 
contain statements with higher ratings. The fact that the statement became isolated as 
a cluster of its own suggests participants see it as an issue separate from the other 
themes that emerged. Ratification by the validation group, and feedback received 
from HD support group members indicating, that the cluster does capture the aspect 
of HD most difficult to manage, and for which alleviation would help most towards 
living with the condition, adds to my confidence in the validity of this cluster’s 
prioritisation. Furthermore this finding resonates with research in long term 
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conditions which consistently highlights the high impact of mental health issues. 
Mental health problems occurring with long term physical symptoms are associated 
with significantly poorer health outcomes and a lower quality of life (Naylor et al 
2012). Neurological disorders generally have a high prevalence of a variety of 
mental health problems and there is a close relationship between mental and physical 
wellbeing Royal College of Psychiatrists (2009). There is an increased level of 
disability in neurological conditions when compounded by psychiatric symptoms 
and these aspects add greatly to stress experienced by caregivers and are a significant 
factor contributing to reasons for resorting to institutional care World Health 
Organisation (2006). 
The findings add weight to the suggestion Gudesblatt and Tarsy (2011) that an 
emphasis in HD research on motor symptoms may be misplaced and that a more 
integrated mental health support approach is needed (Naylor et al 2012). The Royal 
College of Psychiatrists (2009) recommends that all national guidelines for long term 
physical conditions should include specific advice about the detection and treatment 
of co-morbid mental health problems, and The Kings Fund proposes that care for 
people with co-morbid mental and physical health conditions should be a top ten 
priority for service providers (Imison et al 2011). 
Clusters 2, 3 and 4 highlight the importance of flexibility in the delivery of 
appropriate and expert care. Hence access to HD specialist multidisciplinary care 
teams is of high importance to the participants. These findings are in keeping with 
guidelines and research in long term conditions (Department of Health  2005; 
Aspinal et al 2011) which highlight the importance of person-centred services, 
involving holistic integrated and expert multi-disciplinary and multi-agency care 
planning, review and service delivery in order to meet individual and changing 
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needs. Unfortunately this is not how current care is organised and implementing 
changes to meet these aspirations has proved extremely difficult (Sixsmith et al, 
2013). Changes to professional attitudes and ways of working can be as important as 
changes to services (Satink et al 2014; Thomas et al 2010). Prompt referral to 
specialists with neurological expertise and integrated assessment and care planning 
are considered essential within the National Service Framework (Department of 
Health, 2005). The participants in this study went further, calling for neurological 
expertise to be HD specific. The willingness to travel long distances to access such 
expertise, and the positive change to managing life with HD experienced by those 
who have managed to do so is noteworthy. Continued support for concentrated 
centres of excellence is essential but they must also establish ways to devolve their 
expertise to localised interdisciplinary teams. 
In delivering care, services and treatment it is necessary to be aware of differences in 
perspectives of people with HD, caregivers and health professionals. It is important 
to seek the opinions of people with HD with the caveat that the nature of the 
condition may impair insight, making the perspective of caregivers equally valuable. 
Professionals in this study placed a high value on listening to and believing patients, 
whereas carers expressed frustration at difficulty in having their view considered as 
equally relevant. In the context of decision-making concerning artificial hydration 
for dementia patients, nurse-physician communication has been identified as the 
most important factor for optimal care (Bryon et al 2008). In domestic settings 
family members assume the care role and where patient insight may be compromised 
it is difficult to see why carer-professional communication shouldn’t be held with the 
same high regard when difficult care or treatment decisions must be reached. 
However, professionals should also keep in mind that some family caregivers may 
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inherit the condition and that subtle cognitive changes can occur many years prior to 
diagnosis and impair insight and judgement (Paulsen et al 2007). Unless impaired 
capacity is established in the person with HD, choice is a right (Katona and 
Livingston 2013), and even if capacity is impaired, it may be counter-productive to 
highlight the fact. However the insight and expertise of carers should also be 
respected and integrated into care plans, otherwise professionals risk overloading 
carers’ capacity to cope with their role.  
Indeed, the problem of impaired insight is a central theme connecting the four 
statements associated with significant differences of opinion between subgroups. 
Professionals need to consider that impairment exists in spite of competence. An 
over-zealous concern to foster patient autonomy, at the expense of professional 
judgement and of seeking caregiver advice has potential to cause harm, for example 
through trying untested pharmaceutical interventions, allowing to continue driving or 
failing to facilitate access to aids and assistance when needed. 
5.3 Summary 
This study lends weight to research that previously identified a national and indeed 
global health system failure to adequately address co-morbid mental health problems 
occurring with neurological and other conditions with long term physical symptoms, 
in line with recommendations from the Royal College of Psychiatrists (2009) in the 
UK and the World Health Organisation (2006) report on the challenge to public 
health presented by neurological disorders. Specialist HD expertise is highly valued 
enabling timely input reflecting appreciation of needs at stages of the disease 
trajectory. Care, treatment and service provision need to adopt a flexible, integrated, 
interdisciplinary approach. Professionals need to value carer opinions and 
perspectives as well as their own judgement and balance them with the views of their 
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patients with HD. Support for centres providing specialist HD multi-disciplinary 
expertise is justified and methods of devolving their knowledge and skills to local 
services should be sought.  
5.4  Relevance of the World Health Organisation (WHO) International 
Classification of Functioning, Disability and Health (ICF) 
 
The ICF framework was referred to in the introduction to this thesis and in the 
methodology section as a conceptual model used as an aid to considering whether 
broader aspects of the health condition (in this case HD) were being addrerssed in 
this study. It was not used for classification.  
In the methodology section it was suggested that if the concept mapping method was 
successful in presenting a comprehensive map of the the areas in which people with 
HD may need help towards living with the condition then the map would incorporate 
some statements relating to each component of the ICF model. Some of the resulting 
statements such as those that call for treatment for chorea and help with swallowing 
do relate to impairment of body function and structure. Limitations on activities are 
considered in statements that value help with sleeping, having sex, smoking and 
being able to drive. The range of statements forming the cluster labelled ‘social 
living’ closely relate to restrictions on participation. Statements about shop and town 
facilities, employers making reasonable adjustments to enable continued working 
and aids and adaptations incorporate environmental factors. The impact of personal 
factors is acknowledged in statements such as those concerned with genetic testing 
and the family implications of this, spending money while able, having a positive 
attitude and living for today. Regarding the factors influencing person’s functioning, 
support and relationships are addressed in statements concerned with family, friends 
and social network; attitudes are considered in statements about having community 
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understanding, visiting carers being flexible about the care they will give, being 
listened to as an adult and believed and respected; the natural and human 
environment is considered in statements to do with issues such as availability of 
manageable and appetising food, a care home environment being made to feel as a 
home should feel and having accessible town and shop facilities; Services systems 
and policies are addressed in statements about timely assessment for aids and 
adaptations, effective interagency working, and referral to a specialist HD centre; 
and products and technology are referred to in statements concerned with 
medication, aids and equipment and genetic testing.   
Therefore the concept map derived from the study methodology has been found to 
embrace all components of the WHO ICF model adding to confidence that the 
method has successfully facilitated participants to be able to express views about a 
comprehensive range of areas of impact of the health condition (HD) where the 
various kinds of help were identified as being valued and needed.                     
The model conceptualises illness as a normal part of life experience: we will all be ill 
or impaired at some point and we can all experience disability to some degree (WHO 
2001). The idea of ‘disabled people’ being distinct from the healthy population is 
seen as an untenable proposition as is the notion that health ends where disability 
begins (WHO 2001). It is a perspective that can serve well to illuminate the 
complexity of the caregiver / care-receiver relationship assumed in this study and in 
much of the HD literature. The hereditary nature of HD meant that some of those 
who participated as caregivers may well be positive for the HD mutation (whether or 
not confirmed through genetic testing) and may have already been affected by early 
symptoms which are often subtle and can include psychological and cognitive 
impairment long before motor signs are observable (Andersson et al 2012). 
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Caregivers tended to express annoyance that some health professionals believe 
patient reports rather than seek a caregiver perspective, arguing that the patient has 
impaired insight. But in some cases health professionals may be aware of possible 
impaired insight in the caregiver also. Williams et al (2012) highlight the complexity 
of caregiving roles given that multiple family members may be ill with HD. 
The understanding within the ICF model that illness can be regarded as normal 
stresses the need to anticipate and plan for comorbidities among people with HD and 
this appears to explain the high priority given particularly by caregivers of doing so 
through timeliness in care delivery. The flexibility required by participants reflects 
the fluctuating state of health that the ICF model recognises. Health professionals 
need to remain aware that their time spent with the patient though critical (as 
opportunities to intervene and compensate for function and limit disability) is brief 
compared to the time the family spend trying to manage the impact of the condition. 
The patient presentation during consultations cannot be regarded as reliable and 
consistent; difficulties the family may face during periods of lower functioning must 
be taken into account in decision-making. 
The finding that living with HD can be helped if provision of treatment, care and 
services is timely and flexible and that even more importantly the need for expert 
assessment and treatment for mental health conditions is appreciated strongly 
suggests a view among participants that the course and impact of the condition do 
not have to follow a trajectory of increasing despair. Instead this representative 
group established that the conclusion they draw from their experience is that the 
impact can be modified and managed despite relentless pathophysiological 
deterioration. Physiological changes alone are not held to determine the experience 
of living with HD- this has at least as much to do with organisation of health and 
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social care and welfare systems in our society. Whitehead and Dahlgren (2006) 
suggest that where differences in health are systematic and socially produced they 
are unfair and unjust.  A lack of provision of psychiatric services for people with HD 
because the disease is considered by many psychiatrists to be a purely organic 
disorder is highlighted by Kenny and Wilson (2012), who indicate that people 
without HD would have easier access to assessment and treatment than people with 
HD presenting with the same psychiatric symptoms. This implies that people with 
HD suffer prolonged untreated psychiatric symptoms due to social inequity and 
injustice as described by Whitehead and Dahlgren (2006). 
The model of the main determinants of health developed by Dahlgren and Whitehead 
(1991) illustrates how general socio-economic, cultural and environmental living and 
working conditions such as the work environment, education, unemployment and 
housing impact on the wellbeing of people living within their social networks. The 
model suggests that while individual factors such as lifestyle and constitution (in this 
case living with HD) are important determinants of personal health, policies and 
strategies targeted solely at the individual level will fail to affect important 
influences. Health care services are among the higher level determining factors that 
must be addressed in efforts to improve health for individuals (Dahlgren and 
Whitehead 1991).   
The key findings of this study then can be considered to highlight inequality through 
the failure of the health care system to provide services to this minority group that 
are far more accessible to most members of society who need them.     
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5.5  Conclusions 
Contribution to knowledge 
The literature review in Chapter Two identified the need to understand patient, 
caregiver and health professional perspectives about what helps people to live with 
HD as a gap in the body of knowledge. The study has addressed that gap and has 
resulted in the first concept map that visually presents the way that an inclusive 
participant group conceptualise factors they consider to be helpful and how these 
factors are prioritised. The graphic representation facilitates explanation of the 
results to health professionals, researchers, voluntary organisations and HD family 
support groups so that decision-making about the kind of help to be sought and 
provided in future may be better informed.  
Community and institutional contexts are accounted for. The study has shown that 
expert assessment and treatment for co-morbid mental health problems occurring 
with HD, access to professionals with HD expertise, timeliness and flexibility in the 
organisation and provision of care and services are regarded as the most important 
priority areas needing to be addressed. This has important implications for the 
current emphasis of research for effective treatments which is currently 
disproportionately focussed on the movement disorder.  
The need for well-integrated interdisciplinary and interagency working that adopts a 
family-centred approach is also highlighted. There needs to be recognition of 
frustration felt by caregivers some of whom are also at risk of or have HD who are 
expected to provide ongoing care and often are left feeling excluded from 
discussions about what the patient needs. Professionals need to view principles of 
confidentiality as being in place to protect the privacy and dignity of patients rather 
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than to act as an obstacle to involving caregivers in joint planning to improve the 
quality of life of people with HD and their families. The importance of planning 
ahead to avoid crises rather than responding reactively is stressed and professionals 
must be aware that problems with insight and psychological defence mechanisms 
may prevent people with HD and some caregivers also from being able to initiate 
plans and ask for what they will need until it becomes too late. Therefore 
professionals must be prepared to proactively engage with the families to build a 
plan while working to enable those who cope by ‘living for today’ to maximise their 
potential physically, psychologically and socially in the present.  
It is important to note that participants from all subgroups looked to healthcare 
systems to provide what is helpful and to note the hopes expressed by each regarding 
the kind of help most needed. For caregivers mainly this is expert care, aids, 
equipment and facilities; for people with HD this is effective medical treatment for 
the many aspects of their condition and support to carry on living independently for 
as long as possible and for professionals this is to strive to deliver on these hopes of 
patients and family caregivers.  
Framework for dissemination 
The non-neutral stance and the role of the primary investigator as an advocate for 
people with HD and family members have been acknowledged earlier (3.2). A 
background of involvement with support networks and care home settings and the 
position of a nurse educator have in the past served to facilitate activity aimed at 
contributing to improving care, treatment and services for this group. The findings of 
this study will now add confidence to making assertions about where help should be 
focussed on behalf of the stakeholders.   
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Responsibility for ensuring the findings of this study are disseminated effectively to 
maximise potential to benefit the HD community is acknowledged and regarded 
seriously.  People with HD, family caregivers and health professionals have been 
generous with their time, knowledge and views, and have courageously engaged in 
sharing emotionally charged personal accounts of their experiences to illustrate and 
contextualise the statements they arrived at. Their trust that these efforts will make 
some difference and their entitlement to take the opportunity to express points of 
view and be heard will be respected through the implementation of an eight-point 
dissemination plan.  
Support group meetings 
Engagement with support groups for people with HD and family caregivers and 
groups of participating health care professionals has been ongoing since the planning 
stages and throughout the PhD process. The principal investigator met with the 
research steering group (HDA branch members) monthly during the year post data 
collection until the group disbanded due to practical difficulties relating to changed 
circumstances and has presented the preliminary results to each member.  
Contact with all participating groups has been maintained and the principal 
investigator has visited each to update on progress at least once since data collection 
and has visited some of the groups several times. In May 2013 a programme of 
presenting findings to groups across England and Scotland will commence and this 
will include groups to which study participants are members. It is anticipated that 
nine engagements will be spread over the next 18 months.  
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People with HD, family caregivers and health professionals value these presentations 
as they are interactive and tend to reaffirm their shared sense of what is most 
important adding to their confidence in working to access what is needed.   
European Huntington’s Disease Network (EHDN) / International Huntington’s 
Association (IHA) Involvement 
 
Having frequently attended and previously presented at both of these international 
fora for researchers, health and social care professionals and families affected by 
HD, and as a member of two EHDN working groups (quality of life and advanced 
care working groups) the principal investigator will seek to utilise the platforms to 
present the study findings and initiate discussion about how to make service 
planners, health professionals and researchers aware of the highest priorities 
identified by the participants.  
As a result of involvement with the EHDN the principal investigator has already 
taken part in a steering group supported by DeNDRoN and the HDA tasked with 
identifying priorities for HD researchers and preliminary findings presented to this 
group have influenced the strategy for working to establish areas for future research.  
International Neuroscience Nursing Presentations 
The principal investigator has presented aspects of this study including the design 
rationale, the development of the research question, the concept mapping method 
and key preliminary findings at neuroscience nursing conferences and symposia in 
Canada; Sweden; Belgium and England during progress. In the autumn of 2013 the 
findings will be presented at the World Federation of Neuroscience Nurses Congress 
in Gifu, Japan. Although primarily a nursing forum, this organisation is open to 
Allied Health Professionals and provides an opening to inform professionals with 
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broader neurological expertise about what is important to people with HD. In doing 
so a contribution towards improving HD expertise among generic neurological 
health experts as called for in the third highest priority cluster in this study.   
Specialist Huntington’s Facility engagements 
One engagement to present the findings to staff at a large specialist HD care facility 
is arranged for autumn 2013 and the principal investigator will work to secure 
invitations to similar venues to do the same. 
Elderly Care Facilities, Community Care team and Nursing Homes 
As a link lecturer to various elderly care facilities in both hospital and nursing home 
settings and to a community care team where staff members occasionally encounter 
people with Huntington’s disease the principal investigator frequently hosts seminars 
and will be able to present the findings of this study informally. Arguably the need to 
present these findings among staff who only occasionally encounter clients affected 
by the condition is even greater than among staff at a specialist HD centre where 
there is more likely to be a reasonable HD knowledge base.  
Pre and Post Registration Nurse Education 
As a lecturer in nursing and module leader for part of the second year undergraduate 
programme titled ‘Long Term Conditions’ the principal investigator has been able to 
ensure students learn about care for people with neurological disorders including 
Huntington’s disease, Parkinson’s disease, Multiple Sclerosis, Stroke and 
Alzheimer’s disease. The students are given scenarios to explore in ‘Enquiry-Based 
Learning’, and the material provided to students is influenced by the results of this 
study. 
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Similarly the results are relevant to and will be integrated into a number of post 
registration nursing programmes that the principal investigator teaches on.  
Journal Publications 
Manuscripts will be submitted to peer reviewed journals including Movement 
Disorders, Journal of Clinical Nursing, Journal of Advanced Nursing, and Journal 
of Huntington’s Disease for consideration. Papers to be based on the thesis will be: 
 What helps people with Huntington’s disease live with their condition? 
 A review of perceived experience and responses to the challenges of 
Huntington’s disease. 
 Living with a neurological disorder: are the challenges generic or disease-
specific?  
 Concept Mapping: a novel method for nursing research 
Involvement in Future Research Activity 
At the time of completing this thesis the principal investigator has been appointed to 
a new post within the University of East Anglia School of Nursing Sciences . This 
will involve teaching and a supervised role as a member of an experienced team 
dedicated to securing research grant applications and undertaking high quality 
international research. The team has strong links with large private sector care 
provider organisations and a successful track record of research relating to 
neurological disorders and will provide a supportive learning environment fostering 
further development and opportunities to continue to engage in Huntington’s 
disease-related research.  
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Limitations 
People with HD and family carer participants were mainly Huntington’s Disease 
Association (HDA) branch meeting attendees. They cannot be claimed to be 
representative of affected people and caregivers who do not have involvement with a 
supportive network such as the HDA.  
The software programme (Ariadne®) used for analysis is less widely used than that 
designed and marketed by the developers of the concept mapping method (Concept 
Systems®, Kane and Trochim, 2007). However in an unpublished paper (in progress) 
a member of our own research team (Flaherty 2012) has identified over 240 health-
related published concept mapping studies and a substantial minority use Ariadne® 
and found the software to be appropriate for concept mapping analysis (e.g. van 
Bon-Martens et al, 2011, Minkmann et al 2009). Ideally both software packages 
would have been used to analyse the data to check that results were similar but this 
was not possible due to financial restrictions.  
Because of the impact on cognition of their advanced disease none of the participants 
who have HD, living in a nursing home were considered to have the capacity to 
understand and be able to carry out the prioritising or clustering tasks despite their 
valuable contribution to the brainstorming process. Therefore the attempt to compare 
a nursing home-based perspective to that of community-based participants only 
accounts for views of caregivers and health professionals. Clearly had it been 
possible such a comparison should have also represented views from people with 
HD. 
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Personal Reflections 
While I have tried to maintain objectivity the influence of my own experience of 
professional involvement with people with HD during in choosing to study the topic 
of this thesis is acknowledged. To attempt to consider the nature of this influence I 
have reflected on the contexts of my past enagement: as a staff nurse in a specialised 
nursing home, as a guest at homes of numerous families affected by HD in a number 
of countries while on study tours and as a clinical nurse tutor at specialist care 
homes.   
Using a structured model (Gibbs 1988) I carried out numerous personal reflections 
on this involvement over the fifteen years prior to commencing this study and finally 
combined my conclusions about what I felt I had learned from nursing this patient 
group as a staff nurse, nurse manager and clinical nurse tutor at various care home 
settings into a book which was distributed via the Huntington’s Disease Association 
and the Scottish Huntington’s Association mainly to affected families and to care 
home staff (Smith 2005) and later incorporated some of the conclusions into a 
further book (Smith 2011).  I converted many of my reflections on anecdotes from 
families I stayed with in the UK, USA, Australia and Europe, into songs that I am 
frequently invited to perform at HD family meetings in many of those countries 
(Smith 2007).   
This leads me to realise that I have been seeking to understand what helps people 
live with HD and to appreciate the perspectives of affected family members for 
many years prior to formulating the question for my PhD studies. In the books I 
drew together tips on how to give care that came from working with colleagues and 
observing what they did that seemed to be helpful. In the songs I presented what I 
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understood family members to be trying to convey about their experiences of living 
with HD.  
Although I have acknowledged a non-neutral stance – clearly I had formulated some 
views on the topic ahead of undertaking the study- I am aware that I have been 
driven to investigate by a persistent sense of inadequacy that I have attributed to 
having no idea of what really helps people with HD or of what we professionals 
should regard as priorities when we seek to be helpful. I did not anticipate that 
addressing mental health problems would feature so highly in the results, but as I 
skim through my pre-study writings, although not specifically stated, I can see that 
the importance of flexibility and timeliness in care and service provision was 
appreciated and implied.      
It would be unfortunate to carry out a study and fail to learn enough to be able to 
identify some aspects that with hindsight could have been improved on.  
Design  
The involvement of 40 members of the Huntington’s Disease Association (caregivers 
and people with HD), and of health professionals and researchers within the 
supervision team and steering group, in critiquing and verifying the design and 
proposal for the ethics committee was a positive aspect, but a more diverse and 
representative consultation could have been achieved. Attendees at European 
Huntington’s Association and the European Huntington’s Disease Network include 
people with HD, family caregivers, health professionals and researchers with HD 
expertise. It is likely that a substantial number of volunteers from these groups 
would be keen to take part in sharing ideas to ensure international perspectives were 
accommodated. I am particularly pleased that the concept mapping approach 
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generated subjective opinions and allowed for quantitative analysis of how these 
were prioritised and conceptualised, and would be unlikely to have considered an 
alternative method. But ideas about how to recruit, particularly how to include 
people without involvement in support groups might be an example of an area where 
greater diversity of opinion regarding design detail could have been beneficial. 
Recruitment 
The failure to recruit sufficient numbers of participants for the study by the 
originally planned method of access via a clinic database and the need to resort to 
recruiting from HDA branches may be informative with regard to ways in which 
many affected individuals and family members tend to deal with the condition. There 
appears to be very little evidence to inform an explanation for this but I can lend 
anecdotal support to a small qualitative study by Lowit and Teijlingen (2005) 
involving 10 HD family caregivers. The study found that whereas people with other 
serious health conditions and their caregivers value support meetings, for many 
people with HD and family members the advantages of avoiding confrontation with 
the future impact of HD by meeting others perhaps with more advanced disease 
exceed any benefits of feeling supported within groups.  
When potential recruits from the clinic database declined to take part in the study no 
reason was asked for but the wish to avoid having to think about what help may be 
needed in future and particularly to avoid meeting anyone with more obvious 
symptoms than themselves was frequently expressed, in keeping with the findings of 
Lowit and Teijlingen (2005). The consequent low representation of non-members of 
support groups in my own study sample is acknowledged and there appears to be 
justification for considering further qualitative studies in this area that do not adopt a 
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group-orientated design. That said, there is no evidence to indicate that the HD 
support group members who took part in my own study did not share views held by 
non-group members. Some participants did take part individually and on reflection I 
feel confident that efforts to limit this potential for recruitment bias resulted in a 
meaningful representation of what is felt by stakeholders to help people live with 
HD.  
Having touched on the issue of recruitment, inclusion of participants from various 
European countries, and perhaps beyond would also have been achievable and could 
add to confidence regarding the relevance of the results beyond this country. Near to 
the end of my data collection activity, members of a large support group in Scotland 
expressed an interest in participating. I had to decline because my ethics permission 
did not extend into Scotland. It would have been possible to obtain permission in the 
region but time would not allow. With hindsight I should have anticipated this and 
sought Scottish permission earlier.  
Overall lesson learned 
I would consider utilising an electronic means of allowing people to enter their 
prioritising and clustering data. Many people asked for this, and many professionals 
in particular would have been happier to complete both tasks if this had been an 
option.  
I have learned that with any large project it is important to start writing up early, 
rather than rely on notes at a later date. I found that it is useful to read exemplar 
theses early on, and get a feel for what it should look like. I have gained greater 
confidence that by carrying out research I am not perceived as a nuisance. It is a 
worthwhile contribution.  I shouldn’t have feared so much all the time that people 
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would see it as such an intrusion. Feedback about how people found the activities 
therapeutic should be more readily believed. That said, I would still prefer to err on 
the side of caution, respecting privacy and dignity, but when they indicate being 
keen to take part, I should relax a little more and believe them.   
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Appendix 3.2   Recruitment documents including invitation letters, information 
document, consent forms and reply slips. 
 
3.2A: Letter of invitation to take part addressed to people with HD 
 
University of Cambridge 
 
Cambridge Centre for Brain Repair 
Addenbrooke’s NHS Trust 
Date --------------- 
Name Address of Recipient Here 
Dear -------------- 
You are invited to join in with some research about Huntington’s disease 
(HD). If you would like to know what this research is about please read the 
documents that are with this letter. You may want help with reading them. 
You could ask a carer to help, or talk to your doctor (GP). You could ask 
them to help you decide if it’s a good idea to join in with the research.  
Also, do you have a ‘main’ carer?  I mean, someone who helps you manage 
your HD, who would be the right person to talk about caring for you, in this 
study?  If so, please would you give that person the enclosed ‘Carer Pack’?  
Thank you. 
In about a week, Steve Smith, the Chief Investigator for the study, will ring 
you to ask if you are interested in taking part. If you are, he will arrange to 
visit you at your home, to discuss what is involved. Just tell Steve if you don’t 
want to take part, it is not a problem. 
If you have any questions about the study, please contact Mr Steve Smith, 
Lecturer University of East Anglia, Faculty of Health, School of Nursing 
and Midwifery, Edith Cavell Building, Norwich NR4 7TJ. Or ring and 
leave a message on 01603 597022, or e mail steve.smith@uea.ac.uk .  Steve 
will get back to you. 
Very many thanks, 
Yours Sincerely 
 
Dr. Roger Barker, PhD, MRCP 
Centre for Brain Repair 
Forvie Site, Robinson Way 
Cambridge, CB2 2PY 
UK 
Tel: +44 (0)1223 331184 
 
Fax: +44 (0)1223 331174 
 
Email: rab46@cam.ac.uk 
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Dr Roger Barker 
Appendix 3.2 B: Letter of invitation to take part addressed to caregegivers for 
people with HD 
 University of Cambridge 
Cambridge Centre for Brain Repair 
Addenbrooke’s NHS Trust 
Date --------------- 
Name Address of Recipient Here 
Dear -------------- 
You are invited to take part in a research project. It is to do with your role as 
a carer for someone who has Huntington’s disease (HD), and has also been 
invited to take part. The person with HD was asked to give this ‘carer pack’ to 
the person they wish to be regarded as their carer for this study.  
In about one week after this letter is posted, the Chief Investigator, Steve 
Smith, will ring you to ask if you are interested in taking part. If you are he will 
arrange to visit you to discuss what the study involves. Meanwhile, if you are 
interested, please read the enclosed information. There is no need to fill in or 
sign any forms yet.       
If you wish to ask any questions about the project meanwhile, please contact:  
Mr Steve Smith, Lecturer, 
University of East Anglia, Faculty of Health, 
School of Nursing and Midwifery, Edith Cavell Building, Norwich NR4 
7TJ. Or ring and leave a message on 01603 597022, or e mail 
steve.smith@uea.ac.uk .  Steve will get back to you. 
Very many thanks, 
Yours Sincerely 
Dr. Roger Barker. 
Dr. Roger Barker, PhD, MRCP 
Centre for Brain Repair 
Forvie Site, Robinson Way 
Cambridge, CB2 2PY 
UK 
Tel: +44 (0)1223 331184 
 
Fax: +44 (0)1223 331174 
 
Email: rab46@cam.ac.uk 
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Appendix 3.2 C  Letter of invitation to take part addressed to Health Professionals  
University of Cambridge 
Cambridge Centre for Brain Repair 
Addenbrooke’s NHS Trust 
Date --------------- 
Name Address of Recipient Here 
Dear -------------- 
You are invited to take part in a research project related to your work as a 
Health-related Professional, providing or organising care and / or support for 
people with Huntington’s disease. If you may be interested to know about the 
project, please read the enclosed information document.  
About a week after sending you this, the Chief Investigator, Steve Smith, will 
ring you to ask whether you are interested in taking part in the study. If you 
are, he will make arrangements with you regarding taking consent and 
details of meetings to carry out the study. 
If you would like to discuss the project or ask any questions about it, 
please contact:  
Steve Smith, Lecturer, University of East Anglia, Faculty of Health, 
School of Nursing and Midwifery, Edith Cavell Building, Norwich NR4 
7TJ. Or ring and leave a message on 01603 597022. or e mail 
steve.smith@uea.ac.uk .  Steve will get back to you. 
Very many thanks, 
Yours Sincerely 
Dr Roger Barker 
 
 
Dr. Roger Barker, PhD, MRCP 
Centre for Brain Repair 
Forvie Site, Robinson Way 
Cambridge, CB2 2PY 
UK 
Tel: +44 (0)1223 331184 
 
Fax: +44 (0)1223 331174 
 
Email: rab46@cam.ac.uk 
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Appendix 3.2D Information document for people with HD 
Information Sheet For People who Have HD.   
1. Title:  What helps me manage my Huntington’s disease? 
2. Invitation  
Would you like to join in with some research about Huntington’s disease, or ‘HD’?  
It would mean talking about your HD. Nothing would be done to you. A researcher 
called Steve who is a nurse would be asking you some questions.  
 You do not have to do this. Before you decide if you want to join in, it is important 
for you to understand what the research is for and what you would be doing.  
Please take time to read the writing below, or get someone to help you or read it to 
you.  
It is a good idea to talk to others about it if you’re not sure whether to join in. You 
could speak to your carer or to your GP (doctor). Do get in touch with us if you want 
to know more about it.  
  Thank you for reading this. 
3. What is the research for? 
We hope to find out what helps people with Huntington’s disease (HD) manage their 
HD. We want to know what people with HD and their carers and doctors and nurses 
and others who care think about this.  
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We would like to know if doctors and nurses and other professionals know what 
people with HD think is helpful. And we want to know how important these things 
are to you.        
We think this will help people who care to be more helpful to people with HD in 
future.    
4. Why was I chosen? 
You were one of 13 people with HD chosen from a list kept at the Brain Repair 
Centre Clinic in Cambridge. 10 health professionals, were also chosen. And we want 
to enrol 10 carers, chosen by people with HD.        
5. Do I have to join in? 
It is up to you to decide if you want to join in. If you decide to join in you can 
change your mind at any time. It will not affect the care you receive. You don’t 
have to give a reason if you stop joining in the research.    
6. What do I have to do? 
In about a week after sending you this information, the Chief Investigator (Steve) 
will ring you to see if you are interested to join in. If you don’t want to, just tell 
Steve. It’s not a problem. If you are interested, Steve will arrange to visit you to 
discuss the study, and make sure you understand what you would have to do.  
If you agree to join in, Steve will ask you to sign the consent form and fill in the 
reply slip. You can keep a copy of each of these documents so that you can read 
them at any time.  
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If you take part, this will mean coming to two meetings. Steve will discuss with you 
how you will get there. 
The first meeting will last two hours, with a break in the middle for refreshments. 
This meeting will be with about 7 other people who have HD. Steve and an assistant 
will be there to lead the meeting and help if you’re not sure what to do. Your carer 
may be in the building, in case he or she is needed, but will not be in the meeting 
with you. The idea of this meeting is to get ideas only from people who have HD.  
 
We will ask you all as a group, to agree on statements about things that you think 
help you to manage your HD.  
The second meeting will also last two hours, with a break for refreshments. This time 
the other people with HD, and carers, and health professionals will all be there. This 
meeting will be about deciding which statements about what helps people to manage 
their HD are most important, and which are not so important.  
On the day we will be there to help to make sure you understand how to do it. But 
there will be no ‘right’ or ‘wrong’ answers. We want your ideas. 
There is one more thing we would like you to help with. After the meetings are 
finished Steve and the research team will work to make a report of the results of the 
study. We would like to send you a copy of a draft of this report, for you to comment 
on. You could point out anything you do or don’t agree with. Then a final report will 
be written, and you will be given a copy. The Huntington’s Disease Association will 
also receive a copy. 
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An important thing to note is that we will audio record the meetings. This is to help 
us remember what was said as we write about the study. It will help us if we are not 
sure what any written statements mean. After the report is written the tape will be 
destroyed. H 
7. Are there any risks to me? 
Talking about how HD has affected you could upset you and make you think about 
some things you like to forget.         
8. Could joining in the study do me some good?   
On the other hand, it might feel good to talk about things that help you to manage. 
You might feel good that this will help people in future, to know what helps people 
with HD. 
But, the research will not help you personally.  
9. Will my taking part in this study be kept confidential? 
Steve will keep the forms you sign with your name and other details locked safely. 
He may publish some of your ideas but will not tell anyone your personal details. 
Steve will tape record what you say to remind him later. The tape will be kept locked 
safely and will be destroyed when the research is finished. 
The others in the room will be asked to keep what you say confidential. But we 
cannot guarantee they will. You do not have to say anything that you don’t want 
others to know.   
10. What will happen to the results of the research study? 
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We will try to publish results in research journals to do with health. Also, we will 
give the Huntington’s Disease Association a report, to print in the newsletter if they 
wish.   
The chief investigator (Steve) will talk about the study at meetings about HD.     
11. Who is organising and funding the research? 
This study is part of a PhD project for the chief investigator (Steve), and is paid for 
by the University of East Anglia, School of Nursing Midwifery.    
12. Who has reviewed the study? 
The study has been reviewed by experienced health researchers at the University of 
East Anglia. It has been approved by the Local Research Ethics Committee. It will 
be monitored by a research team including experienced researchers, a person with 
HD, and a carer, and a Family Care Advisor from the Huntington’s Disease 
Association.  
13. Contact for Further Information 
Very many thanks for taking part in this study if you do decide to. If you wish to 
discuss it further or ask any questions about it, please contact the chief investigator: 
Steve Smith 
University of East Anglia, 
Faculty of Health, 
School of Nursing and Midwifery 
Edith Cavell Building 
Norwich 
NR4 7TJ. 
Tel: 01603 59 7022 (leave a message if not there and Steve will get back to you) 
Or e mail: steve.smith@uea.ac.uk 
Declaration: 
I have read and understood this information sheet. 
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Signed _______________________  Name (Print) 
___________________________ 
Date ______________________    
OR: 
Declaration: 
My carer has read this information sheet to me and I understand it.  
Signed _______________________   
Name (Print) ___________________________     Date ______________________    
Please Note: You should sign and return one copy of this information sheet and 
a consent form, and keep a 2nd copy of each. 
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Reply Slip 
If you have decided that you wish to take part in the study: ‘What Helps Me Manage 
My Huntington’s Disease?’, please complete this reply slip or ask you carer to fill it 
in for you, with YOUR answers, and hand it to Steve Smith with the consent form, 
signed and dated, and the information sheet, also signed and dated (one copy only of 
each document). 
Full Name ____________________________  Date of Birth  ______________ 
Address_____________________________________________________________
_____________________________________________________________  
Phone ________________________ 
How long is it since you were first affected by the symptoms of HD?   
_________________________________________________________ 
Signed __________________________ Date __________________ 
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Appendix 3.2 E  Information document for caregivers for people with HD 
Information Sheet For Carers of People With HD.  
1. Title:  What helps me manage my Huntington’s disease? 
2. Invitation  
Would you like to join in with some research about Huntington’s disease, or ‘HD’?  
It would mean talking about your experience of caring for a person who has HD. 
Nothing would be done to you. A researcher called Steve who is a nurse would be 
asking you some questions.  
 You do not have to do this. Before you decide if you want to join in, it is important 
for you to understand what the research is for and what you would be doing.  
Please take time to read the writing below, or get someone to help you or read it to 
you.  
It is a good idea to talk to others about it if you’re not sure whether to join in. You 
could speak to your GP (doctor) about it. Do get in touch with us if you want to 
know more about it.  
Thank you for reading this. 
3. What is the research for? 
We hope to find out what helps people with Huntington’s disease (HD) manage their 
HD. We want to know what people with HD and their carers and doctors and nurses 
and others who care think about this.  
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We would like to know if doctors and nurses and other professionals know what 
people with HD and their carers think is helpful. And we want to know how 
important these things are to you.        
We think this will help people who care to be more helpful to people with HD in 
future. 
4. Why was I chosen? 
You were chosen by the person you care for who has HD. He or she was sent an 
invitation and a pack for carers, and was asked to give the ‘carer pack’ to the person 
they feel can best act as their main carer for this study. The person you care for with 
HD is one of 13 people with HD chosen from a list kept at the Brain Repair Centre 
Clinic in Cambridge. 10 health professionals, were also chosen.  
5. Do I have to join in? 
It is up to you to decide if you want to join in. If you decide to join in you can 
change your mind at any time. It will not affect the care you receive. You don’t have 
to give a reason if you stop joining in the research.   
6. What do I have to do? 
In about a week after sending the person you care for, who has HD this information, 
the Chief Investigator (Steve) will ring to see if he or she, and if you are interested to 
join in. If you don’t want to, just tell Steve. It’s not a problem. If you are both 
interested, Steve will arrange to visit you to discuss the study, and make sure you 
understand what you would have to do.  
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If you agree to join in, Steve will ask you to sign the consent form and fill in the 
reply slip. You can keep a copy of each of these documents so that you can read 
them at any time.  
If you take part, this will mean coming to two meetings. Steve will discuss with you 
how you will get there. 
The first meeting will last two hours, with a break in the middle for refreshments. 
This meeting will be with about 9 other people who care for someone who has HD. 
Steve and an assistant will be there to lead the meeting and help if you’re not sure 
what to do.    
We will ask you all as a group, to agree on statements about things that you think 
help people to manage their HD.  
The second meeting will also last two hours, with a break for refreshments. This 
time, people with HD, and health professionals will all be there as well as carers. 
This meeting will be about deciding which statements about what helps people to 
manage their HD are most important, and which are not so important.  
On the day we will be there to help to make sure you understand how to do it. But 
there will be no ‘right’ or ‘wrong’ answers. We want your ideas. 
There is one more thing we would like you to help with. After the meetings are 
finished Steve and the research team will work to make a report of the results of the 
study. We would like to send you a copy of a draft of this report, for you to comment 
on. You could point out anything you do or don’t agree with. Then a final report will 
be written, and you will be given a copy. The Huntington’s Disease Association will 
also get a copy. 
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An important thing to note is that we will audio record the meetings. This is to help 
us remember what was said as we write about the study. It will help us if we are not 
sure what any written statements mean. After the report is written the tape will be 
destroyed.  
7. Are there any risks to me? 
Talking about how caring for someone who has HD has affected you could upset you 
and make you think about some things you like to forget.         
8. Could joining in the study do me some good?   
On the other hand, it might feel good to talk about things that help the person you 
care for to manage. And what helps you. You might feel good that this will help 
people in future, to know what helps people with HD. 
But, the research will not help you personally.  
9. Will my taking part in this study be kept confidential? 
Steve will keep the forms you sign with your name and other details locked safely. 
He may publish some of your ideas but will not tell anyone your personal details. 
Steve will tape record what you say to remind him later. The tape will be kept locked 
safely and will be destroyed when the research is finished. 
The others in the room will be asked to keep what you say confidential. But we 
cannot guarantee they will. You do not have to say anything that you don’t want 
others to know.   
10. What will happen to the results of the research study? 
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We will try to publish results in research journals to do with health. Also, we will 
give the Huntington’s Disease Association a report, to print in the newsletter if they 
wish.   
The chief investigator (Steve) will talk about the study at meetings about HD.     
11. Who is organising and funding the research? 
This study is part of a PhD project for the chief investigator (Steve), and is paid for 
by the University of East Anglia, School of Nursing Midwifery.    
 
 
12. Who has reviewed the study? 
The study has been reviewed by experienced health researchers at the University of 
East Anglia. It has been approved by the Local Research Ethics Committee. It will 
be monitored by a research team including experienced researchers, a person with 
HD, and a carer, and a Family Care Advisor from the Huntington’s Disease 
Association.  
13. Contact for Further Information 
Very many thanks for taking part in this study if you do decide to. If you wish to 
discuss it further or ask any questions about it, please contact the chief investigator: 
Steve Smith 
University of East Anglia, 
Faculty of Health, 
School of Nursing and Midwifery 
Edith Cavell Building 
Norwich 
NR4 7TJ. 
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Tel: 01603 59 7022 (leave a message if not there and Steve will get back to you) 
Or e mail: steve.smith@uea.ac.uk 
Declaration: 
I have read and understood this information sheet. 
 
Signed _______________________  Name (Print) 
___________________________ 
Date ______________________    
Carer information sheet version 4, 11 06 09.  
Please Note: You should sign and return one copy of this information sheet and 
a consent form, and keep a 2nd copy of each. 
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Reply Slip 
If you have decided that you wish to take part in the study: ‘What Helps Me Manage 
My Huntington’s Disease?’, please complete this slip and send it to Steve Smith with 
the consent form, signed and dated, and the information sheet, also signed and dated 
(one copy only of each document). 
Full Name ________________________________________   
Date of Birth  ______________ 
Gender   Male   Female (please delete as applicable). 
Address_____________________________________________________________
_____________________________________________________________ 
How long have you cared for the person with HD taking part in this study? 
_____________ 
If you have cared for others with HD, how many years have you spent caring for a 
person with HD in total?  _______________________ 
What is your relationship to the person with HD that you are caring for? 
________________ 
 
Name Address and phone number of your GP. 
________________________________________________________________ 
Phone number or e mail address for the researcher (Steve) to contact you on, if 
needed, to discuss arrangements for the meetings: 
205 
 
______________________________________ 
Signed __________________________ Date __________________ 
Appendix 3.2 F  Information document for Health Professionals  
Information Sheet For Health Professionals 
1. Title:  What helps me manage my Huntington’s disease? 
2. Invitation  
You are being invited to take part in a research study. Before you decide whether to 
accept, it is important for you to understand why the research is being done and what 
it will involve. Please take time to read the following information carefully and 
discuss it with others if you wish. Ask us if there is anything that is not clear or if 
you would like more information.  
Thank you for reading this. 
 
3. What is the purpose of the study? 
The aim of this study is to determine what helps people with Huntington’s disease 
(HD) manage their condition, from the perspectives of people with HD, their carers 
and of health professionals- that is, qualified health-related professionals such as 
nurses, doctors, physiotherapists, and speech and language therapists, and social 
workers.  
The study will examine similarities and differences in the views of each of these 
three groups regarding what can help people to manage their HD, and the level of 
priority accorded to factors that can help.  
It is anticipated that the knowledge resulting from the study will be useful to health 
professionals, carers and people with HD in planning how they can work together to 
make it easier to manage life with HD. 
4. Why have I been chosen? 
You were among 10 health and social care professionals selected from attendance 
lists at professional meetings concerned with care for people with Huntington’s 
disease (HD). The selection was by ‘purposive’ sampling- this means ensuring 
representation from a range of professional backgrounds, and convenience- 
geographically close to limit potential barriers to meeting. 13 people who are 
diagnosed with HD (including 5 with advanced HD) and 10 carers have also been 
recruited to take part.    
5. Do I have to take part? 
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It is up to you to decide whether or not to take part. In about one week after 
sending you this invitation, the Chief Investigator, Steve Smith, will ring you to 
see if you are interested and answer any questions you may have about the study. 
If you do decide to take part you should sign one copy of this information sheet, 
and reply slip giving your contact details, and sign a copy of the consent form, 
and return these signed documents to Steve Smith  in the pre-paid envelope.  
You should keep the other copies of each document. If you decide to take part you 
are still free to withdraw at any time and without giving a reason.  
 
6. What do I have to do? 
If you agree to take part, and return the completed and signed consent form and reply 
slip to the chief investigator in the enclosed stamped addressed envelope, then the 
chief investigator will contact you to make arrangements regarding the details of two 
meetings with other health professionals. The meetings are each expected to last 
about two hours including a break with light refreshment provided. If this 
commitment seems too demanding, it is possible to arrange to do the second activity 
individually, from your home or work base.    
In the first meeting, the group are asked to try to agree on statements that identify 
some of things that can be most helpful towards enabling people with HD to manage 
their condition. In the first meeting you will be with other health professionals, and 
not with people with HD or their carers.  
The second meeting can be attended by all three groups together- people with HD, 
carers and Health professionals, but, as said, above, you can carry out the second 
meeting activities on your own, at a time and location you prefer. This second 
session involves deciding an order of priority for the statements and then grouping 
them into themes, or ‘clusters’.  
Reasonable travel expenses will be reimbursed. 
11. What are the possible disadvantages and risks of taking part? 
A risk assessment process has highlighted the potential situation in which the chief 
investigator becomes aware of unprofessional practice, potentially harmful to a 
patient with HD. In such circumstances the chief investigator would be duty bound 
to report the matter to the appropriate authority, after notifying the health 
professional concerned.  
12. What are the possible benefits of taking part? 
On the other hand, you may benefit by getting to discuss some difficult issues with 
others who have worked to help patients with HD or their caregivers to manage 
them. You may also feel a benefit from the satisfaction of taking part in research that 
is aimed at improving understanding of HD and how it affects individuals, carers and 
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families, and at bringing the aims of interventions by health professionals more in 
line with the needs of the people they work to help. With an increasing emphasis on 
evaluating performance in terms of patient reported outcomes (PRO’s), greater 
understanding of any differences between patient, caregiver and clinician 
perspectives may benefit your future work in this area.   
That said, it should be emphasised that there is no claim to offer a direct definite 
benefit to you personally. 
 
16. Will my taking part in this study be kept confidential? 
Clearly, the members of the group will get to know each other to some extent, and 
will know what you have said during discussions. While the chief investigator will 
emphasise to the group, the importance of keeping any personal information 
discussed confidential, he cannot guarantee that all members will do so. You should 
feel under no pressure to disclose any personal information that you do not wish to 
share with the group, bearing in mind that someone may repeat it.  
Otherwise, yes, your taking part will be kept confidential. Written records of your 
personal identifying details held will be kept on computer with password security, 
and on a document also protected by further password security.  
The group discussions will be tape recorded for analysis. The tape will be kept under 
secure conditions until analysed and then will be destroyed. The security 
arrangements have been approved by the regional ethics committee.  
Regarding publication of results, no personal identifying details of participants will 
be published. 
17. What will happen to the results of the research study? 
The aim is that results will be published in research journals related to health, for 
example, Neurology, or International Journal of Quality of Life Research, or the 
Journal of Clinical Nursing, or Journal of Advanced Nursing. Also, a report will be 
given to the Huntington’s Disease Association, for publication in the newsletter and 
as they deem appropriate. Participants will be invited to comment on a draft of the 
report before it is finalised, and will be given a copy of the final report.   
The chief investigator frequently presents to professional and family groups 
associated with HD, in the UK and abroad and will present a summary wherever 
appropriate.   
18. Who is organising and funding the research? 
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This study is being carried out as a PhD project for the chief investigator, and is 
supported and funded by the University of East Anglia, School of Nursing 
Midwifery, within the Faculty of Health.  
19. Who has reviewed the study? 
The study has been overseen and reviewed by a research team including three 
experienced health researchers (supervisors, including health professionals) at the 
University of East Anglia, Faculty of Health, a person with HD, a carer and a 
representative from the Huntington’s Disease Association. It has also been approved 
by the Local Research Ethics Committee.  
 
20. Contact for Further Information 
Very many thanks for taking part in this study if you do decide to. If you wish to 
discuss it further or ask any questions about it, please contact the chief investigator: 
Steve Smith 
University of East Anglia, 
Faculty of Health, 
School of Nursing and Midwifery 
Edith Cavell Building 
Norwich 
NR4 7TJ. 
Tel: 01603 59 7022 (leave a message if not there and Steve will get back to you) 
Or e mail: steve.smith@uea.ac.uk 
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Reply Slip 
 
Declaration: 
I have read and understood this information sheet. 
 
 
Signed _______________________  Name (Print) 
___________________________ 
 
Date ______________________    
Please Note: You should sign and return one copy of this information sheet and 
a consent form, and keep a 2nd copy of each. 
 
 
Please complete the following: 
   
Name of profession and position ________________________________________ 
 
Address_____________________________________________________________
___________________________________________________________________ 
Date of Birth  ___________________    Gender (tick as applicable)  M □        F □ 
How long (in years) have you had professional experience of involvement with 
people who have Huntington’s disease? ----------------- 
How many patients with HD have you been professionally involved with in the past 
two years? _______________ 
 
Daytime phone number ________________________ 
 
E mail address ___________________________ 
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Appendix 3.2 G Consent form for people with HD 
Consent Form 
For people with Huntington’s Disease  
Title:  What Helps Me manage My Huntington’s Disease?   
Name of Researcher: Steve Smith 
Please tick to confirm  
 I confirm that I have read and understand the information sheet for the research 
project called ‘What Helps Me manage My Huntington’s Disease?’    
 □ 
 I have had a chance to think about it and ask any questions. I am sure that I know 
enough about it to help me decide about joining in.     
 □ 
 I understand that the sessions will be recorded, and after the researchers analyse the 
statements with the aid of the recording, the tape will be destroyed.    □ 
I know that I don’t have to do this, It is my own choice. If I start joining in with the 
research I know that I can stop if want to at any time. I will still be cared for in the 
same way, whether I join in or not.        
   □ 
 I agree to take part in the above research study.      □ 
I agree that the chief investigator (Steve) should tell my GP about me taking part in 
the study, and should to tell my GP if there are any concerns about my health or 
welfare during the research.         
  □ 
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Name of Participant  _________________  Signature  _____________   Date 
___________ 
When complete, 1 copy for patient; 1 copy for researcher site file.  
Participant Identification Number (researcher to complete):  ________________ 
 
Appendix 3.2 H   Consent form for caregivers for people with HD 
Consent Form 
For Carers for people with Huntington’s Disease 
 
Title: What Helps Me Manage My Huntington’s Disease? 
 
Name of Researcher: Steve Smith 
 
Please tick box to confirm  
 
 I confirm that I have read and understand the information sheet for the above study. 
 □ 
 
 I have had the opportunity to consider the information, ask questions and have had 
these answered satisfactorily.        
  □ 
 
 I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected.   
 □ 
 
I understand that the sessions will be recorded, and after the researchers analyse the 
statements with the aid of the recording, the tape will be destroyed.   
  □ 
 I agree to take part in the above research study.      
  □ 
 
I agree that the chief investigator (Steve) should tell my GP about me taking part in 
the study, and should to tell my GP if there are any concerns about my health or 
welfare during the research.           
    □ 
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Name of Participant  ________________________   
Date _______________ 
 
Signature  __________________________ 
 
When complete, 1 copy for patient; 1 copy for researcher site file.  
Patient Identification Number (Researcher to complete):  _____________________ 
 
213 
 
Appendix 3.2 I   Consent form for caregivers for Health Professionals 
Consent Form 
For professionals caring for or supporting people with Huntington’s Disease 
Title:  What Helps Me Manage My Huntington’s Disease? 
Name of chief investigator:  Steve Smith 
 
Please tick to confirm  
 
 I confirm that I have read and understand the information sheet dated regarding the 
above study.             
   □ 
 
 I have had the opportunity to consider the information, ask questions and am 
satisfied that any questions I have are answered satisfactorily.   
  □ 
 • 
I understand that the sessions will be recorded, and after the researchers analyse 
the statements with the aid of the recording, the tape will be destroyed.    
 □ 
 I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason.         
  □ 
 
 I agree to take part in the above research study.         
 □ 
 
 
Name of Participant ________________________ Profession  
_______________________  
 
Signature  __________________________  Date _______________ 
 
 
When complete, 1 copy for participant; 1 copy to chief investigator in pre-paid 
envelope.  
Participant Identification Number for this study (Researcher to complete): 
___________ 
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Appendix 3.2 J   Letter to G.P.  
 
 
 
Dear  Dr. 
 Re : Your Patient...... ...  Participation in a research study: ‘What 
Helps Me Manage My Huntington’s Disease?   
 
I am a lecturer in nursing at the University of East Anglia School of Nursing 
and Midwifery, within the Faculty of Health. I am also a PhD student and am 
currently undertaking the above study.  
 
Your patient, named above was recruited via the database at the Cambridge 
Centre for Brain Repair at Addenbrooke’s Hospital, Cambridge and has 
given consent to take part and for me to contact you. The patient is either a 
participant who has HD or is a carer for a person with HD. 
 
I enclose an information sheet about the study, so that you know what is 
involved. I have contacted you now, because I recognise that speaking about 
Huntington’s disease may have the potential to cause participants some 
distress. If I was to discover that your patient is very distressed I would want 
to contact you and inform you, and perhaps consult you for advice.  
 
I do have many years experience of nursing people with HD, and liaising with 
family carers and do not feel that the risk of psychological harm will be great, 
but I hope you will agree that this would be a sensible precaution. 
 
If you have any comments to make regarding this project and your patient’s 
involvement, I would be most grateful to hear from you.  
 
Yours sincerely 
 
Steve Smith 
 
   
FACULTY OF HEALTH 
Edith Cavell Building 
University of East Anglia 
Norwich   
Norfolk NR4 7TJ 
Telephone 
01603 597022 
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Appendix 3.2 K  Information for consultees 
 Consultee 
Information sheet. 
We would be very grateful if you would consider agreeing to be a consultee for [-----
------Name-----------] who has Huntington’s disease (HD), and is invited to take part 
in the study named: ‘What helps me manage my Huntington’s disease?’   
Why does the person need to have a consultee? 
Unfortunately this person is not able to give informed consent to take part in the 
research. But with help s/he may be able to understand what it is about and what 
choosing to join in would involve. The person may be able to indicate being willing 
to take part.  
To find out what helps people manage their Huntington’s disease (HD) it is 
important that people severely affected by the condition are able to give their views 
if they want to.  
A consultee is needed to give advice and offer opinion, to help the chief investigator 
decide about whether it is suitable to allow the person severely affected by HD to 
take part in the study.   
What do I have to do? 
If you agree to be a consultee, you should first read and make sure you understand 
the ‘information sheet for people with HD’, enclosed.  
A consultee must be prepared to be consulted about the possible involvement of the 
potential participant in this research study who has HD. You should read and make 
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sure you understand the information sheet provided for this person so that you are 
clear about what he or she would be expected to do if he or she does take part. 
 
If the person you are consultee for indicates being willing to take part, you may be 
consulted for your opinion on whether he or she would be content to take part, or 
whether doing so might be upsetting for him or her.  
You should base this opinion on what you think the person’s past and present wishes 
and feelings would have been about taking part in the research. For example, you 
could consider whether the person has previously expressed specific or general 
support for research about managing with HD.  
You should bear in mind that you are not being asked for your personal view on 
taking part, but for what you think the person with HD would want to express. You 
could also give advice about times of the day that might be unsuitable for the person 
to take part. For example, the person might find this sort of activity too tiring, 
perhaps in the evening.  
You could advise on any other factors that should be considered such as the kind of 
environment that might be a problem for the person, or would be more comfortable. 
You may advise the chief investigator (Steve) at any time if you feel that taking part 
is becoming too tiring for the person or for some other reason you feel they should 
stop being involved. 
You may find it helpful to have independent advice about whether to accept this role 
of consultee. You could ask your GP for this advice, or a consultant with specialist 
knowledge of HD, or a family advisor with the Huntington’s Disease Association 
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(HDA).  Your local family advisor can be accessed via the HDA at:  Tel 
.................................    
E mail .................................................. HDA advisor’s name 
............................................ 
If you do decide to accept the role of consultee, please sign and date the ‘consultee 
reply slip’ (enclosed) and hand it to the chief investigator (Steve Smith).  
Many thanks for reading this consultee information sheet. 
Appendix 3.2 L  Consultee reply slip 
Consultee 
Reply Slip 
Study title:  What helps me manage my Huntington’s disease? 
Please tick box if the statement is true:   
I have read and understood the Consultee information sheet    
   □ 
I understand the role of a consultee with regard to this study and am happy to accept 
the role            
 □ 
I have read and understood the information sheet about this research project, for 
people with HD.           
 □ 
I understand the research process and what the person I am consultee for will 
experience and be expected to do as a participant.     
 □ 
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Name of consultee ................................................... 
Address...........................................................................................................................
........................................................................................................................................
............................ Name of potential participant lacking capacity to give informed 
consent:  
......................................................... 
Consultee- please sign to confirm the following statement is true: 
………………………….. 
I have read and understand the information sheet for people with HD, for the study 
named ‘What helps me manage my Huntington’s disease?’ and I agree to accept the 
role of consultee for the person with HD who lacks capacity to give consent. 
Signature of consultee  ............................................... Date......................................... 
219 
 
Appendix 3.2 M  Consultee confirmation document 
Consultee Confirmation: 
Participant’s expression of willingness to take part in the study titled: 
‘What helps me manage my Huntington’s disease?’ 
Please tick box if statement is true: 
1) I have read the information sheet about the above study, for people with HD to the 
person named below, and, as best as I can, I have explained what the study involves. 
 □ 
2) The person named below has indicated to me some understanding of what the 
research is about and what taking part will involve       
 □ 
3) The person named below has indicated being willing to take part, and I am happy 
to sign to confirm that this is the case.       
 □ 
4) The person named below understands that the sessions will be audio-recorded.  
 □ 
5) The person named below agrees to the chief investigator informing their GP in the 
event of concerns arising about his or her health or wellbeing.    
 □ 
6) In my view it is appropriate that the person named below should be allowed to 
take part in the research.         
 □ 
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Name of Consultee  ............................................................... 
Name of person with HD who lacks capacity to give informed consent :  
 
.................................. 
 
I confirm that the six numbered statements above are all true. 
 
Signature of consultee  ......................................  Date..................... 
 
 
Signature or mark of participant ..................................... Date ................. 
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Appendix 3.2 N  Invitation letter to people with advanced HD following approved 
amendment by Research Ethics Committee 
 
 
Dr Sophie Duport 
Royal Hospital for Neuro-Disability 
Research Department 
Royal Hospital for Neuro-disability 
West Hill 
Putney 
London 
 
SW15 3SW 
Date --------------- 
Name Address of Recipient Here 
Dear -------------- 
Would you like to help with some research?  It is about Huntington’s disease.  
If so please read the other papers that tell you about it.  
You may like your carer or your GP to help you understand it.  
You could ask them to help you decide if it’s a good idea to join in the research.   
Next week, the researcher, Steve Smith, will ring to see if you are interested to take part.  
If you are he will arrange to come and see you to discuss it.  
If you don’t want to take part, just tell Steve. It’s not a problem.  
Steve can be contacted by writing to: Mr Steve Smith, Lecturer 
University of East Anglia, Faculty of Health, School of Nursing and Midwifery,  
Edith Cavell Building, Norwich NR4 7TJ.  
OR, ring and leave a message on 01603 597022, or e mail steve.smith@uea.ac.uk .   
Steve will get back to you. 
Very many thanks,  
Yours Sincerely 
Dr Sophie Duport. 
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Appendix 3.2 O  Invitation letter to people with advanced HD following approved 
amendment by Research Ethics Committee 
 
From: Sue Hill 
Family Care Advisor, 
Huntington’s Disease Association. 01553 648 438. 
sue_hill@hda.org.uk 
 
Dear 
You are invited to take part in a research project. It is to do with your role as 
a carer for someone who has Huntington’s disease (HD), who has also been 
invited to take part. The person with HD was asked to give this ‘carer pack’ to 
the person they wish to be regarded as their carer for this study.  
In about one week after you receive this letter, the Chief Investigator, Steve 
Smith, will ring you to ask if you are interested in taking part. If you are he will 
arrange to visit you to discuss what the study involves. Meanwhile, if you are 
interested, please read the enclosed information. There is no need to fill in or 
sign any forms yet.       
If you wish to ask any questions about the project meanwhile, please contact:  
Mr Steve Smith, Lecturer, 
University of East Anglia, Faculty of Health, 
School of Nursing and Midwifery, Edith Cavell Building, Norwich NR4 
7TJ. Or ring and leave a message on 01603 597022, or e mail 
steve.smith@uea.ac.uk .  Steve will get back to you. 
 
Very many thanks, 
Yours Sincerely 
 
Sue Hill, 
Family Care Advisor, Huntington’s Disease Association. 
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Appendix 3.2 P Invitation letter to people with advanced HD following approved 
amendment by Research Ethics 
Committee 
 
From: Sue Hill 
Family Care Advisor, 
Huntington’s Disease Association. 01553 648 438. 
sue_hill@hda.org.uk 
 
Dear  
You are invited to join in with some research about Huntington’s disease 
(HD). If you would like to know what this research is about please read the 
documents that are with this letter. You may want help with reading them. 
You could ask a carer to help, or talk to your doctor (GP). You could ask 
them to help you decide if it’s a good idea to join in with the research.  
Also, do you have a ‘main’ carer?  I mean, someone who helps you manage 
your HD, who would be the right person to talk about caring for you, in this 
study?  If so, please would you give that person the enclosed ‘Carer Pack’?  
Thank you. 
In about a week, Steve Smith, the Chief Investigator for the study, will ring 
you to ask if you are interested in taking part. If you are, he will arrange to 
visit you at your home, to discuss what is involved. Just tell Steve if you don’t 
want to take part, it is not a problem. 
If you have any questions about the study, please contact Mr Steve Smith, 
Lecturer University of East Anglia, Faculty of Health, School of Nursing 
and Midwifery, Edith Cavell Building, Norwich NR4 7TJ. Or ring and 
leave a message on 01603 597022, or e mail steve.smith@uea.ac.uk .  Steve 
will get back to you. 
Very many thanks, 
Yours Sincerely 
Sue Hill, 
Huntington’s Disease Association  
Regional Care Advisor 
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Appendix 3.2 Q  
Information Sheet For Carers of People With HD.  
1. Title:  What helps me manage my Huntington’s disease? 
2. Invitation  
Would you like to join in with some research about Huntington’s disease, or ‘HD’?  
It would mean talking about your experience of caring for a person who has HD. 
Nothing would be done to you. A researcher called Steve who is a nurse would be 
asking you some questions.  
 You do not have to do this. Before you decide if you want to join in, it is important 
for you to understand what the research is for and what you would be doing.  
Please take time to read the writing below, or get someone to help you or read it to 
you.  
It is a good idea to talk to others about it if you’re not sure whether to join in. You 
could speak to your GP (doctor) about it. Do get in touch with us if you want to 
know more about it.  
Thank you for reading this. 
3. What is the research for? 
We hope to find out what helps people with Huntington’s disease (HD) manage their 
HD. We want to know what people with HD and their carers and doctors and nurses 
and others who care think about this.  
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We would like to know if doctors and nurses and other professionals know what 
people with HD and their carers think is helpful. And we want to know how 
important these things are to you.        
We think this will help people who care to be more helpful to people with HD in 
future. 
4. Why was I chosen? 
You were chosen by the person you care for who has HD. He or she was sent an 
invitation and a pack for carers, and was asked to give the ‘carer pack’ to the person 
they feel can best act as their main carer for this study. The person you care for with 
HD is one of 13 people with HD either chosen from a list kept at the Brain Repair 
Centre Clinic in Cambridge, or a resident at the Royal Hospital for Neuro-disability, 
or selected by the Huntington’s Disease Association Regional Care Advisor. 10 
health professionals, were also chosen.  
5. Do I have to join in? 
It is up to you to decide if you want to join in. If you decide to join in you can 
change your mind at any time. It will not affect the care you receive. You don’t have 
to give a reason if you stop joining in the research.   
6. What do I have to do? 
In about a week after the person you care for, who has HD receives an invitation, 
the Chief Investigator (Steve) will ring to see if he or she, and if you are interested to 
join in. If you don’t want to, just tell Steve. It’s not a problem. If you are both 
interested, Steve will arrange to visit you to discuss the study, and make sure you 
understand what you would have to do.  
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If you agree to join in, Steve will ask you to sign the consent form and fill in the 
reply slip. You can keep a copy of each of these documents so that you can read 
them at any time.  
If you take part, this will either mean you coming to two meetings, with other carers, 
or Steve visiting you twice to speak to you individually, depending on your 
preference. If you decide to come to the meetings, Steve will discuss with you how 
you will get there. 
If you choose to come to the meetings, The first meeting will last two hours, with a 
break in the middle for refreshments. This meeting will be with about 9 other people 
who care for someone who has HD. Steve and an assistant will be there to lead the 
meeting and help if you’re not sure what to do.    
We will ask you all as a group, to agree on statements about things that you think 
help people to manage their HD.  
The second meeting will also last two hours, with a break for refreshments. This 
time, people with HD, and health professionals will all be there as well as carers. 
This meeting will be about deciding which statements about what helps people to 
manage their HD are most important, and which are not so important.  
On the day we will be there to help to make sure you understand how to do it. But 
there will be no ‘right’ or ‘wrong’ answers. We want your ideas. 
If you choose instead for Steve to visit you individually, you will be asked to make 
statements about what is helpful to people with HD on the first visit, and to decide 
which statements you feel are most important on the second visit. 
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There is one more thing we would like you to help with. After the meetings are 
finished Steve and the research team will work to make a report of the results of the 
study. We would like to send you a copy of a draft of this report, for you to comment 
on. You could point out anything you do or don’t agree with. Then a final report will 
be written, and you will be given a copy. The Huntington’s Disease Association will 
also get a copy. 
An important thing to note is that we will audio record the meetings. This is to help 
us remember what was said as we write about the study. It will help us if we are not 
sure what any written statements mean. After the report is written the tape will be 
destroyed. H 
7. Are there any risks to me? 
Talking about how caring for someone who has HD has affected you could upset you 
and make you think about some things you like to forget.         
If you told us something that made us think the person you care for is not being 
treated well, or is at risk of harm, we would tell the person’s GP. The GP would then 
help us decide if we need to do anything else, to protect the person. If you told us 
something that made us think either you or the person you care for is thinking about 
self harm or suicide, we would tell the GP, who again, would help us decide if we 
need to do more to protect either or both of you.  
8. Could joining in the study do me some good?   
On the other hand, it might feel good to talk about things that help the person you 
care for to manage. And what helps you. You might feel good that this will help 
228 
 
people in future, to know what helps people with HD.  But, the research will not help 
you personally.  
9. Will my taking part in this study be kept confidential? 
Steve will keep the forms you sign with your name and other details locked safely. 
He may publish some of your ideas but will not tell anyone your personal details. 
Steve will tape record what you say to remind him later. The tape will be kept locked 
safely and will be destroyed when the research is finished. 
If you decide to join in group discussions, the others in the room will be asked to 
keep what you say confidential. But we cannot guarantee they will. You do not have 
to say anything that you don’t want others to know.   
10. What will happen to the results of the research study? 
We will try to publish results in research journals to do with health. Also, we will 
give the Huntington’s Disease Association a report, to print in the newsletter if they 
wish.   
The chief investigator (Steve) will talk about the study at meetings about HD.     
11. Who is organising and funding the research? 
This study is part of a PhD project for the chief investigator (Steve), and is paid for 
by the University of East Anglia, School of Nursing Midwifery.    
12. Who has reviewed the study? 
The study has been reviewed by experienced health researchers at the University of 
East Anglia. It has been approved by the Local Research Ethics Committee. It will 
be monitored by a research team including experienced researchers, a person with 
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HD, and a carer, and a Family Care Advisor from the Huntington’s Disease 
Association.  
13. Contact for Further Information 
Very many thanks for taking part in this study if you do decide to. If you wish to 
discuss it further or ask any questions about it, please contact the chief investigator: 
Steve Smith 
University of East Anglia, 
Faculty of Health, 
School of Nursing and Midwifery 
Edith Cavell Building 
Norwich    NR4 7TJ. 
Tel: 01603 59 7022 (leave a message if not there and Steve will get back to you)  Or 
e mail: steve.smith@uea.ac.uk 
 
What should I do if I’m not happy with any aspect of the study? 
You could contact the Huntington’s Disease Association and to talk to the local 
Family Advisor, Sue Hill, tel: 01353 648438, or e mail: sue_hill@hda.org.uk  to 
discuss any concerns, or you could make a complaint  to Rachel Mold, Faculty 
Research Manager, tel: 01603 5973949, e mail: r.mold@uea.ac.uk.  
Declaration: 
I have read and understood this information sheet. 
Signed _______________________  Name (Print) 
___________________________ 
Date ______________________    
Please Note: You should sign and return one copy of this information sheet and 
a consent form, and keep a 2nd copy of each. 
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Reply Slip 
If you have decided that you wish to take part in the study: ‘What Helps Me Manage 
My Huntington’s Disease?’, please complete this slip and send it to Steve Smith with 
the consent form, signed and dated, and the information sheet, also signed and dated 
(one copy only of each document). 
Full Name __________________________     Date of Birth  ______________ 
Gender   Male   Female (please delete as applicable). 
Address_____________________________________________________________
_____________________________________________________________ 
How long have you cared for the person with HD taking part in this study? 
_____________ 
If you have cared for others with HD, how many years have you spent caring for a 
person with HD in total?  _______________________ 
What is your relationship to the person with HD that you are caring for? 
________________ 
Name Address and phone number of your GP. 
________________________________________________________________ 
Phone number or e mail address for the researcher (Steve) to contact you on, if 
needed, to discuss arrangements for the meetings: 
______________________________________ 
 
Signed __________________________ Date __________________ 
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Appendix 3.2 R  
Information Sheet For People With HD.  
1. Title:  What helps me manage my Huntington’s disease? 
2. Invitation  
Would you like to join in with some research about Huntington’s disease, or ‘HD’?  
It would mean talking about your experience of caring for a person who has HD. 
Nothing would be done to you. A researcher called Steve who is a nurse would be 
asking you some questions.  
 You do not have to do this. Before you decide if you want to join in, it is important 
for you to understand what the research is for and what you would be doing.  
Please take time to read the writing below, or get someone to help you or read it to 
you.  
It is a good idea to talk to others about it if you’re not sure whether to join in. You 
could speak to your GP (doctor) about it. Do get in touch with us if you want to 
know more about it.  
Thank you for reading this. 
3. What is the research for? 
We hope to find out what helps people with Huntington’s disease (HD) manage their 
HD. We want to know what people with HD and their carers and doctors and nurses 
and others who care think about this.  
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We would like to know if doctors and nurses and other professionals know what 
people with HD and their carers think is helpful. And we want to know how 
important these things are to you.        
We think this will help people who care to be more helpful to people with HD in 
future. 
4. Why was I chosen? 
You are one of 13 people with HD either chosen from a list kept at the Brain Repair 
Centre Clinic in Cambridge, or are a resident at the Royal Hospital for Neuro-
disability, or were selected by the Huntington’s Disease Association Regional Care 
Advisor. 10 health professionals, were also chosen.  
5. Do I have to join in? 
It is up to you to decide if you want to join in. If you decide to join in you can 
change your mind at any time. It will not affect the care you receive. You don’t have 
to give a reason if you stop joining in the research.   
6. What do I have to do? 
In about a week after you receive an invitation, the Chief Investigator (Steve) will 
ring to see if you are interested to join in. If you don’t want to, just tell Steve. It’s not 
a problem. If you are interested, Steve will arrange to visit you to discuss the study, 
and make sure you understand what you would have to do.  
If you agree to join in, Steve will ask you to sign the consent form and fill in the 
reply slip. You can keep a copy of each of these documents so that you can read 
them at any time.  
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If you take part, this will either mean you coming to two meetings, with other people 
with HD, or Steve visiting you twice to speak to you individually, depending on your 
preference. If you decide to come to the meetings, Steve will discuss with you how 
you will get there. 
If you choose to come to the meetings, The first meeting will last two hours, with a 
break in the middle for refreshments. This meeting will be with about 9 other people 
who care for someone who has HD. Steve and an assistant will be there to lead the 
meeting and help if you’re not sure what to do.    
We will ask you all as a group, to agree on statements about things that you think 
help people to manage their HD.  
The second meeting will also last two hours, with a break for refreshments. This 
time, people with HD, and health professionals will all be there as well as carers. 
This meeting will be about deciding which statements about what helps people to 
manage their HD are most important, and which are not so important.  
On the day we will be there to help to make sure you understand how to do it. But 
there will be no ‘right’ or ‘wrong’ answers. We want your ideas. 
If you choose instead for Steve to visit you individually, you will be asked to make 
statements about what is helpful to people with HD on the first visit, and to decide 
which statements you feel are most important on the second visit. 
There is one more thing we would like you to help with. After the meetings are 
finished Steve and the research team will work to make a report of the results of the 
study. We would like to send you a copy of a draft of this report, for you to comment 
on. You could point out anything you do or don’t agree with. Then a final report will 
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be written, and you will be given a copy. The Huntington’s Disease Association will 
also get a copy. 
An important thing to note is that we will audio record the meetings. This is to help 
us remember what was said as we write about the study. It will help us if we are not 
sure what any written statements mean. After the report is written the tape will be 
destroyed. H 
7. Are there any risks to me? 
Talking about how HD has affected you could upset you and make you think about 
some things you like to forget.         
If you told us something that made us think the person you care for is not being 
treated well, or is at risk of harm, we would tell the person’s GP. The GP would then 
help us decide if we need to do anything else, to protect the person. If you told us 
something that made us think either you or the person you care for is thinking about 
self harm or suicide, we would tell the GP, who again, would help us decide if we 
need to do more to protect either or both of you.  
8. Could joining in the study do me some good?   
On the other hand, it might feel good to talk about things that help you to manage. 
You might feel good that this will help people in future, to know what helps people 
live with HD. 
But, the research will not help you personally.   
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9. Will my taking part in this study be kept confidential? 
Steve will keep the forms you sign with your name and other details locked safely. 
He may publish some of your ideas but will not tell anyone your personal details. 
Steve will tape record what you say to remind him later. The tape will be kept locked 
safely and will be destroyed when the research is finished. 
If you decide to join in group discussions, the others in the room will be asked to 
keep what you say confidential. But we cannot guarantee they will. You do not have 
to say anything that you don’t want others to know.   
10. What will happen to the results of the research study? 
We will try to publish results in research journals to do with health. Also, we will 
give the Huntington’s Disease Association a report, to print in the newsletter if they 
wish.   
The chief investigator (Steve) will talk about the study at meetings about HD.     
11. Who is organising and funding the research? 
This study is part of a PhD project for the chief investigator (Steve), and is paid for 
by the University of East Anglia, School of Nursing Midwifery.    
12. Who has reviewed the study? 
The study has been reviewed by experienced health researchers at the University of 
East Anglia. It has been approved by the Local Research Ethics Committee. It will 
be monitored by a research team including experienced researchers, a person with 
HD, and a carer, and a Family Care Advisor from the Huntington’s Disease 
Association.  
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13. Contact for Further Information 
Very many thanks for taking part in this study if you do decide to. If you wish to 
discuss it further or ask any questions about it, please contact the chief investigator: 
Steve Smith 
University of East Anglia, 
Faculty of Health, 
School of Nursing and Midwifery 
Edith Cavell Building 
Norwich    NR4 7TJ. 
Tel: 01603 59 7022 (leave a message if not there and Steve will get back to you)  Or 
e mail: steve.smith@uea.ac.uk 
 
 
What should I do if I’m not happy with any aspect of the study? 
You could contact the Huntington’s Disease Association and to talk to the local 
Family Advisor, Sue Hill, tel: 01353 648438, or e mail: sue_hill@hda.org.uk  to 
discuss any concerns, or you could make a complaint  to Rachel Mold, Faculty 
Research Manager, tel: 01603 5973949, e mail: r.mold@uea.ac.uk.  
Declaration: 
I have read and understood this information sheet. 
 
Signed _______________________  Name (Print) __________________________ 
Date ______________________    
Please Note: You should sign and return one copy of this information sheet and a 
consent form, and keep a 2nd copy of each. 
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Reply Slip 
If you have decided that you wish to take part in the study: ‘What Helps Me Manage 
My Huntington’s Disease?’, please complete this slip and send it to Steve Smith with 
the consent form, signed and dated, and the information sheet, also signed and dated 
(one copy only of each document). 
Full Name __________________________     Date of Birth  ______________ 
Gender   Male   Female (please delete as applicable). 
Address_____________________________________________________________
_____________________________________________________________ 
How long have you been affected by symptoms of HD? _____________ 
Name Address and phone number of your GP. 
________________________________________________________________ 
Phone number or e mail address for the researcher (Steve) to contact you on, if 
needed, to discuss arrangements for the meetings: 
______________________________________ 
 
 
Signed __________________________ Date __________________ 
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Appendix 3.3  Data Entry Forms 
Entry form prioritising task 
ID number participant:  
DATE ------------------------- 
Please enter the number of the statements as they have been prioritized. 
 
least  
important 
   
most  
important 
 1 2 3 4 5 
statement 
1 
     
2      
3      
4      
5      
6      
7      
8      
9      
10       
11      
12      
13      
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14      
15      
(min.) 
16 
     
17      
18      
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Appendix 3.3  Data Entry Form (clustering task, Page 1) 
ID number participant:  
Name:  
Date:  
 
Please enter the number of the statements as they have been clustered. 
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  Appendix 3.3 Entry form clustering task, page 2 
ID number participant:  
DATE ----------------------- 
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Appendix 3.4  Test for Normal Distribution 
Tests of Normality 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Having medications to help 
sleep 
.162 64 .000 .880 64 .000 
Medication against chorea .184 64 .000 .868 64 .000 
Having appropriately timed 
medication reviews 
.187 64 .000 .916 64 .000 
Medication against chorea 
to help me with activities of 
living 
.235 64 .000 .849 64 .000 
Knowing that the effects of 
medications for HD are 
available 
.224 64 .000 .883 64 .000 
Knowing side effectsof 
drugs for HD can be serious 
.236 64 .000 .870 64 .000 
Recognition that 
antipsychotic medication 
can be helpful in HD 
.165 64 .000 .898 64 .000 
Knowing that sedative 
medication will not be given 
solely to manage behaviour  
.175 64 .000 .882 64 .000 
Having good quality 
healthcare professionals 
and carers 
.211 64 .000 .855 64 .000 
Having community 
understanding 
.218 64 .000 .891 64 .000 
a. Lilliefors Significance Correction 
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Appendix 4.1  Table depicting each of the numbered 94 statements, showing 
which statements each data point on the map, Fig 4.1, represents.  
1 Having medicines to help sleep 
2 Medication against chorea 
3 Having appropriately timed reviews of medication 
4 Medication against chorea to help the person with HD do activities such as sleep,  
               have a sex life, reduce distress, reduce fatigue and carry out activities of living. 
5 knowing that the effects of medications for HD are variable 
6 Knowing that side effects of drugs for HD can be serious 
7 recognition that antipsychotic medication can be helpful in HD 
8 Knowing that sedative medication will not be given solely to manage behaviour 
9 Having good quality healthcare professionals and carers who are good  
               communicators; share information; stay calm and avoid confrontation  
10 Having community understanding 
11 Regular and timely access to health and social care assessment 
12 Having a positive outlook on life 
13 Living for today 
14 Making choices about care including end of life care in advance and having the  
               choice respected 
15 Assessment of management of aggression if it occurs. 
16 If obsessive behaviour and impulsivity are recognised as serious symptoms of HD 
17 If there is expert assessment and treatment of mental health problems (eg.  
               Depression, anxiety) occurring along with HD 
18 If professionals help the person with HD to get a life 
19 Having help to socialise 
20 If the person with HD has help to be able to get out and about 
21 Knowing in advance the detailed plans for what will happen today and / or at  
               forthcoming events 
 
22 Timeliness in access to care homes 
23 Not being cared for in an inappropriate setting (eg. A psychiatric or elderly setting  
               where staff don't know about HD). 
24 Having a familiar daily routine. 
25 Being prudent with money 
26 Spending money while he or she is able to 
27 Having someone to sort out his or her access to financial benefits 
28 Direct access to cash benefits to spend on what is needed now 
29 If they are enabled to maintain the roles that they feel suit their gender 
30 If employers make reasonable adjustments to enable continued employment 
31 If they accept the diagnosis. 
32 Having accessible town, transport and shop facilities 
33 Having alcohol 
34 Having cigarettes 
35 Being involved in a Huntington's Disease Association support group 
36 Having the opportunity to be involved in research 
37 Having a stable relationship with a partner 
38 If informal carers have training in HD 
39 Having access to the right level of  information about  HD at the right time 
40 Having support from the Huntington's Disease Association 
41 Access to professionals who are expert in HD 
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42 Access to a multi-disciplinary team that is expert in HD 
43 Being referred to a specialist National HD centre 
44 Effective multi-disciplinary working 
45 Effective interagency working 
46 When service provision is planned for when it will be needed, rather than  
               thought about  once things have already got difficult 
47 If professionals follow up patients who do not keep appointments 
48 Having the goal of a normal life when considering the use of medication 
49 The availability of a genetic test 
50 Pre-test and post-test counselling 
51 Not knowing whether other family members are genetically positive for HD 
52 Knowing if other family members are genetically positive for HD 
53 Availability of pre-implantation diagnosis 
54 Timely introduction of tube feeding 
55 Having assistance to eat and drink 
56 Having family and friends who offer practical support 
57 If there is availability of food that is appetising and manageable 
58 Having practical strategies to enable him or her to eat out without  
               embarrassment 
59 Practical advice on specific foods and textures 
60 If he or she is able to talk freely and openly about HD within the family 
1 Having a supportive network of family and friends 
62 Having appropriate training to use equipment 
63 Having a smoking aid 
64 Having aids to enable daily living (eg. Aids that help with Communication,  
               mobility, furniture, bathroom and falls prevention). 
65 Having timely access to appropriate aids and adaptations 
66 Regular timely assessment for aids and adaptations 
67 A prompt diagnosis 
68 If professionals work with all members of the family 
69 If people with HD know the role of each professional 
70 Speech and language therapy involvement to help with swallowing problems 
71 If visiting carers are flexible regarding the specific type of care they provide in the  
               household (for example, being  prepared to help children, so that the spouse  can  
               help the person with HD, if the person with HD  doesn't want help from the  
               professional carer). 
72 If professional carers are flexible about who they help in the household (for  
               example, being  prepared to help children, so that the spouse  can help the  
               person with HD, if the person with HD  doesn't want help from the professional  
               carer). 
73 Participating in intellectual activities 
74 Participating in physical activities 
75 Being able to take up hobbies and pastimes 
76 Still being able to drive. 
77 Being able to undertake domestic activities such as cooking, gardening and  
               cleaning 
78 Being able to go away from the care home to engage in community activities 
79 Having meaningful relationships with other care home residents 
80 If a care home environment is made to feel as home should feel 
81 Continuity of health and social care professionals 
82 Having continuity of care staff, (eg, professional carers in homes or that visit at  
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               home). 
83 Having opportunities for meaningful conversation 
84 Recognition that facial and neck pain can be a problem in HD.  
85 Speech and language therapy involvement in maintaining ability to communicate. 
86 Access to experimental treatments (not as part of  research, but to find a   
               treatment  that works for the person with HD). 
87 Having a choice about seeing a male or a female GP 
88 If care is available where the person with HD needs it. 
89 care is available when the person with HD needs it. 
90 If carers are listened to as an adult and believed and respected.  
91 If they are listened to as an adult and believed and respected 
92 If family carers are believed when they report reaching a tipping point, 
               where care  at home is no longer manageable. 
93 If the family carer has a break from looking after him or her. 
94 If there is information about HD for health professionals in general medical    
               settings 
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 Table presenting 94 statements in order of priority according to mean scores, 
for all participants.  
Rank Mean  
               rating Statement name  
1 4.12 Access to professionals who are expert in HD 
2 4.09 Having a supportive network of family and friends 
3 3.95 Having a familiar daily routine. 
4 3.92 Speech and language therapy involvement to help with swallowing  
                             problems 
5 3.92 If care is available when the person with HD needs it. 
6 3.88 Having family and friends who offer practical support 
7 3.86 If family carers are believed when they report reaching a tipping point,  
                             where care  at home is no longer manageable. 
8 3.82 Having a stable relationship with a partner 
9 3.82 Access to a multi-disciplinary team that is expert in HD 
10 3.80 If the family carer has a break from looking after him or her. 
11 3.80 Having good quality healthcare professionals and carers who are good  
                             communicators; share information; stay calm and avoid confrontation   
12 3.75 Medication against chorea to help the person with HD do activities such  
                             as sleep, have a sex life, reduce distress, reduce fatigue and carry out  
                             activities of living. 
13 3.75 If care is available where the person with HD needs it. 
14 3.72 If there is expert assessment and treatment of mental health problems  
                             (eg. Depression, anxiety) occurring along with HD 
15 3.72 Not being cared for in an inappropriate setting (eg. A psychiatric or  
                             elderly setting where staff don't know about HD). 
16 3.72 If they are listened to as an adult and believed and respected. 
17 3.63 Having aids to enable daily living (eg. Aids that help with communication,  
                             mobility, furniture, bathroom and falls prevention). 
18 3.62 If the person with HD has help to be able to get out and about 
19 3.62 Speech and language therapy involvement in maintaining ability to 
                              communicate 
20 3.59 Making choices about care including end of life care in advance and  
                             having the choice respected 
21 3.58 Having support from the Huntington's Disease Association. 
22 3.58 Having a positive outlook on life  
23 3.57 If he or she is able to talk freely and openly about HD within the family 
24 3.52 Being referred to a specialist National HD centre 
25 3.52 Having continuity of care staff, (eg, professional carers in homes or that  
                             visit at home). 
26 3.49 Having opportunities for meaningful conversation 
27 3.49 If carers are listened to as an adult and believed and respected 
28 3.48 Medication against chorea 
29 3.48 Being involved in a Huntington's Disease Association support group 
30 3.46 Regular and timely access to health and social care assessment 
31 3.43 When service provision is planned for when it will be needed, rather than  
                              thought about  once things have already got difficult 
32 3.35 Having help to socialise 
33 3.35 Having assistance to eat and drink 
34 3.32 A prompt diagnosis 
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35 3.31 Continuity of health and social care professionals 
36 3.28 Having timely access to appropriate aids and Adaptations 
37 3.26 If they accept the diagnosis. 
38 3.22 Having appropriately timed reviews of medication 
39 3.22 Having medicines to help sleep 
40 3.22 Having access to the right level of  information about  HD at the right time 
41 3.18 Regular timely assessment for aids and adaptations 
42 3.17 If informal carers have training in HD 
43 3.17 If there is availability of food that is appetising and Manageable 
44 3.13 Having the goal of a normal life when considering the use of medication 
45 3.11 Pre-test and post-test counselling 
46 3.11 If professionals work with all members of the family 
47 3.11 If there is information about HD for health professionals in general  
                              medical settings 
48 3.09 Effective multi-disciplinary working 
49 3.08 Living for today 
50 3.06 Assessment of management of aggression if it occurs. 
51 3.05 Participating in physical activities 
52 3.03 Having someone to sort out his or her access to financial benefits 
53 3.03 The availability of a genetic test 
54 3.02 If obsessive behaviour and impulsivity are recognised as serious  
                             symptoms of HD 
55 3.02 If a care home environment is made to feel as home should feel 
56 2.98 If visiting carers are flexible regarding the specific type of care they  
                             provide 
57 2.91 If professionals help the person with HD to get a life 
58 2.85 recognition that antipsychotic medication can be helpful in HD 
59 2.83 Knowing in advance the detailed plans for what will happen today and /  
                             or at forthcoming events 
60 2.83 Having the opportunity to be involved in research 
61 2.83 Effective interagency working 
62 2.83 Being able to take up hobbies and pastimes 
63 2.83 Practical advice on specific foods and textures 
64 2.78 Having practical strategies to enable him or her to eat out without  
                             embarrassment 
65 2.78 Being able to go away from the care home to engage in community 
activities 
66 2.77 Having community understanding 
67 2.71 Having accessible town, transport and shop facilities 
68 2.71 If professional carers are flexible about who they help in the household  
                             (for example, being  prepared to help children, so that the spouse  can  
                             help the person with HD, if the person with HD  doesn't want help from  
                             the professional carer). 
69 2.66 If employers make reasonable adjustments to enable continued  
                             employment 
70 2.63 Direct access to cash benefits to spend on what is needed now 
71 2.63 If professionals follow up patients who do not keep Appointments 
72 2.63 If people with HD know the role of each professional 
73 2.62 Availability of pre-implantation diagnosis 
74 2.60 Participating in intellectual activities 
75 2.57 Access to experimental treatments (not as part of research, but to find a  
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                             treatment  that works for the person with HD). 
76 2.55 Timely introduction of tube feeding 
77 2.55 Being able to undertake domestic activities such as cooking, gardening  
                              and cleaning 
78 2.54 Timeliness in access to care homes 
79 2.51 Knowing that sedative medication will not be given solely to manage  
                             behaviour 
80 2.51 If they are enabled to maintain the roles that they feel suit their gender 
81 2.45 Knowing that side effects of drugs for HD can be Serious 
82 2.42 knowing that the effects of medications for HD are variable 
83 2.35 Having appropriate training to use equipment 
84 2.28 Still being able to drive. 
85 2.23 Knowing if other family members are genetically positive for HD 
86 2.13 Recognition that facial and neck pain can be a problem in HD. 
87 2.12 Spending money while he or she is able to 
88 2.00 Having meaningful relationships with other care home Residents 
89 1.89 Having alcohol 
90 1.86 Not knowing whether other family members are genetically positive for  
                             HD 
91 1.85 Having a choice about seeing a male or a female GP 
92 1.83 Having cigarettes 
93 1.68 Being prudent with money 
94 1.66 Having a smoking aid 
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Appendix 4.3  Table presenting 94 statements in order of priority according to 
mean scores, for people with HD  
Rank Rating Statement 
1 4.32 Access to professionals who are expert in HD 
2 4.11 Having a positive outlook on life     
3 4.11 Having a supportive network of family and friends 
4 4.05 If care is available where the person with HD needs it. 
5 4.00 Having a stable relationship with a partner 
6 3.95 Speech and language therapy involvement to help with  
                              swallowing problems 
7 3.89 If the family carer has a break from looking after him or her. 
8 3.84 Having family and friends who offer practical support 
9 3.79 If there is expert assessment and treatment of mental health problems  
                             (eg. Depression, anxiety) occurring along with HD 
10 3.79 If they are listened to as an adult and believed and respected. 
11 3.74 Speech and language therapy involvement in maintaining ability to  
                             communicate 
12 3.68 Medication against chorea to help the person with HD do activities such  
                             as sleep, have a sex life, reduce distress, reduce fatigue and carry out  
                             activities of living. 
13 3.68 Having support from the Huntington's Disease Association. 
14 3.67 Having good quality healthcare professionals and carers who are good  
                             communicators; share information; stay calm and avoid confrontation 
15 3.63 Having help to socialise 
16 3.63 If carers are listened to as an adult and believed and Respected 
17 3.58 Making choices about care including end of life care in advance and  
                             having the choice respected 
18 3.58 Not being cared for in an inappropriate setting (eg. A psychiatric or  
                             elderly setting where staff don't know about HD). 
19 3.58 Access to a multi-disciplinary team that is expert in HD 
20 3.58 The availability of a genetic test 
21 3.58 Having continuity of care staff, (eg, professional carers in homes or that  
                             visit at home). 
22 3.58 If care is available when the person with HD needs it. 
23 3.58 If there is information about HD for health professionals in general  
                             medical settings 
24 3.53 Medication against chorea 
25 3.53 Continuity of health and social care professionals 
26 3.47 Having a familiar daily routine. 
27 3.47 If they accept the diagnosis. 
28 3.47 If family carers are believed when they report reaching a tipping point,  
                             where care  at home is no longer manageable. 
29 3.42 If the person with HD has help to be able to get out and about 
30 3.42 Still being able to drive. 
31 3.32 If obsessive behaviour and impulsivity are recognised as serious  
                             symptoms of HD 
32 3.32 Being involved in a Huntington's Disease Association support group                              
33 3.32 When service provision is planned for when it will be needed, rather than  
                              thought about  once things have already got difficult 
34 3.32 If there is availability of food that is appetising and Manageable 
35 3.28 If visiting carers are flexible regarding the specific type of care they   
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                             provide 
36 3.26 Participating in physical activities 
37 3.26 Being able to take up hobbies and pastimes 
38 3.26 Having opportunities for meaningful conversation 
39 3.21 Having someone to sort out his or her access to financial benefits 
40 3.21 Having the opportunity to be involved in research 
41 3.21 Being referred to a specialist National HD centre 
42 3.21 A prompt diagnosis 
43 3.17 Having the goal of a normal life when considering the use of medication 
44 3.16 Regular and timely access to health and social care assessment 
45 3.16 Access to experimental treatments (not as part of research, but to find a  
                              treatment that works for the person with HD). 
46 3.11 Living for today 
47 3.11 Having aids to enable daily living (eg. Aids that help with Communication,  
                              mobility, furniture, bathroom and falls prevention). 
48 3.05 recognition that antipsychotic medication can be helpful in HD 
49 3.05 Effective multi-disciplinary working 
50 3.05 If professionals work with all members of the family 
51 3.00 If informal carers have training in HD 
52 3.00 Participating in intellectual activities 
53 2.95 If professional carers are flexible about who they help in the household  
                             (for example, being  prepared to help children, so that the spouse  can  
                             help the person with HD, if the person with HD  doesn't want help from  
                             the professional carer). 
54 2.89 Having medicines to help sleep  
55 2.89 Having assistance to eat and drink 
56 2.89 Practical advice on specific foods and textures   
57 2.89 If he or she is able to talk freely and openly about HD within the family 
58 2.89 Being able to undertake domestic activities such as cooking, gardening  
                             and cleaning 
59 2.84 Having access to the right level of  information about  HD at the right time 
60 2.84 Pre-test and post-test counselling 
61 2.84 Having practical strategies to enable him or her to eat out without  
                             embarrassment 
62 2.79 Having appropriately timed reviews of medication 
63 2.79 Assessment of management of aggression if it occurs. 
64 2.79 If a care home environment is made to feel as home should feel 
65 2.74 knowing that the effects of medications for HD are variable 
66 2.74 Having community understanding 
67 2.74 Having accessible town, transport and shop facilities 
68 2.68 Being able to go away from the care home to engage in community  
                             activities 
69 2.63 If people with HD know the role of each professional 
70 2.58 Knowing that sedative medication will not be given solely to manage  
                             behaviour 
71 2.58 Spending money while he or she is able to 
72 2.58 Direct access to cash benefits to spend on what is needed now 
73 2.58 Knowing if other family members are genetically positive for HD 
74 2.53 If professionals follow up patients who do not keep appointments 
75 2.53 Availability of pre-implantation diagnosis 
76 2.47 If employers make reasonable adjustments to enable continued  
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                              employment 
77 2.47 Regular timely assessment for aids and adaptations 
78 2.42 Knowing that side effects of drugs for HD can be serious 
79 2.42 Effective interagency working 
80 2.37 If they are enabled to maintain the roles that they feel suit their gender 
81 2.37 Having timely access to appropriate aids and Adaptations 
82 2.37 Recognition that facial and neck pain can be a problem in HD.  
83 2.32 Knowing in advance the detailed plans for what will happen today and /  
                             or at forthcoming events 
84 2.32 Timeliness in access to care homes 
85 2.32 Having alcohol 
86 2.26 Timely introduction of tube feeding 
87 2.26 Having appropriate training to use equipment 
88 2.21 If professionals help the person with HD to get a life 
89 2.00 Not knowing whether other family members are genetically positive for  
                             HD 
90 2.00 Having a choice about seeing a male or a female GP 
91 1.95 Being prudent with money 
92 1.89 Having cigarettes 
93 1.89 Having meaningful relationships with other care home residents                          
94 1.63 Having a smoking aid 
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Appendix 4 4.  Table presenting 94 statements in order of priority according to 
mean scores, for caregivers  
Rank Mean  
              rating     Statement  
1 4.23 If care is available when the person with HD needs it. 
1 4.19 Having a familiar daily routine. 
3 4.19 If family carers are believed when they report reaching a tipping point,  
                             where care  at home is no longer manageable. 
4 4.15 Having a supportive network of family and friends 
5 4.12 Being referred to a specialist National HD centre 
6 4.04 If the person with HD has help to be able to get out and about 
7 4.04 Having a stable relationship with a partner 
8 4.04 Access to professionals who are expert in HD 
9 4.04 Having family and friends who offer practical support 
10 4.00 Having good quality healthcare professionals and carers who are good  
                             communicators; share information; stay calm and avoid confrontation 
11 3.88 Having support from the Huntington's Disease Association. 
12 3.88 Speech and language therapy involvement to help with swallowing  
                             problems 
13 3.88 Having continuity of care staff, (eg, professional carers in homes or that  
                             visit at home). 
14 3.88 If the family carer has a break from looking after him or her. 
15 3.85 Being involved in a Huntington's Disease Association support group 
16 3.81 If he or she is able to talk freely and openly about HD within the family 
17 3.77 Access to a multi-disciplinary team that is expert in HD 
18 3.73 Having aids to enable daily living (eg. Aids that help with Communication,  
                             mobility, furniture, bathroom and falls prevention). 
19 3.69 Not being cared for in an inappropriate setting (eg. A psychiatric or  
                             elderly setting where staff don't know about HD). 
20 3.62 Having a positive outlook on life 
21 3.62 Having access to the right level of  information about  HD at the right time 
22 3.62 If care is available where the person with HD needs it. 
23 3.58 If there is expert assessment and treatment of mental health problems  
                             (eg. Depression, anxiety) occurring along with HD 
24 3.58 Having timely access to appropriate aids and adaptations 
25 3.58 If carers are listened to as an adult and believed and respected 
26 3.54 Speech and language therapy involvement in maintaining ability to  
                             communicate 
27 3.50 Medication against chorea to help the person with HD do activities such  
                              as sleep, have a sex life, reduce distress, reduce fatigue and carry out  
                              activities of living. 
28 3.46 Having help to socialise 
29 3.46 Having opportunities for meaningful conversation 
30 3.38 If informal carers have training in HD 
31 3.38 Having assistance to eat and drink 
32 3.38 Regular timely assessment for aids and adaptations 
33 3.38 A prompt diagnosis 
34 3.35 Continuity of health and social care professionals 
35 3.31 Participating in physical activities 
36 3.27 Regular and timely access to health and social care assessment 
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37 3.27 If they accept the diagnosis. 
38 3.23 Having medicines to help sleep 
39 3.23 If professionals help the person with HD to get a life 
40 3.23 When service provision is planned for when it will be needed, rather than  
                              thought about  once things have already got difficult 
41 3.20 Having appropriately timed reviews of medication 
42 3.19 Having someone to sort out his or her access to financial benefits 
43 3.19 If they are listened to as an adult and believed and respected. 
44 3.16 Making choices about care including end of life care in advance and  
                             having the choice respected     
45 3.15 Assessment of management of aggression if it occurs. 
46 3.15 If a care home environment is made to feel as home should feel 
47 3.12 Medication against chorea 
48 3.12 If there is availability of food that is appetising and Manageable 
49 3.08 If professionals work with all members of the family 
50 3.08 If visiting carers are flexible regarding the specific type of care they  
                             provide 
51 3.08 If there is information about HD for health professionals in general  
                             medical settings 
52 3.04 If obsessive behaviour and impulsivity are recognised as serious  
                             symptoms of HD 
53 3.00 Living for today 
54 3.00 Having the opportunity to be involved in research  
55 3.00 Having the goal of a normal life when considering the use of medication 
56 3.00 Pre-test and post-test counselling 
57 2.92 The availability of a genetic test 
58 2.92 Being able to take up hobbies and pastimes  
59 2.77 Knowing in advance the detailed plans for what will happen today and /  
                             or at forthcoming events 
60 2.77 Having accessible town, transport and shop facilities 
61 2.77 Effective interagency working 
62 2.77 If people with HD know the role of each professional 
63 2.73 Direct access to cash benefits to spend on what is needed now 
64 2.73 If professionals follow up patients who do not keep appointments 
65 2.73 Having appropriate training to use equipment 
66 2.72 Practical advice on specific foods and textures  (n=25) 
67 2.69 Having community understanding 
68 2.65 Effective multi-disciplinary working 
69 2.65 Being able to go away from the care home to engage in community  
                             activities 
70 2.65 Access to experimental treatments (not as part of research, but to find a  
                             treatment  that works for the person with HD). 
71 2.58 Availability of pre-implantation diagnosis 
72 2.54 Knowing that side effects of drugs for HD can be Serious 
73 2.54 Having practical strategies to enable him or her to eat out without  
                             embarrassment 
74 2.54 If professional carers are flexible about who they help in the household  
                             (for example, being  prepared to help children, so that the spouse  can  
                             help the person with HD, if the person with HD  doesn't want help from  
                             the professional carer). 
75 2.50 Timeliness in access to care homes 
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76 2.50 Participating in intellectual activities 
77 2.46 Timely introduction of tube feeding 
78 2.42 recognition that antipsychotic medication can be helpful in HD 
79 2.35 If they are enabled to maintain the roles that they feel suit their gender 
80 2.31 Knowing that sedative medication will not be given solely to manage  
                             behaviour 
81 2.31 If employers make reasonable adjustments to enable continued  
                             employment 
82 2.27 knowing that the effects of medications for HD are variable 
83 2.27 Being able to undertake domestic activities such as cooking, gardening  
                             and cleaning 
84 2.15 Having meaningful relationships with other care home residents 
85 2.00 Spending money while he or she is able to 
86 2.00 Knowing if other family members are genetically positive for HD 
87 2.00 Recognition that facial and neck pain can be a problem in HD.  
88 1.92 Not knowing whether other family members are genetically positive for  
                             HD 
89 1.88 Having alcohol 
90 1.77 Still being able to drive. 
91 1.58 Having cigarettes 
92 1.50 Being prudent with money 
93 1.50 Having a choice about seeing a male or a female GP 
94 1.46 Having a smoking aid 
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Appendix 4.5  Table presenting 94 statements in order of priority according to 
mean scores, for Health Care Professionals  
 
Rank Mean         Statement 
              rating 
1 4.35 If they are listened to as an adult and believed and respected. 
2 4.15 Medication against chorea to help the person with HD do activities such  
                             as sleep, have a sex life, reduce distress, reduce fatigue and carry out  
                             activities of living. 
3 4.15 Making choices about care including end of life care in advance and  
                             having the choice respected 
4 4.10 Having a familiar daily routine. 
5 4.10 Access to a multi-disciplinary team that is expert in HD 
6 4.05 Access to professionals who are expert in HD 
7 4.00 Regular and timely access to health and social care assessment 
8 4.00 Having a supportive network of family and friends 
9 4.00 Having aids to enable daily living (eg. Aids that help with Communication,  
                             mobility, furniture, bathroom and falls prevention). 
10 3.95 Speech and language therapy involvement to help with swallowing  
                             problems 
11 3.90 Medication against chorea 
12 3.90 Not being cared for in an inappropriate setting (eg. A psychiatric or  
                             elderly setting where staff don't know about HD). 
13 3.90 If he or she is able to talk freely and openly about HD within the family 
14 3.85 If there is expert assessment and treatment of mental health problems  
                             (eg. Depression, anxiety) occurring along with HD 
15 3.85 If care is available when the person with HD needs it. 
16 3.80 When service provision is planned for when it will be needed, rather than  
                              thought about  once things have already got difficult 
17 3.80 If family carers are believed when they report reaching a tipping point,  
                             where care  at home is no longer manageable. 
18 3.75 Having assistance to eat and drink 
19 3.75 Having timely access to appropriate aids and adaptations 
20 3.75 Having opportunities for meaningful conversation 
21 3.70 Effective multi-disciplinary working 
22 3.70 Having family and friends who offer practical support 
23 3.65 Having appropriately timed reviews of medication 
24 3.65 Having good quality healthcare professionals and carers who are good  
                              communicators; share information; stay calm and avoid confrontation 
25 3.65 If care is available where the person with HD needs it. 
26 3.60 Regular timely assessment for aids and adaptations 
27 3.60 Speech and language therapy involvement in maintaining ability to  
                             communicate 
28 3.60 If the family carer has a break from looking after him or her. 
29 3.50 Having medicines to help sleep 
30 3.50 Pre-test and post-test counselling 
31 3.40 Knowing in advance the detailed plans for what will happen today and /  
                             or at forthcoming events 
32 3.35 Having a stable relationship with a partner 
33 3.35 A prompt diagnosis 
34 3.30 If employers make reasonable adjustments to enable continued  
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                             employment 
35 3.30 Effective interagency working 
36 3.25 If the person with HD has help to be able to get out and about 
37 3.25 Having the goal of a normal life when considering the use of medication 
38 3.25 If carers are listened to as an adult and believed and respected 
39 3.20 recognition that antipsychotic medication can be helpful in HD 
40 3.20 Assessment of management of aggression if it occurs. 
41 3.20 If professionals work with all members of the family 
42 3.15 Living for today 
43 3.15 If professionals help the person with HD to get a life 
44 3.15 Being involved in a Huntington's Disease Association support group 
45 3.10 Having support from the Huntington's Disease Association. 
46 3.10 If there is availability of food that is appetising and manageable 
47 3.05 If they accept the diagnosis. 
48 3.05 If informal carers have training in HD 
49 3.05 Having access to the right level of  information about  HD at the right time 
50 3.05 Being referred to a specialist National HD centre 
51 3.05 Having practical strategies to enable him or her to eat out without  
                             embarrassment 
52 3.05 Being able to go away from the care home to engage in community  
                             activities 
53 3.05 If a care home environment is made to feel as home should feel 
54 3.05 Continuity of health and social care professionals 
55 3.00 Having a positive outlook on life            
56 3.00 Having continuity of care staff, (eg, professional carers in homes or that  
                             visit at home). 
57 2.95 Having help to socialise 
58 2.95 Timely introduction of tube feeding 
59 2.90 Having community understanding 
60 2.90 Practical advice on specific foods and textures 
61 2.85 If they are enabled to maintain the roles that they feel suit their gender 
62 2.80 Timeliness in access to care homes 
63 2.75 Availability of pre-implantation diagnosis 
64 2.70 Knowing that sedative medication will not be given solely to manage  
                             behaviour  
65 2.70 If obsessive behaviour and impulsivity are recognised as serious  
                             symptoms of HD 
66 2.70 If professional carers are flexible about who they help in the household  
                             (for example, being  prepared to help children, so that the spouse  can  
                             help the person with HD, if the person with HD  doesn't want help from  
                             the professional carer). 
67 2.70 If there is information about HD for health professionals in general  
                             medical settings 
68 2.65 Having someone to sort out his or her access to financial benefits 
69 2.65 The availability of a genetic test 
70 2.60 Having accessible town, transport and shop facilities 
71 2.60 If professionals follow up patients who do not keep appointments 
72 2.60 If visiting carers are flexible regarding the specific type of care they  
                             provide 
73 2.60 Being able to undertake domestic activities such as cooking, gardening  
                             and cleaning 
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74 2.55 Direct access to cash benefits to spend on what is needed now 
75 2.50 Participating in physical activities 
76 2.45 If people with HD know the role of each professional 
77 2.35 Knowing that side effects of drugs for HD can be serious 
78 2.35 Participating in intellectual activities 
79 2.30 knowing that the effects of medications for HD are variable 
80 2.30 Being able to take up hobbies and pastimes 
81 2.25 Having the opportunity to be involved in research 
82 2.20 Knowing if other family members are genetically positive for HD 
83 2.15 Having a choice about seeing a male or a female GP 
84 2.10 Having cigarettes 
85 2.05 Recognition that facial and neck pain can be a problem in HD. 
86 1.95 Having appropriate training to use equipment 
87 1.95 Having a smoking aid 
88 1.90 Having meaningful relationships with other care home residents 
89 1.90 Access to experimental treatments (not as part of research, but to find a  
                             treatment  that works for the person with HD). 
90 1.85 Spending money while he or she is able to 
91 1.85 Still being able to drive. 
92 1.65 Being prudent with money 
93 1.65 Not knowing whether other family members are genetically positive for  
                             HD 
94 1.50 Having alcohol 
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Appendix 4.6  Table presenting 94 statements in order of priority according to 
mean scores, for the Nursing Home Subgroup  (Caregivers and Health 
Professionals only - no people with HD included) (n=19, 11 professionals, 8 
caregivers). 
 
Rank Mean 
              Rating            Statement  
1 4.32 Access to a multi-disciplinary team that is expert in HD 
2 4.26 Having a familiar daily routine. 
3 4.21 Access to professionals who are expert in HD 
4 4.11 Medication against chorea to help the person with HD do activities such  
                             as sleep, have a sex life, reduce distress, reduce fatigue and carry out  
                             activities of living. 
5 4.05 Having a supportive network of family and friends 
 
6 3.95 Speech and language therapy involvement to help with swallowing  
                              problems 
7 3.89 Medication against chorea 
8 3.89 If he or she is able to talk freely and openly about HD within the family 
9 3.89 Having aids to enable daily living (eg. Aids that help with Communication,  
                             mobility, furniture, bathroom and falls prevention). 
10 3.84 If care is available where the person with HD needs it. 
11 3.84 If care is available when the person with HD needs it. 
12 3.84 If family carers are believed when they report reaching a tipping point,  
                             where care  at home is no longer manageable. 
13 3.79 Having assistance to eat and drink 
14 3.74 Being referred to a specialist National HD centre 
15 3.68 If they accept the diagnosis. 
16 3.68 Having a stable relationship with a partner 
17 3.63 If the person with HD has help to be able to get out and about 
18 3.63 Not being cared for in an inappropriate setting (eg. A psychiatric or  
                             elderly setting where staff don't know about HD). 
19 3.63 If they are listened to as an adult and believed and respected. 
20 3.58 Being involved in a Huntington's Disease Association support group 
21 3.58 When service provision is planned for when it will be needed, rather than  
                             thought about  once things have already got difficult 
22 3.58 Having family and friends who offer practical support 
 
23 3.58 Speech and language therapy involvement in maintaining ability to  
                             communicate 
24 3.58 If the family carer has a break from looking after him or her. 
25 3.53 Having good quality healthcare professionals and carers who are good  
                             communicators; share information; stay calm and avoid confrontation 
26 3.53 If carers are listened to as an adult and believed and respected 
27 3.42 Having medicines to help sleep 
28 3.42 recognition that antipsychotic medication can be helpful in HD 
29 3.42 Regular and timely access to health and social care assessment 
30 3.42 Having access to the right level of  information about  HD at the right time 
31 3.42 Having timely access to appropriate aids and adaptations 
32 3.42 Having continuity of care staff, (eg, professional carers in homes or that  
                             visit at home). 
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33 3.37 Regular timely assessment for aids and adaptations 
34 3.37 Having opportunities for meaningful conversation 
35 3.32 If there is expert assessment and treatment of mental health problems  
                             (eg. Depression, anxiety) occurring along with HD 
36 3.32 Having support from the Huntington's Disease association. 
37 3.32 Having the goal of a normal life when considering the use of medication 
38 3.26 Having appropriately timed reviews of medication 
39 3.26 If professionals help the person with HD to get a life 
40 3.21 Having help to socialise 
41 3.21 Knowing in advance the detailed plans for what will happen today and /  
                             or at forthcoming events 
42 3.16 Assessment of management of aggression if it occurs. 
43 3.16 Timely introduction of tube feeding 
44 3.16 If there is availability of food that is appetising and Manageable 
45 3.16 Participating in physical activities 
46 3.16 If a care home environment is made to feel as home should feel 
47 3.11 Making choices about care including end of life care in  
                             advance and having the choice respected 
48 3.05 If employers make reasonable adjustments to enable continued  
                             employment 
49 3.05 A prompt diagnosis 
50 3.05 Being able to go away from the care home to engage in community  
                             activities 
51 3.00 Effective multi-disciplinary working 
52 3.00 Pre-test and post-test counselling 
53 3.00 Practical advice on specific foods and textures 
54 3.00 Continuity of health and social care professionals 
55 2.94 Having a positive outlook on life 
56 2.89 Living for today 
57 2.89 Availability of pre-implantation diagnosis 
58 2.84 Having accessible town, transport and shop facilities 
59 2.84 If informal carers have training in HD 
60 2.84 Effective interagency working 
61 2.84 If professionals work with all members of the family 
62 2.84 If visiting carers are flexible regarding the specific type of care they  
                             provide 
63 2.74 If obsessive behaviour and impulsivity are recognised as serious  
                             symptoms of HD 
64 2.74 Having practical strategies to enable him or her to eat out without  
                             embarrassment 
65 2.68 Having someone to sort out his or her access to financial benefits 
66 2.63 Knowing that sedative medication will not be given solely to manage  
                             behaviour 
67 2.63 Having community understanding 
68 2.63 If they are enabled to maintain the roles that they feel suit their gender 
69 2.63 If professionals follow up patients who do not keep appointments 
70 2.63 Being able to take up hobbies and pastimes 
71 2.63 If there is information about HD for health professionals in general  
                             medical settings 
72 2.58 If professional carers are flexible about who they help in the household  
                             (for example, being  prepared to help children, so that the spouse  can  
262 
 
                             help the person with HD, if the person with HD  doesn't want help from  
                             the professional carer). 
73 2.53 Direct access to cash benefits to spend on what is needed now 
74 2.47 Timeliness in access to care homes 
75 2.42 Having the opportunity to be involved in research 
76 2.42 If people with HD know the role of each professional 
77 2.37 Being able to undertake domestic activities such as cooking, gardening  
                             and cleaning 
78 2.32 knowing that the effects of medications for HD are variable 
79 2.32 Knowing if other family members are genetically positive for HD 
80 2.32 Participating in intellectual activities 
81 2.32 Access to experimental treatments (not as part of research, but to find a  
                              treatment  that works for the person with HD). 
82 2.26 The availability of a genetic test 
83 2.26 Recognition that facial and neck pain can be a problem in HD. 
84 2.21 Knowing that side effects of drugs for HD can be Serious 
85 2.21 Having a choice about seeing a male or a female GP 
86 2.11 Having cigarettes 
87 2.11 Having appropriate training to use equipment 
88 2.11 Still being able to drive. 
89 2.11 Having meaningful relationships with other care home Residents 
90 1.95 Not knowing whether other family members are genetically positive for  
                             HD 
91 1.84 Spending money while he or she is able to 
92 1.84 Having a smoking aid 
93 1.79 Being prudent with money 
94 1.68 Having alcohol 
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Appendix 4.7  Table presenting 94 statements in order of priority according to 
mean scores, for the Community-Based Subgroup  (Caregivers and Health 
Professionals only - no people with HD included)  (n=27: 18 caregivers, 9 
professionals). 
 
Rank     Mean  
              Rating       Statement 
1 4.23 If care is available when the person with HD needs it. 
2 4.15 If family carers are believed when they report reaching a tipping point,  
                             where care at home is no longer manageable. 
3 4.12 Having family and friends who offer practical support 
4 4.12 Having a familiar daily routine. 
5 4.08 Having a supportive network of family and friends 
6 4.04 Having good quality healthcare professionals and carers who are good  
                             communicators; share information; stay calm and avoid confrontation 
7 4.00 Making choices about care including end of life care in advance and  
                             having the choice respected 
8 3.96 If there is expert assessment and treatment of mental health problems  
                              (eg. Depression, anxiety) occurring along with HD 
9 3.96 Speech and language therapy involvement to help with swallowing  
                             problems 
10 3.96 Not being cared for in an inappropriate setting (eg. A psychiatric or  
                             elderly setting where staff don't know about HD). 
11 3.88 If the family carer has a break from looking after him or her. 
12 3.88 If he or she is able to talk freely and openly about HD within the family 
13 3.88 Access to professionals who are expert in HD 
14 3.88 Having a stable relationship with a partner 
15 3.85 Having timely access to appropriate aids and adaptations 
16 3.81 If they are listened to as an adult and believed and respected. 
17 3.77 Having aids to enable daily living (eg. Aids that help with Communication,  
                             mobility, furniture, bathroom and falls prevention). 
18 3.77 Regular and timely access to health and social care assessment 
19 3.73 Access to a multi-disciplinary team that is expert in HD  
20 3.69 Having opportunities for meaningful conversation 
21 3.69 Having support from the Huntington's Disease Association. 
22 3.69 If the person with HD has help to be able to get out and about 
23 3.62 Being referred to a specialist National HD centre 
24 3.62 A prompt diagnosis 
25 3.58 Regular timely assessment for aids and adaptations 
26 3.58 Having continuity of care staff, (eg, professional carers in homes or that  
                             visit at home). 
27 3.58 Having a positive outlook on life 
28 3.54 Speech and language therapy involvement in maintaining ability to  
                             communicate 
29 3.54 If informal carers have training in HD 
30 3.50 Medication against chorea to help the person with HD do activities such  
                             as sleep, have a sex life, reduce distress, reduce fatigue and carry out  
                             activities of living. 
31 3.50 Being involved in a Huntington's Disease Association support group 
32 3.48 Having appropriately timed reviews of medication 
33 3.46 If care is available where the person with HD needs it. 
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34 3.46 When service provision is planned for when it will be needed, rather than  
                             thought about  once things have already got difficult 
35 3.42 If carers are listened to as an adult and believed and respected 
36 3.42 If professionals work with all members of the family 
37 3.38 Having access to the right level of  information about  HD at the right time 
38 3.38 Continuity of health and social care professionals 
39 3.38 Pre-test and post-test counselling 
40 3.31 Having assistance to eat and drink 
41 3.27 Effective multi-disciplinary working 
42 3.23 Having medicines to help sleep 
43 3.19 Having help to socialise 
44 3.19 Effective interagency working  
45 3.19 Assessment of management of aggression if it occurs. 
46 3.19 The availability of a genetic test  
47 3.12 If there is availability of food that is appetising and manageable 
48 3.12 If professionals help the person with HD to get a life 
49 3.12 Having someone to sort out his or her access to financial Benefits 
50 3.12 If a care home environment is made to feel as home should feel 
51 3.12 Living for today  
52 3.08 Medication against chorea 
53 3.08 If there is information about HD for health professionals in general  
                             medical settings 
54 3.00 Having the goal of a normal life when considering the use of Medication 
55 3.00 If obsessive behaviour and impulsivity are recognised as serious  
                             symptoms of HD 
56 2.96 Knowing in advance the detailed plans for what will happen today and /  
                             or at forthcoming events 
57 2.88 If they accept the diagnosis. 
58 2.85 If visiting carers are flexible regarding the specific type of care they  
                             provide 
59 2.85 If people with HD know the role of each professional  
60 2.81 Timeliness in access to care homes 
61 2.81 Having community understanding 
62 2.77 Having practical strategies to enable him or her to eat out without  
                             embarrassment 
63 2.77 If professionals follow up patients who do not keep appointments 
64 2.77 Having the opportunity to be involved in research 
65 2.73 Participating in physical activities 
66 2.72 Practical advice on specific foods and textures 
67 2.65 Direct access to cash benefits to spend on what is needed now 
68 2.65 Having accessible town, transport and shop facilities  
69 2.65 Knowing that side effects of drugs for HD can be serious 
70 2.62 Being able to go away from the care home to engage in community  
                             activities 
71 2.62 If professional carers are flexible about who they help in the household  
                             (for example, being  prepared to help children, so that the spouse  can  
                             help the person with HD, if the person with HD  doesn't want help from  
                             the professional carer). 
72 2.58 Having appropriate training to use equipment 
73 2.58 If they are enabled to maintain the roles that they feel suit their gender 
74 2.58 If employers make reasonable adjustments to enable Continued  
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                              employment 
75 2.58 Being able to take up hobbies and pastimes 
76 2.50 Being able to undertake domestic activities such as cooking, gardening  
                             and cleaning 
77 2.42 Participating in intellectual activities 
78 2.42 Availability of pre-implantation diagnosis 
79 2.38 Timely introduction of tube feeding 
80 2.38 Knowing that sedative medication will not be given solely to manage  
                             behaviour 
81 2.31 recognition that antipsychotic medication can be helpful in HD 
82 2.27 knowing that the effects of medications for HD are variable 
83 2.23 Access to experimental treatments (not as part of research, but to find a  
                             treatment  that works for the person with HD). 
84 2.00 Having meaningful relationships with other care home residents 
85 1.96 Knowing if other family members are genetically positive for HD 
86 1.92 Spending money while he or she is able to 
87 1.80 Recognition that facial and neck pain can be a problem in HD. 
88 1.73 Not knowing whether other family members are genetically positive for  
                             HD 
89 1.73 Having alcohol 
90 1.62 Still being able to drive. 
91 1.62 Having cigarettes 
92 1.58 Having a smoking aid 
93 1.46 Having a choice about seeing a male or a female GP 
94 1.38 Being prudent with money 
 
